WO2015165279A1 - 多氟化合物作为布鲁顿酪氨酸激酶抑制剂 - Google Patents
多氟化合物作为布鲁顿酪氨酸激酶抑制剂 Download PDFInfo
- Publication number
- WO2015165279A1 WO2015165279A1 PCT/CN2015/000290 CN2015000290W WO2015165279A1 WO 2015165279 A1 WO2015165279 A1 WO 2015165279A1 CN 2015000290 W CN2015000290 W CN 2015000290W WO 2015165279 A1 WO2015165279 A1 WO 2015165279A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- mmol
- group
- fluoro
- pyrazolo
- amino
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 336
- 102000001714 Agammaglobulinaemia Tyrosine Kinase Human genes 0.000 title description 19
- 108010029445 Agammaglobulinaemia Tyrosine Kinase Proteins 0.000 title description 19
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 title description 2
- 239000005483 tyrosine kinase inhibitor Substances 0.000 title description 2
- 238000000034 method Methods 0.000 claims abstract description 151
- 150000003839 salts Chemical class 0.000 claims abstract description 23
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 20
- 201000010099 disease Diseases 0.000 claims abstract description 18
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 16
- 208000023275 Autoimmune disease Diseases 0.000 claims abstract description 15
- 208000027866 inflammatory disease Diseases 0.000 claims abstract description 7
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 157
- -1 hydroxy, carboxy Chemical group 0.000 claims description 119
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 41
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 33
- 229910052757 nitrogen Inorganic materials 0.000 claims description 31
- 229920006395 saturated elastomer Polymers 0.000 claims description 30
- 125000000217 alkyl group Chemical group 0.000 claims description 28
- 239000000203 mixture Substances 0.000 claims description 26
- 229910052736 halogen Inorganic materials 0.000 claims description 24
- 150000002367 halogens Chemical class 0.000 claims description 24
- 125000003545 alkoxy group Chemical group 0.000 claims description 19
- 125000001072 heteroaryl group Chemical group 0.000 claims description 19
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 18
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 17
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims description 16
- 125000003277 amino group Chemical group 0.000 claims description 16
- 230000000694 effects Effects 0.000 claims description 16
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 16
- 229910052739 hydrogen Inorganic materials 0.000 claims description 16
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 15
- 125000003118 aryl group Chemical group 0.000 claims description 15
- 239000001257 hydrogen Substances 0.000 claims description 15
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims description 15
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 15
- 125000003368 amide group Chemical group 0.000 claims description 14
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims description 13
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 13
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 12
- 230000002401 inhibitory effect Effects 0.000 claims description 12
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 12
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 12
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims description 11
- 229910052799 carbon Inorganic materials 0.000 claims description 11
- 150000002148 esters Chemical class 0.000 claims description 11
- 125000000623 heterocyclic group Chemical group 0.000 claims description 11
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 11
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 claims description 10
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 10
- 239000003814 drug Substances 0.000 claims description 10
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 10
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 9
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims description 8
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 8
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims description 8
- 150000002923 oximes Chemical class 0.000 claims description 8
- 125000004044 trifluoroacetyl group Chemical group FC(C(=O)*)(F)F 0.000 claims description 8
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 claims description 7
- 125000002252 acyl group Chemical group 0.000 claims description 7
- 201000011510 cancer Diseases 0.000 claims description 7
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 6
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 claims description 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 6
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 6
- 206010006451 bronchitis Diseases 0.000 claims description 6
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 6
- 230000005764 inhibitory process Effects 0.000 claims description 6
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims description 6
- 229910052717 sulfur Inorganic materials 0.000 claims description 6
- 208000034578 Multiple myelomas Diseases 0.000 claims description 5
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 5
- 150000001408 amides Chemical class 0.000 claims description 5
- 230000001684 chronic effect Effects 0.000 claims description 5
- CISNNLXXANUBPI-UHFFFAOYSA-N cyano(nitro)azanide Chemical compound [O-][N+](=O)[N-]C#N CISNNLXXANUBPI-UHFFFAOYSA-N 0.000 claims description 5
- 125000000000 cycloalkoxy group Chemical group 0.000 claims description 5
- 208000026278 immune system disease Diseases 0.000 claims description 5
- 125000005188 oxoalkyl group Chemical group 0.000 claims description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- 206010025323 Lymphomas Diseases 0.000 claims description 4
- 239000004480 active ingredient Substances 0.000 claims description 4
- 125000003342 alkenyl group Chemical group 0.000 claims description 4
- 125000002877 alkyl aryl group Chemical group 0.000 claims description 4
- 125000005119 alkyl cycloalkyl group Chemical group 0.000 claims description 4
- 125000004656 alkyl sulfonylamino group Chemical group 0.000 claims description 4
- MWPLVEDNUUSJAV-UHFFFAOYSA-N anthracene Natural products C1=CC=CC2=CC3=CC=CC=C3C=C21 MWPLVEDNUUSJAV-UHFFFAOYSA-N 0.000 claims description 4
- 125000005885 heterocycloalkylalkyl group Chemical group 0.000 claims description 4
- 230000036210 malignancy Effects 0.000 claims description 4
- 125000003386 piperidinyl group Chemical group 0.000 claims description 4
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 4
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 4
- 125000001424 substituent group Chemical group 0.000 claims description 4
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims description 3
- 206010003011 Appendicitis Diseases 0.000 claims description 3
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 claims description 3
- 208000033222 Biliary cirrhosis primary Diseases 0.000 claims description 3
- 206010013700 Drug hypersensitivity Diseases 0.000 claims description 3
- 208000007882 Gastritis Diseases 0.000 claims description 3
- 208000005577 Gastroenteritis Diseases 0.000 claims description 3
- 208000024869 Goodpasture syndrome Diseases 0.000 claims description 3
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 claims description 3
- 206010020850 Hyperthyroidism Diseases 0.000 claims description 3
- 208000003250 Mixed connective tissue disease Diseases 0.000 claims description 3
- 208000005647 Mumps Diseases 0.000 claims description 3
- 208000009525 Myocarditis Diseases 0.000 claims description 3
- 206010029132 Nephritis haemorrhagic Diseases 0.000 claims description 3
- 206010029240 Neuritis Diseases 0.000 claims description 3
- 201000011152 Pemphigus Diseases 0.000 claims description 3
- 241000721454 Pemphigus Species 0.000 claims description 3
- 208000031845 Pernicious anaemia Diseases 0.000 claims description 3
- 201000007100 Pharyngitis Diseases 0.000 claims description 3
- 206010035664 Pneumonia Diseases 0.000 claims description 3
- 206010036105 Polyneuropathy Diseases 0.000 claims description 3
- 208000012654 Primary biliary cholangitis Diseases 0.000 claims description 3
- 206010039085 Rhinitis allergic Diseases 0.000 claims description 3
- 206010039710 Scleroderma Diseases 0.000 claims description 3
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 3
- 230000001154 acute effect Effects 0.000 claims description 3
- 125000005213 alkyl heteroaryl group Chemical group 0.000 claims description 3
- 201000010105 allergic rhinitis Diseases 0.000 claims description 3
- 208000006673 asthma Diseases 0.000 claims description 3
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 claims description 3
- 230000009286 beneficial effect Effects 0.000 claims description 3
- 201000001352 cholecystitis Diseases 0.000 claims description 3
- 208000016644 chronic atrophic gastritis Diseases 0.000 claims description 3
- 125000004122 cyclic group Chemical group 0.000 claims description 3
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims description 3
- 229910052731 fluorine Inorganic materials 0.000 claims description 3
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims description 3
- 206010023332 keratitis Diseases 0.000 claims description 3
- 208000010805 mumps infectious disease Diseases 0.000 claims description 3
- 206010028417 myasthenia gravis Diseases 0.000 claims description 3
- 229910052760 oxygen Inorganic materials 0.000 claims description 3
- 201000001976 pemphigus vulgaris Diseases 0.000 claims description 3
- 208000019629 polyneuritis Diseases 0.000 claims description 3
- 230000002685 pulmonary effect Effects 0.000 claims description 3
- 206010039083 rhinitis Diseases 0.000 claims description 3
- 208000003265 stomatitis Diseases 0.000 claims description 3
- 208000011580 syndromic disease Diseases 0.000 claims description 3
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 3
- 210000001685 thyroid gland Anatomy 0.000 claims description 3
- 206010044008 tonsillitis Diseases 0.000 claims description 3
- 208000035408 type 1 diabetes mellitus 1 Diseases 0.000 claims description 3
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims description 2
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 claims description 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 2
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims description 2
- 206010034277 Pemphigoid Diseases 0.000 claims description 2
- 125000004422 alkyl sulphonamide group Chemical group 0.000 claims description 2
- 125000005577 anthracene group Chemical group 0.000 claims description 2
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 2
- 229910052805 deuterium Inorganic materials 0.000 claims description 2
- 125000004185 ester group Chemical group 0.000 claims description 2
- 239000011737 fluorine Substances 0.000 claims description 2
- 125000001153 fluoro group Chemical group F* 0.000 claims description 2
- 230000001926 lymphatic effect Effects 0.000 claims description 2
- 210000002966 serum Anatomy 0.000 claims description 2
- 206010043778 thyroiditis Diseases 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims 4
- 208000016025 Waldenstroem macroglobulinemia Diseases 0.000 claims 3
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 claims 3
- 150000002431 hydrogen Chemical class 0.000 claims 3
- 208000004732 Systemic Vasculitis Diseases 0.000 claims 2
- 208000018359 Systemic autoimmune disease Diseases 0.000 claims 2
- 206010047115 Vasculitis Diseases 0.000 claims 2
- 230000003325 follicular Effects 0.000 claims 2
- 210000000056 organ Anatomy 0.000 claims 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims 1
- 125000000041 C6-C10 aryl group Chemical group 0.000 claims 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 1
- 208000001204 Hashimoto Disease Diseases 0.000 claims 1
- 208000030836 Hashimoto thyroiditis Diseases 0.000 claims 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims 1
- 229910052794 bromium Inorganic materials 0.000 claims 1
- 230000001413 cellular effect Effects 0.000 claims 1
- 229910052801 chlorine Inorganic materials 0.000 claims 1
- 239000000460 chlorine Substances 0.000 claims 1
- 201000005311 drug allergy Diseases 0.000 claims 1
- 201000003444 follicular lymphoma Diseases 0.000 claims 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 claims 1
- 206010040400 serum sickness Diseases 0.000 claims 1
- 229910052724 xenon Inorganic materials 0.000 claims 1
- FHNFHKCVQCLJFQ-UHFFFAOYSA-N xenon atom Chemical compound [Xe] FHNFHKCVQCLJFQ-UHFFFAOYSA-N 0.000 claims 1
- 238000002360 preparation method Methods 0.000 abstract description 9
- 208000035475 disorder Diseases 0.000 abstract 2
- OGEBRHQLRGFBNV-RZDIXWSQSA-N chembl2036808 Chemical class C12=NC(NCCCC)=NC=C2C(C=2C=CC(F)=CC=2)=NN1C[C@H]1CC[C@H](N)CC1 OGEBRHQLRGFBNV-RZDIXWSQSA-N 0.000 abstract 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 452
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 336
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 321
- 239000000243 solution Substances 0.000 description 305
- 238000006243 chemical reaction Methods 0.000 description 243
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 238
- 239000012071 phase Substances 0.000 description 211
- 235000019439 ethyl acetate Nutrition 0.000 description 205
- 239000012043 crude product Substances 0.000 description 123
- 238000004724 ultra fast liquid chromatography Methods 0.000 description 120
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 118
- 230000003595 spectral effect Effects 0.000 description 118
- 230000002829 reductive effect Effects 0.000 description 111
- 230000002441 reversible effect Effects 0.000 description 104
- 238000010828 elution Methods 0.000 description 101
- 238000004128 high performance liquid chromatography Methods 0.000 description 100
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 91
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 83
- 239000012074 organic phase Substances 0.000 description 76
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 75
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 70
- 239000011541 reaction mixture Substances 0.000 description 66
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 54
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 44
- OYRRZWATULMEPF-UHFFFAOYSA-N pyrimidin-4-amine Chemical compound NC1=CC=NC=N1 OYRRZWATULMEPF-UHFFFAOYSA-N 0.000 description 44
- 239000000706 filtrate Substances 0.000 description 42
- 239000002904 solvent Substances 0.000 description 38
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 36
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 36
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 36
- 206010057190 Respiratory tract infections Diseases 0.000 description 36
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 36
- 239000012044 organic layer Substances 0.000 description 34
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 34
- 239000011734 sodium Substances 0.000 description 34
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 33
- 229910052708 sodium Inorganic materials 0.000 description 33
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 32
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 32
- 239000000543 intermediate Substances 0.000 description 29
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 29
- 239000012299 nitrogen atmosphere Substances 0.000 description 27
- 239000013078 crystal Substances 0.000 description 25
- 239000007821 HATU Substances 0.000 description 23
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 23
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 23
- 239000002585 base Substances 0.000 description 22
- 238000001816 cooling Methods 0.000 description 22
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 21
- 238000001035 drying Methods 0.000 description 21
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 21
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 20
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 20
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 18
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 18
- 229910000029 sodium carbonate Inorganic materials 0.000 description 18
- SGCLBIRCSTXTIU-UHFFFAOYSA-N boric acid;2,3-dimethylbutane-2,3-diol Chemical compound OB(O)O.CC(C)(O)C(C)(C)O.CC(C)(O)C(C)(C)O SGCLBIRCSTXTIU-UHFFFAOYSA-N 0.000 description 17
- 239000003054 catalyst Substances 0.000 description 17
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 17
- 235000019341 magnesium sulphate Nutrition 0.000 description 17
- 235000011056 potassium acetate Nutrition 0.000 description 17
- 229910000027 potassium carbonate Inorganic materials 0.000 description 17
- LHCPRYRLDOSKHK-UHFFFAOYSA-N 7-deaza-8-aza-adenine Chemical compound NC1=NC=NC2=C1C=NN2 LHCPRYRLDOSKHK-UHFFFAOYSA-N 0.000 description 16
- 239000003208 petroleum Substances 0.000 description 15
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 14
- MRQYTJXVULSNIS-UHFFFAOYSA-N 4-bromo-3-fluorophenol Chemical compound OC1=CC=C(Br)C(F)=C1 MRQYTJXVULSNIS-UHFFFAOYSA-N 0.000 description 14
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 13
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 12
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- 230000009471 action Effects 0.000 description 12
- NXQGGXCHGDYOHB-UHFFFAOYSA-L cyclopenta-1,4-dien-1-yl(diphenyl)phosphane;dichloropalladium;iron(2+) Chemical compound [Fe+2].Cl[Pd]Cl.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 NXQGGXCHGDYOHB-UHFFFAOYSA-L 0.000 description 12
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 12
- JJBLUWAYDKGBCI-SNVBAGLBSA-N FC1=C(C=CC(=C1)OC1=C(C(=CC(=C1F)F)F)F)C1=NN(C=C1)[C@H]1CNCC1 Chemical compound FC1=C(C=CC(=C1)OC1=C(C(=CC(=C1F)F)F)F)C1=NN(C=C1)[C@H]1CNCC1 JJBLUWAYDKGBCI-SNVBAGLBSA-N 0.000 description 11
- 239000012267 brine Substances 0.000 description 11
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 10
- 239000008346 aqueous phase Substances 0.000 description 10
- 239000007788 liquid Substances 0.000 description 10
- 229910000160 potassium phosphate Inorganic materials 0.000 description 10
- 235000011009 potassium phosphates Nutrition 0.000 description 10
- 239000000047 product Substances 0.000 description 10
- HQAIUXZORKJOJY-UHFFFAOYSA-N 3-iodo-2h-pyrazolo[3,4-d]pyrimidin-4-amine Chemical class NC1=NC=NC2=NNC(I)=C12 HQAIUXZORKJOJY-UHFFFAOYSA-N 0.000 description 9
- 229940124291 BTK inhibitor Drugs 0.000 description 9
- 238000000926 separation method Methods 0.000 description 9
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 9
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 8
- FQUUMFIWAKWSHE-UHFFFAOYSA-N FC1=C(C=CC(=C1)OC1=C(C(=CC(=C1F)F)F)F)C1=NNC2=NC=NC(=C21)N Chemical compound FC1=C(C=CC(=C1)OC1=C(C(=CC(=C1F)F)F)F)C1=NNC2=NC=NC(=C21)N FQUUMFIWAKWSHE-UHFFFAOYSA-N 0.000 description 8
- 239000003795 chemical substances by application Substances 0.000 description 8
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 8
- 239000000284 extract Substances 0.000 description 8
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 7
- 238000006069 Suzuki reaction reaction Methods 0.000 description 7
- LPQZERIRKRYGGM-UHFFFAOYSA-N tert-butyl pyrrolidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCCC1 LPQZERIRKRYGGM-UHFFFAOYSA-N 0.000 description 7
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 6
- 0 CC(C)(C)OC(NC1CC(*)CCC1)=O Chemical compound CC(C)(C)OC(NC1CC(*)CCC1)=O 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 6
- HFBMWMNUJJDEQZ-UHFFFAOYSA-N acryloyl chloride Chemical compound ClC(=O)C=C HFBMWMNUJJDEQZ-UHFFFAOYSA-N 0.000 description 6
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 6
- 229910000024 caesium carbonate Inorganic materials 0.000 description 6
- 125000004432 carbon atom Chemical group C* 0.000 description 6
- 238000009826 distribution Methods 0.000 description 6
- 239000012065 filter cake Substances 0.000 description 6
- 238000001990 intravenous administration Methods 0.000 description 6
- 229910052763 palladium Inorganic materials 0.000 description 6
- VSHBABSXFHFTJN-UHFFFAOYSA-N 4-methoxymorpholine Chemical compound CON1CCOCC1 VSHBABSXFHFTJN-UHFFFAOYSA-N 0.000 description 5
- IJTRDKIJERPSJB-UHFFFAOYSA-N FC1=C(C=CC(=C1)OC1=C(C(=CC(=C1F)F)F)F)B1OC(C(O1)(C)C)(C)C Chemical compound FC1=C(C=CC(=C1)OC1=C(C(=CC(=C1F)F)F)F)B1OC(C(O1)(C)C)(C)C IJTRDKIJERPSJB-UHFFFAOYSA-N 0.000 description 5
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 5
- 230000002378 acidificating effect Effects 0.000 description 5
- 235000019270 ammonium chloride Nutrition 0.000 description 5
- 239000007864 aqueous solution Substances 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 description 5
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 5
- 239000003480 eluent Substances 0.000 description 5
- AIGRXSNSLVJMEA-FQEVSTJZSA-N ethoxy-(4-nitrophenoxy)-phenyl-sulfanylidene-$l^{5}-phosphane Chemical compound O([P@@](=S)(OCC)C=1C=CC=CC=1)C1=CC=C([N+]([O-])=O)C=C1 AIGRXSNSLVJMEA-FQEVSTJZSA-N 0.000 description 5
- 150000002430 hydrocarbons Chemical class 0.000 description 5
- 125000004430 oxygen atom Chemical group O* 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 238000010992 reflux Methods 0.000 description 5
- 238000010898 silica gel chromatography Methods 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- YQXAEBHPCJZKKX-UHFFFAOYSA-N tert-butyl 3-(4-amino-3-iodopyrazolo[3,4-d]pyrimidin-1-yl)piperidine-1-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CCCC1N1C2=NC=NC(N)=C2C(I)=N1 YQXAEBHPCJZKKX-UHFFFAOYSA-N 0.000 description 5
- DNSTUAQHBFISRZ-UHFFFAOYSA-N tert-butyl n-cyclohexylcarbamate Chemical compound CC(C)(C)OC(=O)NC1CCCCC1 DNSTUAQHBFISRZ-UHFFFAOYSA-N 0.000 description 5
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 4
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 4
- MQFIHRROHKUBAJ-UHFFFAOYSA-N 2-[3-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy]pyrimidine Chemical compound FC=1C=C(OC2=NC=CC=N2)C=CC=1B1OC(C(O1)(C)C)(C)C MQFIHRROHKUBAJ-UHFFFAOYSA-N 0.000 description 4
- ASYQJYIEVNXWDV-UHFFFAOYSA-N 3-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenol Chemical compound O1C(C)(C)C(C)(C)OB1C1=CC=C(O)C=C1F ASYQJYIEVNXWDV-UHFFFAOYSA-N 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 4
- XYIDFJBTTYNSTH-UHFFFAOYSA-N BrC1=C(C=C(C=C1)OC1=CC(=CC=C1)F)F Chemical compound BrC1=C(C=C(C=C1)OC1=CC(=CC=C1)F)F XYIDFJBTTYNSTH-UHFFFAOYSA-N 0.000 description 4
- ZLLQKWPZXMMWSC-UHFFFAOYSA-N BrC1=C(C=C(OC=2C(=C(C=C(C=2F)F)F)F)C=C1)F Chemical compound BrC1=C(C=C(OC=2C(=C(C=C(C=2F)F)F)F)C=C1)F ZLLQKWPZXMMWSC-UHFFFAOYSA-N 0.000 description 4
- RGSFGYAAUTVSQA-UHFFFAOYSA-N Cyclopentane Chemical compound C1CCCC1 RGSFGYAAUTVSQA-UHFFFAOYSA-N 0.000 description 4
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 4
- 108091000080 Phosphotransferase Proteins 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 125000001246 bromo group Chemical group Br* 0.000 description 4
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 4
- 239000012039 electrophile Substances 0.000 description 4
- PQVSTLUFSYVLTO-UHFFFAOYSA-N ethyl n-ethoxycarbonylcarbamate Chemical compound CCOC(=O)NC(=O)OCC PQVSTLUFSYVLTO-UHFFFAOYSA-N 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 238000004108 freeze drying Methods 0.000 description 4
- 239000005457 ice water Substances 0.000 description 4
- GLXDVVHUTZTUQK-UHFFFAOYSA-M lithium hydroxide monohydrate Substances [Li+].O.[OH-] GLXDVVHUTZTUQK-UHFFFAOYSA-M 0.000 description 4
- 229940040692 lithium hydroxide monohydrate Drugs 0.000 description 4
- 239000002808 molecular sieve Substances 0.000 description 4
- 102000020233 phosphotransferase Human genes 0.000 description 4
- 230000011664 signaling Effects 0.000 description 4
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 4
- WBHQBSYUUJJSRZ-UHFFFAOYSA-M sodium bisulfate Chemical class [Na+].OS([O-])(=O)=O WBHQBSYUUJJSRZ-UHFFFAOYSA-M 0.000 description 4
- 239000007858 starting material Substances 0.000 description 4
- BOYYWVBZUOVEAW-UHFFFAOYSA-N tert-butyl 3-(4-amino-3-iodopyrazolo[3,4-d]pyrimidin-1-yl)pyrrolidine-1-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CCC1N1C2=NC=NC(N)=C2C(I)=N1 BOYYWVBZUOVEAW-UHFFFAOYSA-N 0.000 description 4
- KWQRKOSMSFLBTJ-UHFFFAOYSA-N tert-butyl 3-methylsulfonyloxypyrrolidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC(OS(C)(=O)=O)C1 KWQRKOSMSFLBTJ-UHFFFAOYSA-N 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- GNDGYPMBTCLMAG-UHFFFAOYSA-N 1-chloro-2-fluoro-4-(3-fluorophenoxy)benzene Chemical compound ClC1=C(C=C(C=C1)OC1=CC(=CC=C1)F)F GNDGYPMBTCLMAG-UHFFFAOYSA-N 0.000 description 3
- QQTYSVBNINDZAH-UHFFFAOYSA-N 2-(4-bromo-3-fluorophenoxy)-4-(trifluoromethyl)pyrimidine Chemical compound C1=C(Br)C(F)=CC(OC=2N=C(C=CN=2)C(F)(F)F)=C1 QQTYSVBNINDZAH-UHFFFAOYSA-N 0.000 description 3
- SJXDLODYPLUKOQ-UHFFFAOYSA-N 2-(4-bromo-3-fluorophenoxy)aniline Chemical compound NC1=CC=CC=C1OC1=CC=C(Br)C(F)=C1 SJXDLODYPLUKOQ-UHFFFAOYSA-N 0.000 description 3
- JHUUPUMBZGWODW-UHFFFAOYSA-N 3,6-dihydro-1,2-dioxine Chemical compound C1OOCC=C1 JHUUPUMBZGWODW-UHFFFAOYSA-N 0.000 description 3
- PEJXLJWULXYPGR-UHFFFAOYSA-N 3-(4-bromo-3-fluorophenoxy)aniline Chemical compound NC1=CC=CC(OC=2C=C(F)C(Br)=CC=2)=C1 PEJXLJWULXYPGR-UHFFFAOYSA-N 0.000 description 3
- AEPGKSJJNYNJNV-UHFFFAOYSA-N 4-(4-bromo-3-fluorophenoxy)quinoline Chemical compound C1=C(Br)C(F)=CC(OC=2C3=CC=CC=C3N=CC=2)=C1 AEPGKSJJNYNJNV-UHFFFAOYSA-N 0.000 description 3
- NLHHRLWOUZZQLW-UHFFFAOYSA-N Acrylonitrile Chemical compound C=CC#N NLHHRLWOUZZQLW-UHFFFAOYSA-N 0.000 description 3
- KDSOSMPIPIFGSV-UHFFFAOYSA-N CS(=O)(=O)NC1=C(C=CC=C1)OC1=CC(=C(C=C1)C1=NN(C2=NC=NC(=C21)N)C1CN(CCC1)C(C=C)=O)F Chemical compound CS(=O)(=O)NC1=C(C=CC=C1)OC1=CC(=C(C=C1)C1=NN(C2=NC=NC(=C21)N)C1CN(CCC1)C(C=C)=O)F KDSOSMPIPIFGSV-UHFFFAOYSA-N 0.000 description 3
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 3
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 3
- ABQSWBNSLHYNTG-IUCAKERBSA-N NC1=C2C(=NC=N1)N(N=C2I)[C@@H]1C[C@H](CC1)NC(OC(C)(C)C)=O Chemical compound NC1=C2C(=NC=N1)N(N=C2I)[C@@H]1C[C@H](CC1)NC(OC(C)(C)C)=O ABQSWBNSLHYNTG-IUCAKERBSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- AJDUFGPZEKPRSU-UHFFFAOYSA-N [4-[(2-methylpropan-2-yl)oxycarbonylamino]cyclohexyl] methanesulfonate Chemical compound CC(C)(C)OC(=O)NC1CCC(OS(C)(=O)=O)CC1 AJDUFGPZEKPRSU-UHFFFAOYSA-N 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 125000000304 alkynyl group Chemical group 0.000 description 3
- 125000003710 aryl alkyl group Chemical group 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 3
- LDHQCZJRKDOVOX-NSCUHMNNSA-M crotonate Chemical compound C\C=C\C([O-])=O LDHQCZJRKDOVOX-NSCUHMNNSA-M 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- NKUGJYBGZTYNFY-ONEGZZNKSA-N ethyl (e)-4-aminobut-2-enoate Chemical compound CCOC(=O)\C=C\CN NKUGJYBGZTYNFY-ONEGZZNKSA-N 0.000 description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
- 238000001704 evaporation Methods 0.000 description 3
- 230000008020 evaporation Effects 0.000 description 3
- 125000005842 heteroatom Chemical group 0.000 description 3
- 229930195733 hydrocarbon Natural products 0.000 description 3
- 150000002576 ketones Chemical class 0.000 description 3
- 238000010172 mouse model Methods 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 125000004483 piperidin-3-yl group Chemical group N1CC(CCC1)* 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 3
- 239000008247 solid mixture Substances 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- OJCLHERKFHHUTB-UHFFFAOYSA-N tert-butyl 3-(hydroxymethyl)piperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCCC(CO)C1 OJCLHERKFHHUTB-UHFFFAOYSA-N 0.000 description 3
- SGEDEVOGLGQLOL-UHFFFAOYSA-N tert-butyl 3-[4-amino-3-(2-fluoro-4-hydroxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carboxylate Chemical compound NC1=C2C(=NC=N1)N(N=C2C1=C(C=C(C=C1)O)F)C1CN(CCC1)C(=O)OC(C)(C)C SGEDEVOGLGQLOL-UHFFFAOYSA-N 0.000 description 3
- IUKYKMHCKDLTJC-UHFFFAOYSA-N tert-butyl n-(3-hydroxycyclohexyl)carbamate Chemical compound CC(C)(C)OC(=O)NC1CCCC(O)C1 IUKYKMHCKDLTJC-UHFFFAOYSA-N 0.000 description 3
- SBUKINULYZANSP-JGVFFNPUSA-N tert-butyl n-[(1s,3r)-3-hydroxycyclopentyl]carbamate Chemical compound CC(C)(C)OC(=O)N[C@H]1CC[C@@H](O)C1 SBUKINULYZANSP-JGVFFNPUSA-N 0.000 description 3
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 3
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 description 2
- REPVLJRCJUVQFA-UHFFFAOYSA-N (-)-isopinocampheol Natural products C1C(O)C(C)C2C(C)(C)C1C2 REPVLJRCJUVQFA-UHFFFAOYSA-N 0.000 description 2
- CYPYTURSJDMMMP-WVCUSYJESA-N (1e,4e)-1,5-diphenylpenta-1,4-dien-3-one;palladium Chemical compound [Pd].[Pd].C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 CYPYTURSJDMMMP-WVCUSYJESA-N 0.000 description 2
- RSHZDTWHCMHLHF-UHFFFAOYSA-N (3-fluorophenyl)-[3-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]methanone Chemical compound FC=1C=C(C=CC=1B1OC(C(O1)(C)C)(C)C)C(=O)C1=CC(=CC=C1)F RSHZDTWHCMHLHF-UHFFFAOYSA-N 0.000 description 2
- QAOSHDKNJBXWMW-UHFFFAOYSA-N (4-bromo-2-fluorophenyl)-(3-fluorophenyl)methanol Chemical compound C=1C=C(Br)C=C(F)C=1C(O)C1=CC=CC(F)=C1 QAOSHDKNJBXWMW-UHFFFAOYSA-N 0.000 description 2
- BCCLQSKLEHLWFT-UHFFFAOYSA-N (4-bromo-3-fluorophenyl)-(3-fluorophenyl)methanol Chemical compound C=1C=C(Br)C(F)=CC=1C(O)C1=CC=CC(F)=C1 BCCLQSKLEHLWFT-UHFFFAOYSA-N 0.000 description 2
- MEDCHSTVMVCNDS-UHFFFAOYSA-N (4-bromo-3-fluorophenyl)-(4-fluorophenyl)methanol Chemical compound C=1C=C(Br)C(F)=CC=1C(O)C1=CC=C(F)C=C1 MEDCHSTVMVCNDS-UHFFFAOYSA-N 0.000 description 2
- VOXJTGROUOLJQQ-UHFFFAOYSA-N (4-bromo-3-fluorophenyl)-(4-fluorophenyl)methanone Chemical compound C1=CC(F)=CC=C1C(=O)C1=CC=C(Br)C(F)=C1 VOXJTGROUOLJQQ-UHFFFAOYSA-N 0.000 description 2
- GNOMFHVRFMTFKG-UHFFFAOYSA-N (4-chloro-3-fluorophenyl)-(2-fluorophenyl)methanol Chemical compound C=1C=CC=C(F)C=1C(O)C1=CC=C(Cl)C(F)=C1 GNOMFHVRFMTFKG-UHFFFAOYSA-N 0.000 description 2
- SPOAWBWHMLBNRC-UHFFFAOYSA-N (4-chloro-3-fluorophenyl)-(2-fluorophenyl)methanone Chemical compound ClC1=C(C=C(C=C1)C(=O)C1=C(C=CC=C1)F)F SPOAWBWHMLBNRC-UHFFFAOYSA-N 0.000 description 2
- POAWTYXNXPEWCO-OWOJBTEDSA-N (e)-3-bromoprop-2-enoic acid Chemical compound OC(=O)\C=C\Br POAWTYXNXPEWCO-OWOJBTEDSA-N 0.000 description 2
- DFQUBYCHLQAFOW-NSCUHMNNSA-N (e)-4-(methylamino)-4-oxobut-2-enoic acid Chemical compound CNC(=O)\C=C\C(O)=O DFQUBYCHLQAFOW-NSCUHMNNSA-N 0.000 description 2
- NTPBBGZZMNNOPS-ARJAWSKDSA-N (z)-2-methoxycarbonylbut-2-enoic acid Chemical compound COC(=O)C(=C/C)\C(O)=O NTPBBGZZMNNOPS-ARJAWSKDSA-N 0.000 description 2
- AWMHCJOHTQSFEM-CYBMUJFWSA-N 1-[(3R)-3-[4-amino-3-(2-fluoro-4-pyrimidin-2-yloxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]pyrrolidin-1-yl]prop-2-en-1-one Chemical compound NC1=C2C(=NC=N1)N(N=C2C1=C(C=C(C=C1)OC1=NC=CC=N1)F)[C@H]1CN(CC1)C(C=C)=O AWMHCJOHTQSFEM-CYBMUJFWSA-N 0.000 description 2
- ILRQCUZBUKSCTQ-MRXNPFEDSA-N 1-[(3R)-3-[4-amino-3-(2-fluoro-4-quinolin-4-yloxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]pyrrolidin-1-yl]prop-2-en-1-one Chemical compound NC1=C2C(=NC=N1)N(N=C2C1=C(C=C(C=C1)OC1=CC=NC2=CC=CC=C12)F)[C@H]1CN(CC1)C(C=C)=O ILRQCUZBUKSCTQ-MRXNPFEDSA-N 0.000 description 2
- WHGUIUXSXFHVKI-LLVKDONJSA-N 1-[(3R)-3-[4-amino-3-[2-fluoro-4-(2,3,5,6-tetrafluorophenoxy)phenyl]pyrazolo[3,4-d]pyrimidin-1-yl]piperidin-1-yl]-2-chloroethanone Chemical compound NC1=C2C(=NC=N1)N(N=C2C1=C(C=C(C=C1)OC1=C(C(=CC(=C1F)F)F)F)F)[C@H]1CN(CCC1)C(CCl)=O WHGUIUXSXFHVKI-LLVKDONJSA-N 0.000 description 2
- AJHLLCZFNHLQLO-VUUHIHSGSA-N 1-[(3R)-3-[4-amino-3-[2-fluoro-4-(2,3,5,6-tetrafluorophenoxy)phenyl]pyrazolo[3,4-d]pyrimidin-1-yl]pyrrolidin-1-yl]-2-chloro-3-hydroxypropan-1-one Chemical compound C1CN(C[C@@H]1N2C3=NC=NC(=C3C(=N2)C4=C(C=C(C=C4)OC5=C(C(=CC(=C5F)F)F)F)F)N)C(=O)C(CO)Cl AJHLLCZFNHLQLO-VUUHIHSGSA-N 0.000 description 2
- GRZBCMDRAWWUQR-GFCCVEGCSA-N 1-[(3R)-3-[4-amino-3-[2-fluoro-4-(2,3,5,6-tetrafluorophenoxy)phenyl]pyrazolo[3,4-d]pyrimidin-1-yl]pyrrolidin-1-yl]-2-cyclopropylethane-1,2-dione Chemical compound NC1=C2C(=NC=N1)N(N=C2C1=C(C=C(C=C1)OC1=C(C(=CC(=C1F)F)F)F)F)[C@H]1CN(CC1)C(C(=O)C1CC1)=O GRZBCMDRAWWUQR-GFCCVEGCSA-N 0.000 description 2
- ZJDIFXCDJKKPIO-LLVKDONJSA-N 1-[(3R)-3-[4-amino-3-[2-fluoro-4-(2,3,5,6-tetrafluorophenoxy)phenyl]pyrazolo[3,4-d]pyrimidin-1-yl]pyrrolidin-1-yl]prop-2-en-1-one Chemical compound NC1=C2C(=NC=N1)N(N=C2C1=C(C=C(C=C1)OC1=C(C(=CC(=C1F)F)F)F)F)[C@H]1CN(CC1)C(C=C)=O ZJDIFXCDJKKPIO-LLVKDONJSA-N 0.000 description 2
- DFLMYGVQULGUFP-OAHLLOKOSA-N 1-[(3R)-3-[4-amino-3-[2-fluoro-4-(2-fluorobenzoyl)phenyl]pyrazolo[3,4-d]pyrimidin-1-yl]pyrrolidin-1-yl]prop-2-en-1-one Chemical compound NC1=C2C(=NC=N1)N(N=C2C1=C(C=C(C=C1)C(C1=C(C=CC=C1)F)=O)F)[C@H]1CN(CC1)C(C=C)=O DFLMYGVQULGUFP-OAHLLOKOSA-N 0.000 description 2
- YXCASHOKXLKEPI-QGZVFWFLSA-N 1-[(3R)-3-[4-amino-3-[2-fluoro-4-(3-fluorobenzoyl)phenyl]pyrazolo[3,4-d]pyrimidin-1-yl]pyrrolidin-1-yl]prop-2-en-1-one Chemical compound NC1=C2C(=NC=N1)N(N=C2C1=C(C=C(C=C1)C(C1=CC(=CC=C1)F)=O)F)[C@H]1CN(CC1)C(C=C)=O YXCASHOKXLKEPI-QGZVFWFLSA-N 0.000 description 2
- QLRDEQPODCORHJ-OAHLLOKOSA-N 1-[(3R)-3-[4-amino-3-[2-fluoro-4-(3-fluorophenoxy)phenyl]pyrazolo[3,4-d]pyrimidin-1-yl]pyrrolidin-1-yl]prop-2-en-1-one Chemical compound NC1=C2C(=NC=N1)N(N=C2C1=C(C=C(C=C1)OC1=CC(=CC=C1)F)F)[C@H]1CN(CC1)C(C=C)=O QLRDEQPODCORHJ-OAHLLOKOSA-N 0.000 description 2
- FFOHOVHHZFRBMX-QGZVFWFLSA-N 1-[(3R)-3-[4-amino-3-[2-fluoro-4-(4-fluorobenzoyl)phenyl]pyrazolo[3,4-d]pyrimidin-1-yl]pyrrolidin-1-yl]prop-2-en-1-one Chemical compound NC1=C2C(=NC=N1)N(N=C2C1=C(C=C(C=C1)C(C1=CC=C(C=C1)F)=O)F)[C@H]1CN(CC1)C(C=C)=O FFOHOVHHZFRBMX-QGZVFWFLSA-N 0.000 description 2
- GAYKBAKKYIPRJE-GFCCVEGCSA-N 1-[(3R)-3-[4-amino-3-[2-fluoro-4-[4-(trifluoromethyl)pyrimidin-2-yl]oxyphenyl]pyrazolo[3,4-d]pyrimidin-1-yl]pyrrolidin-1-yl]prop-2-en-1-one Chemical compound NC1=C2C(=NC=N1)N(N=C2C1=C(C=C(C=C1)OC1=NC=CC(=N1)C(F)(F)F)F)[C@H]1CN(CC1)C(C=C)=O GAYKBAKKYIPRJE-GFCCVEGCSA-N 0.000 description 2
- KTKFBYRSEASFRE-GFCCVEGCSA-N 1-[(3R)-3-[4-amino-3-[4-(4-chloropyrimidin-2-yl)oxy-2-fluorophenyl]pyrazolo[3,4-d]pyrimidin-1-yl]pyrrolidin-1-yl]prop-2-en-1-one Chemical compound NC1=C2C(=NC=N1)N(N=C2C1=C(C=C(C=C1)OC1=NC=CC(=N1)Cl)F)[C@H]1CN(CC1)C(C=C)=O KTKFBYRSEASFRE-GFCCVEGCSA-N 0.000 description 2
- GYEXYRHFFMTVPV-MRXNPFEDSA-N 1-[(3R)-3-[4-amino-3-[4-(6,7-dimethoxyquinolin-4-yl)oxy-2-fluorophenyl]pyrazolo[3,4-d]pyrimidin-1-yl]pyrrolidin-1-yl]prop-2-en-1-one Chemical compound NC1=C2C(=NC=N1)N(N=C2C1=C(C=C(C=C1)OC1=CC=NC2=CC(=C(C=C12)OC)OC)F)[C@H]1CN(CC1)C(C=C)=O GYEXYRHFFMTVPV-MRXNPFEDSA-N 0.000 description 2
- QWYODRZDSFZAHJ-UHFFFAOYSA-N 1-bromo-2-fluoro-4-(2-nitrophenoxy)benzene Chemical compound [O-][N+](=O)C1=CC=CC=C1OC1=CC=C(Br)C(F)=C1 QWYODRZDSFZAHJ-UHFFFAOYSA-N 0.000 description 2
- QDFKKJYEIFBEFC-UHFFFAOYSA-N 1-bromo-3-fluorobenzene Chemical compound FC1=CC=CC(Br)=C1 QDFKKJYEIFBEFC-UHFFFAOYSA-N 0.000 description 2
- APXRHPDHORGIEB-UHFFFAOYSA-N 1H-pyrazolo[4,3-d]pyrimidine Chemical class N1=CN=C2C=NNC2=C1 APXRHPDHORGIEB-UHFFFAOYSA-N 0.000 description 2
- UPJQEJVEXRVVMO-UHFFFAOYSA-N 1h-pyrazolo[3,4-d]pyrimidin-4-amine;hydrochloride Chemical compound Cl.NC1=NC=NC2=C1C=NN2 UPJQEJVEXRVVMO-UHFFFAOYSA-N 0.000 description 2
- ASWDGFAXDKSWGX-UHFFFAOYSA-N 2-(4-bromo-3-fluorophenoxy)pyrimidine Chemical compound C1=C(Br)C(F)=CC(OC=2N=CC=CN=2)=C1 ASWDGFAXDKSWGX-UHFFFAOYSA-N 0.000 description 2
- AAMTXHVZOHPPQR-UHFFFAOYSA-N 2-(hydroxymethyl)prop-2-enoic acid Chemical compound OCC(=C)C(O)=O AAMTXHVZOHPPQR-UHFFFAOYSA-N 0.000 description 2
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 2
- LCSYJVAKMPOJIB-UHFFFAOYSA-N 2-cyclopropyl-2-oxoacetic acid Chemical compound OC(=O)C(=O)C1CC1 LCSYJVAKMPOJIB-UHFFFAOYSA-N 0.000 description 2
- ZWDVQMVZZYIAHO-UHFFFAOYSA-N 2-fluorobenzaldehyde Chemical compound FC1=CC=CC=C1C=O ZWDVQMVZZYIAHO-UHFFFAOYSA-N 0.000 description 2
- OBCPRNLQEXYSBI-UHFFFAOYSA-N 3-(nitromethyl)cyclopentan-1-ol Chemical compound OC1CCC(C[N+]([O-])=O)C1 OBCPRNLQEXYSBI-UHFFFAOYSA-N 0.000 description 2
- ZZKYUIXZEQLWAH-UHFFFAOYSA-N 3-[methyl-[(2-methylpropan-2-yl)oxycarbonyl]amino]propyl methanesulfonate Chemical compound CC(C)(C)OC(=O)N(C)CCCOS(C)(=O)=O ZZKYUIXZEQLWAH-UHFFFAOYSA-N 0.000 description 2
- INUNLMUAPJVRME-UHFFFAOYSA-N 3-chloropropanoyl chloride Chemical compound ClCCC(Cl)=O INUNLMUAPJVRME-UHFFFAOYSA-N 0.000 description 2
- LGAJCZJGBNGDFR-UHFFFAOYSA-N 3-cyclopropyl-3-oxopropanoic acid Chemical compound OC(=O)CC(=O)C1CC1 LGAJCZJGBNGDFR-UHFFFAOYSA-N 0.000 description 2
- YFCMXJOXMRIMRK-UHFFFAOYSA-N 3-iodo-1-(2-trimethylsilylethoxymethyl)pyrazolo[3,4-d]pyrimidin-4-amine Chemical compound N1=CN=C2N(COCC[Si](C)(C)C)N=C(I)C2=C1N YFCMXJOXMRIMRK-UHFFFAOYSA-N 0.000 description 2
- PSMQUBSTPVXJNK-UHFFFAOYSA-N 4-(4-bromo-3-fluorophenoxy)-n-methylpyridine-2-carboxamide Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=C(F)C(Br)=CC=2)=C1 PSMQUBSTPVXJNK-UHFFFAOYSA-N 0.000 description 2
- HQEZKTZQGSTCFM-GFCCVEGCSA-N 4-[[(3R)-3-[4-amino-3-[2-fluoro-4-(2,3,5,6-tetrafluorophenoxy)phenyl]pyrazolo[3,4-d]pyrimidin-1-yl]pyrrolidine-1-carbonyl]amino]but-2-enoic acid Chemical compound NC1=C2C(=NC=N1)N(N=C2C1=C(C=C(C=C1)OC1=C(C(=CC(=C1F)F)F)F)F)[C@H]1CN(CC1)C(=O)NCC=CC(=O)O HQEZKTZQGSTCFM-GFCCVEGCSA-N 0.000 description 2
- SWHUROFMIMHWKS-UHFFFAOYSA-N 4-bromo-3-fluorobenzaldehyde Chemical compound FC1=CC(C=O)=CC=C1Br SWHUROFMIMHWKS-UHFFFAOYSA-N 0.000 description 2
- XLHYAEBESNFTCA-UHFFFAOYSA-N 4-chloro-3-fluorophenol Chemical compound OC1=CC=C(Cl)C(F)=C1 XLHYAEBESNFTCA-UHFFFAOYSA-N 0.000 description 2
- JVVRCYWZTJLJSG-UHFFFAOYSA-N 4-dimethylaminophenol Chemical compound CN(C)C1=CC=C(O)C=C1 JVVRCYWZTJLJSG-UHFFFAOYSA-N 0.000 description 2
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 2
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-dimethylaminopyridine Substances CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
- OTLNPYWUJOZPPA-UHFFFAOYSA-N 4-nitrobenzoic acid Chemical compound OC(=O)C1=CC=C([N+]([O-])=O)C=C1 OTLNPYWUJOZPPA-UHFFFAOYSA-N 0.000 description 2
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 2
- 230000003844 B-cell-activation Effects 0.000 description 2
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 2
- WIPWKQLTPNUMEL-UHFFFAOYSA-N BrC1=C(C=C(C=C1)C(=O)C1=CC(=CC=C1)F)F Chemical compound BrC1=C(C=C(C=C1)C(=O)C1=CC(=CC=C1)F)F WIPWKQLTPNUMEL-UHFFFAOYSA-N 0.000 description 2
- HSEHEJIVJZWPKJ-UHFFFAOYSA-N BrC1=C(C=C(OC2=CC=NC3=CC(=C(C=C23)OC)OC)C=C1)F Chemical compound BrC1=C(C=C(OC2=CC=NC3=CC(=C(C=C23)OC)OC)C=C1)F HSEHEJIVJZWPKJ-UHFFFAOYSA-N 0.000 description 2
- QGSKPWXMFPOAHK-UHFFFAOYSA-N BrC1=CC(=C(C=C1)C(=O)C1=CC(=CC=C1)F)F Chemical compound BrC1=CC(=C(C=C1)C(=O)C1=CC(=CC=C1)F)F QGSKPWXMFPOAHK-UHFFFAOYSA-N 0.000 description 2
- GCHWHHJMCOKFSL-UHFFFAOYSA-N CC(C)(C)OC(=O)NC1CCC(CC1)n1nc(I)c2c(N)ncnc12 Chemical compound CC(C)(C)OC(=O)NC1CCC(CC1)n1nc(I)c2c(N)ncnc12 GCHWHHJMCOKFSL-UHFFFAOYSA-N 0.000 description 2
- GXOACOVBBHBHHG-UHFFFAOYSA-N CC(C)(C)OC(N(C)CCCS(O)(=O)=O)=O Chemical compound CC(C)(C)OC(N(C)CCCS(O)(=O)=O)=O GXOACOVBBHBHHG-UHFFFAOYSA-N 0.000 description 2
- HUTZJNUJLUQXGI-UHFFFAOYSA-N CS(=O)(=O)NC1=CC(=CC=C1)OC1=CC(=C(C=C1)C1=NN(C2=NC=NC(=C21)N)C1CN(CCC1)C(C=C)=O)F Chemical compound CS(=O)(=O)NC1=CC(=CC=C1)OC1=CC(=C(C=C1)C1=NN(C2=NC=NC(=C21)N)C1CN(CCC1)C(C=C)=O)F HUTZJNUJLUQXGI-UHFFFAOYSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- VGCXGMAHQTYDJK-UHFFFAOYSA-N Chloroacetyl chloride Chemical compound ClCC(Cl)=O VGCXGMAHQTYDJK-UHFFFAOYSA-N 0.000 description 2
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
- JSTIGGRXJRRDIW-UHFFFAOYSA-N FC1=C(C=CC(=C1)OC1=C(C(=CC(=C1F)F)F)F)C1=NN(C2=NC=NC(=C21)N)COCC[Si](C)(C)C Chemical compound FC1=C(C=CC(=C1)OC1=C(C(=CC(=C1F)F)F)F)C1=NN(C2=NC=NC(=C21)N)COCC[Si](C)(C)C JSTIGGRXJRRDIW-UHFFFAOYSA-N 0.000 description 2
- PWGLFZDMILGXKB-UHFFFAOYSA-N FC=1C=C(C=CC=1B1OC(C(O1)(C)C)(C)C)C(=O)C1=C(C=CC=C1)F Chemical compound FC=1C=C(C=CC=1B1OC(C(O1)(C)C)(C)C)C(=O)C1=C(C=CC=C1)F PWGLFZDMILGXKB-UHFFFAOYSA-N 0.000 description 2
- NJRYDHJLUGIXRH-UHFFFAOYSA-N FC=1C=C(C=CC=1B1OC(C(O1)(C)C)(C)C)C(=O)C1=CC=C(C=C1)F Chemical compound FC=1C=C(C=CC=1B1OC(C(O1)(C)C)(C)C)C(=O)C1=CC=C(C=C1)F NJRYDHJLUGIXRH-UHFFFAOYSA-N 0.000 description 2
- QPLBJLJNKCFHRM-UHFFFAOYSA-N FC=1C=C(OC2=CC(=CC=C2)[N+](=O)[O-])C=CC=1Br Chemical compound FC=1C=C(OC2=CC(=CC=C2)[N+](=O)[O-])C=CC=1Br QPLBJLJNKCFHRM-UHFFFAOYSA-N 0.000 description 2
- FEBFOOKMYBJXEE-UHFFFAOYSA-N FC=1C=C(OC2=CC=NC3=CC(=C(C=C23)OC)OC)C=CC=1B1OC(C(O1)(C)C)(C)C Chemical compound FC=1C=C(OC2=CC=NC3=CC(=C(C=C23)OC)OC)C=CC=1B1OC(C(O1)(C)C)(C)C FEBFOOKMYBJXEE-UHFFFAOYSA-N 0.000 description 2
- MPMNKBVSPLDVKC-UHFFFAOYSA-N FC=1C=C(OC2=CC=NC3=CC=CC=C23)C=CC=1B1OC(C(O1)(C)C)(C)C Chemical compound FC=1C=C(OC2=CC=NC3=CC=CC=C23)C=CC=1B1OC(C(O1)(C)C)(C)C MPMNKBVSPLDVKC-UHFFFAOYSA-N 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 2
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 229910010082 LiAlH Inorganic materials 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- YJRKHEFMLZKNPP-UHFFFAOYSA-N NC1=C2C(=NC=N1)N(N=C2C1=C(C=C(C=C1)C(=O)C1=CC(=CC=C1)F)F)C1CNCCC1 Chemical compound NC1=C2C(=NC=N1)N(N=C2C1=C(C=C(C=C1)C(=O)C1=CC(=CC=C1)F)F)C1CNCCC1 YJRKHEFMLZKNPP-UHFFFAOYSA-N 0.000 description 2
- FPHSUTLFEIHELO-UHFFFAOYSA-N NC1=C2C(=NC=N1)N(N=C2C1=C(C=C(C=C1)C(C1=CC(=CC=C1)F)=O)F)C1CN(CCC1)C(=O)C=1C=NOC=1C Chemical compound NC1=C2C(=NC=N1)N(N=C2C1=C(C=C(C=C1)C(C1=CC(=CC=C1)F)=O)F)C1CN(CCC1)C(=O)C=1C=NOC=1C FPHSUTLFEIHELO-UHFFFAOYSA-N 0.000 description 2
- SOZGNAMCSJWJFO-UHFFFAOYSA-N NC1=C2C(=NC=N1)N(N=C2C1=C(C=C(C=C1)OC1=C(C(=CC(=C1F)F)F)F)F)C1CC(CCC1)N1C(C=CC1=O)=O Chemical compound NC1=C2C(=NC=N1)N(N=C2C1=C(C=C(C=C1)OC1=C(C(=CC(=C1F)F)F)F)F)C1CC(CCC1)N1C(C=CC1=O)=O SOZGNAMCSJWJFO-UHFFFAOYSA-N 0.000 description 2
- FRORLEGKKRFHPO-UHFFFAOYSA-N NC1=C2C(=NC=N1)N(N=C2C1=C(C=C(C=C1)OC1=C(C(=CC(=C1F)F)F)F)F)C1CCC(CC1)N1C(C=CC1=O)=O Chemical compound NC1=C2C(=NC=N1)N(N=C2C1=C(C=C(C=C1)OC1=C(C(=CC(=C1F)F)F)F)F)C1CCC(CC1)N1C(C=CC1=O)=O FRORLEGKKRFHPO-UHFFFAOYSA-N 0.000 description 2
- FIOZLOJLGUZXDB-UHFFFAOYSA-N NC1=C2C(=NC=N1)N(N=C2C1=C(C=C(C=C1)OC1=C(C(=CC(=C1F)F)F)F)F)C1CCC(CC1)N1C(SCC1=O)=O Chemical compound NC1=C2C(=NC=N1)N(N=C2C1=C(C=C(C=C1)OC1=C(C(=CC(=C1F)F)F)F)F)C1CCC(CC1)N1C(SCC1=O)=O FIOZLOJLGUZXDB-UHFFFAOYSA-N 0.000 description 2
- ZJDIFXCDJKKPIO-UHFFFAOYSA-N NC1=C2C(=NC=N1)N(N=C2C1=C(C=C(C=C1)OC1=C(C(=CC(=C1F)F)F)F)F)C1CN(CC1)C(C=C)=O Chemical compound NC1=C2C(=NC=N1)N(N=C2C1=C(C=C(C=C1)OC1=C(C(=CC(=C1F)F)F)F)F)C1CN(CC1)C(C=C)=O ZJDIFXCDJKKPIO-UHFFFAOYSA-N 0.000 description 2
- YDQWYCHLLYYKOA-UHFFFAOYSA-N NC1=C2C(=NC=N1)N(N=C2C1=C(C=C(C=C1)OC1=C(C(=CC(=C1F)F)F)F)F)C1CN(CCC1)C(=O)C=1N=CNC=1 Chemical compound NC1=C2C(=NC=N1)N(N=C2C1=C(C=C(C=C1)OC1=C(C(=CC(=C1F)F)F)F)F)C1CN(CCC1)C(=O)C=1N=CNC=1 YDQWYCHLLYYKOA-UHFFFAOYSA-N 0.000 description 2
- DKIJJRXDTUFLCH-UHFFFAOYSA-N NC1=C2C(=NC=N1)N(N=C2C1=C(C=C(C=C1)OC1=C(C(=CC(=C1F)F)F)F)F)C1CN(CCC1)C(=O)NC Chemical compound NC1=C2C(=NC=N1)N(N=C2C1=C(C=C(C=C1)OC1=C(C(=CC(=C1F)F)F)F)F)C1CN(CCC1)C(=O)NC DKIJJRXDTUFLCH-UHFFFAOYSA-N 0.000 description 2
- IHORBLRUJDRPPM-UHFFFAOYSA-N NC1=C2C(=NC=N1)N(N=C2C1=C(C=C(C=C1)OC1=C(C(=CC(=C1F)F)F)F)F)C1CN(CCC1)C(C(=C)C(F)(F)F)=O Chemical compound NC1=C2C(=NC=N1)N(N=C2C1=C(C=C(C=C1)OC1=C(C(=CC(=C1F)F)F)F)F)C1CN(CCC1)C(C(=C)C(F)(F)F)=O IHORBLRUJDRPPM-UHFFFAOYSA-N 0.000 description 2
- MPBXLFGPYMCWQO-UHFFFAOYSA-N NC1=C2C(=NC=N1)N(N=C2C1=C(C=C(C=C1)OC1=C(C(=CC(=C1F)F)F)F)F)C1CN(CCC1)C(CC(=O)C1CC1)=O Chemical compound NC1=C2C(=NC=N1)N(N=C2C1=C(C=C(C=C1)OC1=C(C(=CC(=C1F)F)F)F)F)C1CN(CCC1)C(CC(=O)C1CC1)=O MPBXLFGPYMCWQO-UHFFFAOYSA-N 0.000 description 2
- WHGUIUXSXFHVKI-UHFFFAOYSA-N NC1=C2C(=NC=N1)N(N=C2C1=C(C=C(C=C1)OC1=C(C(=CC(=C1F)F)F)F)F)C1CN(CCC1)C(CCl)=O Chemical compound NC1=C2C(=NC=N1)N(N=C2C1=C(C=C(C=C1)OC1=C(C(=CC(=C1F)F)F)F)F)C1CN(CCC1)C(CCl)=O WHGUIUXSXFHVKI-UHFFFAOYSA-N 0.000 description 2
- NAKJTMWTNBTCQK-UHFFFAOYSA-N NC1=C2C(=NC=N1)N(N=C2C1=C(C=C(C=C1)OC1=C(C(=CC(=C1F)F)F)F)F)C1CN(CCC1)C(CN(C)C)=O Chemical compound NC1=C2C(=NC=N1)N(N=C2C1=C(C=C(C=C1)OC1=C(C(=CC(=C1F)F)F)F)F)C1CN(CCC1)C(CN(C)C)=O NAKJTMWTNBTCQK-UHFFFAOYSA-N 0.000 description 2
- TXMQMAQGUKGZAJ-UHFFFAOYSA-N NC1=C2C(=NC=N1)N(N=C2C1=C(C=C(C=C1)OC1=C(C(=CC(=C1F)F)F)F)F)CCCN(C(OC(C)(C)C)=O)C Chemical compound NC1=C2C(=NC=N1)N(N=C2C1=C(C=C(C=C1)OC1=C(C(=CC(=C1F)F)F)F)F)CCCN(C(OC(C)(C)C)=O)C TXMQMAQGUKGZAJ-UHFFFAOYSA-N 0.000 description 2
- SBCFMQPCESGCEN-UHFFFAOYSA-N NC1=C2C(=NC=N1)N(N=C2C1=C(C=C(C=C1)OC1=C(C(=CC(=C1F)F)F)F)F)CCNC(C=C)=O Chemical compound NC1=C2C(=NC=N1)N(N=C2C1=C(C=C(C=C1)OC1=C(C(=CC(=C1F)F)F)F)F)CCNC(C=C)=O SBCFMQPCESGCEN-UHFFFAOYSA-N 0.000 description 2
- ZLAMFBIVDGSLFO-JTQLQIEISA-N NC1=C2C(=NC=N1)N(N=C2C1=C(C=C(C=C1)OC1=C(C(=CC(=C1F)F)F)F)F)[C@@H]1CN(CCC1)C(C(Cl)Cl)=O Chemical compound NC1=C2C(=NC=N1)N(N=C2C1=C(C=C(C=C1)OC1=C(C(=CC(=C1F)F)F)F)F)[C@@H]1CN(CCC1)C(C(Cl)Cl)=O ZLAMFBIVDGSLFO-JTQLQIEISA-N 0.000 description 2
- WHGUIUXSXFHVKI-NSHDSACASA-N NC1=C2C(=NC=N1)N(N=C2C1=C(C=C(C=C1)OC1=C(C(=CC(=C1F)F)F)F)F)[C@@H]1CN(CCC1)C(CCl)=O Chemical compound NC1=C2C(=NC=N1)N(N=C2C1=C(C=C(C=C1)OC1=C(C(=CC(=C1F)F)F)F)F)[C@@H]1CN(CCC1)C(CCl)=O WHGUIUXSXFHVKI-NSHDSACASA-N 0.000 description 2
- OSTQABQZDFNFGW-SNVBAGLBSA-N NC1=C2C(=NC=N1)N(N=C2C1=C(C=C(C=C1)OC1=C(C(=CC(=C1F)F)F)F)F)[C@H]1CN(CC1)C(C#N)=O Chemical compound NC1=C2C(=NC=N1)N(N=C2C1=C(C=C(C=C1)OC1=C(C(=CC(=C1F)F)F)F)F)[C@H]1CN(CC1)C(C#N)=O OSTQABQZDFNFGW-SNVBAGLBSA-N 0.000 description 2
- ZLAMFBIVDGSLFO-SNVBAGLBSA-N NC1=C2C(=NC=N1)N(N=C2C1=C(C=C(C=C1)OC1=C(C(=CC(=C1F)F)F)F)F)[C@H]1CN(CCC1)C(C(Cl)Cl)=O Chemical compound NC1=C2C(=NC=N1)N(N=C2C1=C(C=C(C=C1)OC1=C(C(=CC(=C1F)F)F)F)F)[C@H]1CN(CCC1)C(C(Cl)Cl)=O ZLAMFBIVDGSLFO-SNVBAGLBSA-N 0.000 description 2
- HPTHOKBXRSRFBL-UHFFFAOYSA-N NC1=C2C(=NC=N1)N(N=C2C1=C(C=C(C=C1)OC1=C(C(=CC=C1)F)[N+](=O)[O-])F)C1CN(CCC1)C(C=C)=O Chemical compound NC1=C2C(=NC=N1)N(N=C2C1=C(C=C(C=C1)OC1=C(C(=CC=C1)F)[N+](=O)[O-])F)C1CN(CCC1)C(C=C)=O HPTHOKBXRSRFBL-UHFFFAOYSA-N 0.000 description 2
- JVUHLWXVBKBJNJ-UHFFFAOYSA-N NC1=C2C(=NC=N1)N(N=C2C1=C(C=C(C=C1)OC1=C(C=CC=C1)[N+](=O)[O-])F)C1CN(CCC1)C(=O)OC(C)(C)C Chemical compound NC1=C2C(=NC=N1)N(N=C2C1=C(C=C(C=C1)OC1=C(C=CC=C1)[N+](=O)[O-])F)C1CN(CCC1)C(=O)OC(C)(C)C JVUHLWXVBKBJNJ-UHFFFAOYSA-N 0.000 description 2
- CTFXOUXSBGMYTJ-UHFFFAOYSA-N NC1=C2C(=NC=N1)N(N=C2I)C1CN(CCC1)C(C=C)=O Chemical compound NC1=C2C(=NC=N1)N(N=C2I)C1CN(CCC1)C(C=C)=O CTFXOUXSBGMYTJ-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- 102000001253 Protein Kinase Human genes 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 2
- 229960000583 acetic acid Drugs 0.000 description 2
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 125000006615 aromatic heterocyclic group Chemical group 0.000 description 2
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 2
- 125000002393 azetidinyl group Chemical group 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 125000002619 bicyclic group Chemical group 0.000 description 2
- 238000004166 bioassay Methods 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- UORVGPXVDQYIDP-UHFFFAOYSA-N borane Chemical compound B UORVGPXVDQYIDP-UHFFFAOYSA-N 0.000 description 2
- 229940116229 borneol Drugs 0.000 description 2
- CKDOCTFBFTVPSN-UHFFFAOYSA-N borneol Natural products C1CC2(C)C(C)CC1C2(C)C CKDOCTFBFTVPSN-UHFFFAOYSA-N 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 229960004562 carboplatin Drugs 0.000 description 2
- 230000003197 catalytic effect Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 125000001309 chloro group Chemical group Cl* 0.000 description 2
- MVPPADPHJFYWMZ-UHFFFAOYSA-N chlorobenzene Chemical compound ClC1=CC=CC=C1 MVPPADPHJFYWMZ-UHFFFAOYSA-N 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 229910052802 copper Inorganic materials 0.000 description 2
- 239000010949 copper Substances 0.000 description 2
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 2
- 229960000975 daunorubicin Drugs 0.000 description 2
- JXTHNDFMNIQAHM-UHFFFAOYSA-N dichloroacetic acid Chemical compound OC(=O)C(Cl)Cl JXTHNDFMNIQAHM-UHFFFAOYSA-N 0.000 description 2
- FBCCMZVIWNDFMO-UHFFFAOYSA-N dichloroacetyl chloride Chemical compound ClC(Cl)C(Cl)=O FBCCMZVIWNDFMO-UHFFFAOYSA-N 0.000 description 2
- FAMRKDQNMBBFBR-BQYQJAHWSA-N diethyl azodicarboxylate Substances CCOC(=O)\N=N\C(=O)OCC FAMRKDQNMBBFBR-BQYQJAHWSA-N 0.000 description 2
- 125000005050 dihydrooxazolyl group Chemical group O1C(NC=C1)* 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- DTGKSKDOIYIVQL-UHFFFAOYSA-N dl-isoborneol Natural products C1CC2(C)C(O)CC1C2(C)C DTGKSKDOIYIVQL-UHFFFAOYSA-N 0.000 description 2
- VGJWAMLZUUGEQY-UHFFFAOYSA-N ethyl 3-oxocyclopentane-1-carboxylate Chemical compound CCOC(=O)C1CCC(=O)C1 VGJWAMLZUUGEQY-UHFFFAOYSA-N 0.000 description 2
- FAMRKDQNMBBFBR-UHFFFAOYSA-N ethyl n-ethoxycarbonyliminocarbamate Chemical compound CCOC(=O)N=NC(=O)OCC FAMRKDQNMBBFBR-UHFFFAOYSA-N 0.000 description 2
- RWTNPBWLLIMQHL-UHFFFAOYSA-N fexofenadine Chemical compound C1=CC(C(C)(C(O)=O)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 RWTNPBWLLIMQHL-UHFFFAOYSA-N 0.000 description 2
- ZBHDTYQJAQDBIH-UHFFFAOYSA-N fluoroacetyl chloride Chemical compound FCC(Cl)=O ZBHDTYQJAQDBIH-UHFFFAOYSA-N 0.000 description 2
- 125000002541 furyl group Chemical group 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- DMEGYFMYUHOHGS-UHFFFAOYSA-N heptamethylene Natural products C1CCCCCC1 DMEGYFMYUHOHGS-UHFFFAOYSA-N 0.000 description 2
- 238000000589 high-performance liquid chromatography-mass spectrometry Methods 0.000 description 2
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 2
- 229960001101 ifosfamide Drugs 0.000 description 2
- 239000003701 inert diluent Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 238000004811 liquid chromatography Methods 0.000 description 2
- 239000007791 liquid phase Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- DTKMKZYEOXZPQZ-UHFFFAOYSA-M magnesium;fluorobenzene;bromide Chemical compound [Mg+2].[Br-].FC1=CC=C[C-]=C1 DTKMKZYEOXZPQZ-UHFFFAOYSA-M 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- MJGFBOZCAJSGQW-UHFFFAOYSA-N mercury sodium Chemical compound [Na].[Hg] MJGFBOZCAJSGQW-UHFFFAOYSA-N 0.000 description 2
- 229960000485 methotrexate Drugs 0.000 description 2
- YQFHPXZGXNYYLD-UHFFFAOYSA-N n-methyl-1-methylsulfanyl-2-nitroethenamine Chemical compound CNC(SC)=C[N+]([O-])=O YQFHPXZGXNYYLD-UHFFFAOYSA-N 0.000 description 2
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 2
- 125000002971 oxazolyl group Chemical group 0.000 description 2
- KJIFKLIQANRMOU-UHFFFAOYSA-N oxidanium;4-methylbenzenesulfonate Chemical compound O.CC1=CC=C(S(O)(=O)=O)C=C1 KJIFKLIQANRMOU-UHFFFAOYSA-N 0.000 description 2
- PIBWKRNGBLPSSY-UHFFFAOYSA-L palladium(II) chloride Chemical compound Cl[Pd]Cl PIBWKRNGBLPSSY-UHFFFAOYSA-L 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 150000002989 phenols Chemical class 0.000 description 2
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 125000004193 piperazinyl group Chemical group 0.000 description 2
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 2
- 230000036470 plasma concentration Effects 0.000 description 2
- 125000003367 polycyclic group Chemical group 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- UORVCLMRJXCDCP-UHFFFAOYSA-N propynoic acid Chemical compound OC(=O)C#C UORVCLMRJXCDCP-UHFFFAOYSA-N 0.000 description 2
- 108060006633 protein kinase Proteins 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 125000003373 pyrazinyl group Chemical group 0.000 description 2
- 125000003226 pyrazolyl group Chemical group 0.000 description 2
- GRJJQCWNZGRKAU-UHFFFAOYSA-N pyridin-1-ium;fluoride Chemical compound F.C1=CC=NC=C1 GRJJQCWNZGRKAU-UHFFFAOYSA-N 0.000 description 2
- 125000004076 pyridyl group Chemical group 0.000 description 2
- VSYIXNFGKAGJKY-UHFFFAOYSA-N pyrrolidin-3-ylmethanesulfonic acid Chemical compound OS(=O)(=O)CC1CCNC1 VSYIXNFGKAGJKY-UHFFFAOYSA-N 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 229960004641 rituximab Drugs 0.000 description 2
- 238000002390 rotary evaporation Methods 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- SQGYOTSLMSWVJD-UHFFFAOYSA-N silver(1+) nitrate Chemical compound [Ag+].[O-]N(=O)=O SQGYOTSLMSWVJD-UHFFFAOYSA-N 0.000 description 2
- XGVXKJKTISMIOW-ZDUSSCGKSA-N simurosertib Chemical compound N1N=CC(C=2SC=3C(=O)NC(=NC=3C=2)[C@H]2N3CCC(CC3)C2)=C1C XGVXKJKTISMIOW-ZDUSSCGKSA-N 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 239000012279 sodium borohydride Substances 0.000 description 2
- 229910000033 sodium borohydride Inorganic materials 0.000 description 2
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 125000004434 sulfur atom Chemical group 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000010189 synthetic method Methods 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- HKIGXXRMJFUUKV-UHFFFAOYSA-N tert-butyl 3-(hydroxymethyl)pyrrolidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC(CO)C1 HKIGXXRMJFUUKV-UHFFFAOYSA-N 0.000 description 2
- NEZJCDLNARUJSX-UHFFFAOYSA-N tert-butyl 3-(methylsulfonyloxymethyl)piperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCCC(COS(C)(=O)=O)C1 NEZJCDLNARUJSX-UHFFFAOYSA-N 0.000 description 2
- XFRHYGNZDGDQST-UHFFFAOYSA-N tert-butyl 3-(methylsulfonyloxymethyl)pyrrolidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC(COS(C)(=O)=O)C1 XFRHYGNZDGDQST-UHFFFAOYSA-N 0.000 description 2
- APCBTRDHCDOPNY-UHFFFAOYSA-N tert-butyl 3-hydroxypyrrolidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC(O)C1 APCBTRDHCDOPNY-UHFFFAOYSA-N 0.000 description 2
- WLAZHMYDLUILKR-UHFFFAOYSA-N tert-butyl 3-methylsulfonyloxypiperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCCC(OS(C)(=O)=O)C1 WLAZHMYDLUILKR-UHFFFAOYSA-N 0.000 description 2
- CTEDVGRUGMPBHE-UHFFFAOYSA-N tert-butyl 4-(hydroxymethyl)piperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC(CO)CC1 CTEDVGRUGMPBHE-UHFFFAOYSA-N 0.000 description 2
- RXNQBVRCZIYUJK-UHFFFAOYSA-N tert-butyl 4-(methylsulfonyloxymethyl)piperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC(COS(C)(=O)=O)CC1 RXNQBVRCZIYUJK-UHFFFAOYSA-N 0.000 description 2
- RFDSJHHLGFFVHD-UHFFFAOYSA-N tert-butyl n-(2-hydroxyethyl)-n-methylcarbamate Chemical compound OCCN(C)C(=O)OC(C)(C)C RFDSJHHLGFFVHD-UHFFFAOYSA-N 0.000 description 2
- YNJCFDAODGKHAV-UHFFFAOYSA-N tert-butyl n-(2-hydroxypropyl)carbamate Chemical compound CC(O)CNC(=O)OC(C)(C)C YNJCFDAODGKHAV-UHFFFAOYSA-N 0.000 description 2
- DQARDWKWPIRJEH-UHFFFAOYSA-N tert-butyl n-(4-hydroxycyclohexyl)carbamate Chemical compound CC(C)(C)OC(=O)NC1CCC(O)CC1 DQARDWKWPIRJEH-UHFFFAOYSA-N 0.000 description 2
- SBUKINULYZANSP-YUMQZZPRSA-N tert-butyl n-[(1s,3s)-3-hydroxycyclopentyl]carbamate Chemical compound CC(C)(C)OC(=O)N[C@H]1CC[C@H](O)C1 SBUKINULYZANSP-YUMQZZPRSA-N 0.000 description 2
- UWWUTEZECIYOCW-SFYZADRCSA-N tert-butyl n-[(1s,4r)-4-hydroxycyclopent-2-en-1-yl]carbamate Chemical compound CC(C)(C)OC(=O)N[C@H]1C[C@@H](O)C=C1 UWWUTEZECIYOCW-SFYZADRCSA-N 0.000 description 2
- RQCNHUCCQJMSRG-UHFFFAOYSA-N tert-butyl piperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCCCC1 RQCNHUCCQJMSRG-UHFFFAOYSA-N 0.000 description 2
- 125000000335 thiazolyl group Chemical group 0.000 description 2
- 125000003396 thiol group Chemical class [H]S* 0.000 description 2
- 229960003048 vinblastine Drugs 0.000 description 2
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 2
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 2
- 229960004528 vincristine Drugs 0.000 description 2
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- UGOMMVLRQDMAQQ-UHFFFAOYSA-N xphos Chemical compound CC(C)C1=CC(C(C)C)=CC(C(C)C)=C1C1=CC=CC=C1P(C1CCCCC1)C1CCCCC1 UGOMMVLRQDMAQQ-UHFFFAOYSA-N 0.000 description 2
- VCGRFBXVSFAGGA-UHFFFAOYSA-N (1,1-dioxo-1,4-thiazinan-4-yl)-[6-[[3-(4-fluorophenyl)-5-methyl-1,2-oxazol-4-yl]methoxy]pyridin-3-yl]methanone Chemical compound CC=1ON=C(C=2C=CC(F)=CC=2)C=1COC(N=C1)=CC=C1C(=O)N1CCS(=O)(=O)CC1 VCGRFBXVSFAGGA-UHFFFAOYSA-N 0.000 description 1
- PBZPXQABJBFPGH-UHFFFAOYSA-N (1-prop-2-enoylpyrrolidin-3-yl)methanesulfonic acid Chemical compound C=CC(=O)N1CCC(C1)CS(=O)(=O)O PBZPXQABJBFPGH-UHFFFAOYSA-N 0.000 description 1
- KNXQDJCZSVHEIW-UHFFFAOYSA-N (3-fluorophenyl)boronic acid Chemical compound OB(O)C1=CC=CC(F)=C1 KNXQDJCZSVHEIW-UHFFFAOYSA-N 0.000 description 1
- NXLNNXIXOYSCMB-UHFFFAOYSA-N (4-nitrophenyl) carbonochloridate Chemical compound [O-][N+](=O)C1=CC=C(OC(Cl)=O)C=C1 NXLNNXIXOYSCMB-UHFFFAOYSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- IOUDZAFBPDDAMK-AATRIKPKSA-N (e)-3-(2-fluorophenyl)prop-2-enoic acid Chemical compound OC(=O)\C=C\C1=CC=CC=C1F IOUDZAFBPDDAMK-AATRIKPKSA-N 0.000 description 1
- FSQQTNAZHBEJLS-OWOJBTEDSA-N (e)-4-amino-4-oxobut-2-enoic acid Chemical compound NC(=O)\C=C\C(O)=O FSQQTNAZHBEJLS-OWOJBTEDSA-N 0.000 description 1
- RJUIDDKTATZJFE-NSCUHMNNSA-N (e)-but-2-enoyl chloride Chemical compound C\C=C\C(Cl)=O RJUIDDKTATZJFE-NSCUHMNNSA-N 0.000 description 1
- NXGHEDHQXXXTTP-UHFFFAOYSA-N 1,1-bis(methylsulfanyl)-2-nitroethene Chemical compound CSC(SC)=C[N+]([O-])=O NXGHEDHQXXXTTP-UHFFFAOYSA-N 0.000 description 1
- VKPJOERCBNIOLN-UHFFFAOYSA-N 1,3-benzoxazole-2-carboxylic acid Chemical compound C1=CC=C2OC(C(=O)O)=NC2=C1 VKPJOERCBNIOLN-UHFFFAOYSA-N 0.000 description 1
- SSNCMIDZGFCTST-UHFFFAOYSA-N 1,3-difluoro-2-nitrobenzene Chemical compound [O-][N+](=O)C1=C(F)C=CC=C1F SSNCMIDZGFCTST-UHFFFAOYSA-N 0.000 description 1
- CQHYICHMGNSGQH-UHFFFAOYSA-N 1,3-oxazole-2-carboxylic acid Chemical compound OC(=O)C1=NC=CO1 CQHYICHMGNSGQH-UHFFFAOYSA-N 0.000 description 1
- NOLHRFLIXVQPSZ-UHFFFAOYSA-N 1,3-thiazolidin-4-one Chemical compound O=C1CSCN1 NOLHRFLIXVQPSZ-UHFFFAOYSA-N 0.000 description 1
- FEALJKFIUQDJAV-UHFFFAOYSA-N 1-(aminomethyl)cyclopentan-1-ol Chemical compound NCC1(O)CCCC1 FEALJKFIUQDJAV-UHFFFAOYSA-N 0.000 description 1
- TUSDEZXZIZRFGC-UHFFFAOYSA-N 1-O-galloyl-3,6-(R)-HHDP-beta-D-glucose Natural products OC1C(O2)COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC1C(O)C2OC(=O)C1=CC(O)=C(O)C(O)=C1 TUSDEZXZIZRFGC-UHFFFAOYSA-N 0.000 description 1
- DNUTZBZXLPWRJG-UHFFFAOYSA-N 1-Piperidine carboxylic acid Chemical compound OC(=O)N1CCCCC1 DNUTZBZXLPWRJG-UHFFFAOYSA-N 0.000 description 1
- NXILIHONWRXHFA-UHFFFAOYSA-N 1-[(2-methylpropan-2-yl)oxycarbonyl]piperidine-3-carboxylic acid Chemical compound CC(C)(C)OC(=O)N1CCCC(C(O)=O)C1 NXILIHONWRXHFA-UHFFFAOYSA-N 0.000 description 1
- HRMRQBJUFWFQLX-UHFFFAOYSA-N 1-[(2-methylpropan-2-yl)oxycarbonyl]pyrrolidine-3-carboxylic acid Chemical compound CC(C)(C)OC(=O)N1CCC(C(O)=O)C1 HRMRQBJUFWFQLX-UHFFFAOYSA-N 0.000 description 1
- PCJBOSNRZZIZKH-UHFFFAOYSA-N 1-[(2-methylpropan-2-yl)oxycarbonylamino]propan-2-yl methanesulfonate Chemical compound CS(=O)(=O)OC(C)CNC(=O)OC(C)(C)C PCJBOSNRZZIZKH-UHFFFAOYSA-N 0.000 description 1
- OQRIMQHWVDPNPW-SNVBAGLBSA-N 1-[(3R)-3-[4-amino-3-[2-fluoro-4-(2,3,5,6-tetrafluorophenoxy)phenyl]pyrazolo[3,4-d]pyrimidin-1-yl]pyrrolidin-1-yl]-2-chloroethanone Chemical compound NC1=C2C(=NC=N1)N(N=C2C1=C(C=C(C=C1)OC1=C(C(=CC(=C1F)F)F)F)F)[C@H]1CN(CC1)C(CCl)=O OQRIMQHWVDPNPW-SNVBAGLBSA-N 0.000 description 1
- ZVKZGNUMVRJGIC-GFCCVEGCSA-N 1-[(3R)-3-[4-amino-3-[2-fluoro-4-(2,3,5,6-tetrafluorophenoxy)phenyl]pyrazolo[3,4-d]pyrimidin-1-yl]pyrrolidin-1-yl]-3-methylbutane-1,2-dione Chemical compound NC1=C2C(=NC=N1)N(N=C2C1=C(C=C(C=C1)OC1=C(C(=CC(=C1F)F)F)F)F)[C@H]1CN(CC1)C(C(C(C)C)=O)=O ZVKZGNUMVRJGIC-GFCCVEGCSA-N 0.000 description 1
- CMLIREXKQGESGP-GFCCVEGCSA-N 1-[(3R)-3-[4-amino-3-[2-fluoro-4-(2,3,5,6-tetrafluorophenoxy)phenyl]pyrazolo[3,4-d]pyrimidin-1-yl]pyrrolidin-1-yl]-4-hydroxy-3,3-dimethylbutane-1,2-dione Chemical compound NC1=C2C(=NC=N1)N(N=C2C1=C(C=C(C=C1)OC1=C(C(=CC(=C1F)F)F)F)F)[C@H]1CN(CC1)C(C(C(CO)(C)C)=O)=O CMLIREXKQGESGP-GFCCVEGCSA-N 0.000 description 1
- LVAAZZVRTJPKHJ-UHFFFAOYSA-N 1-[2-[4-amino-3-[2-fluoro-4-(2,3,5,6-tetrafluorophenoxy)phenyl]pyrazolo[3,4-d]pyrimidin-1-yl]propyl]pyrrole-2,5-dione Chemical compound NC1=C2C(=NC=N1)N(N=C2C1=C(C=C(C=C1)OC1=C(C(=CC(=C1F)F)F)F)F)C(CN1C(C=CC1=O)=O)C LVAAZZVRTJPKHJ-UHFFFAOYSA-N 0.000 description 1
- IPWBFGUBXWMIPR-UHFFFAOYSA-N 1-bromo-2-fluorobenzene Chemical group FC1=CC=CC=C1Br IPWBFGUBXWMIPR-UHFFFAOYSA-N 0.000 description 1
- VSKSBSORLCDRHS-UHFFFAOYSA-N 1-fluoro-3-iodobenzene Chemical compound FC1=CC=CC(I)=C1 VSKSBSORLCDRHS-UHFFFAOYSA-N 0.000 description 1
- WQXIFDPMJPHDPE-UHFFFAOYSA-N 1-fluoro-3-phenoxybenzene Chemical compound FC1=CC=CC(OC=2C=CC=CC=2)=C1 WQXIFDPMJPHDPE-UHFFFAOYSA-N 0.000 description 1
- VLSRKCIBHNJFHA-UHFFFAOYSA-N 2-(trifluoromethyl)prop-2-enoic acid Chemical compound OC(=O)C(=C)C(F)(F)F VLSRKCIBHNJFHA-UHFFFAOYSA-N 0.000 description 1
- REKOOGWEUQLFJX-LLVKDONJSA-N 2-[(3R)-3-[4-amino-3-[2-fluoro-4-(2,3,5,6-tetrafluorophenoxy)phenyl]pyrazolo[3,4-d]pyrimidin-1-yl]pyrrolidin-1-yl]acetonitrile Chemical compound NC1=C2C(=NC=N1)N(N=C2C1=C(C=C(C=C1)OC1=C(C(=CC(=C1F)F)F)F)F)[C@H]1CN(CC1)CC#N REKOOGWEUQLFJX-LLVKDONJSA-N 0.000 description 1
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- MYIFLDFUXIHOCJ-UHFFFAOYSA-N 2-amino-2-[2-[2-chloro-4-(3-phenylmethoxyphenyl)sulfanylphenyl]ethyl]propane-1,3-diol;hydrochloride Chemical compound Cl.C1=C(Cl)C(CCC(CO)(CO)N)=CC=C1SC1=CC=CC(OCC=2C=CC=CC=2)=C1 MYIFLDFUXIHOCJ-UHFFFAOYSA-N 0.000 description 1
- SORBEIKZIPTJRS-UHFFFAOYSA-N 2-chloro-2-hydroxyacetic acid Chemical compound OC(Cl)C(O)=O SORBEIKZIPTJRS-UHFFFAOYSA-N 0.000 description 1
- FZRBTBCCMVNZBD-UHFFFAOYSA-N 2-chloro-4-(trifluoromethyl)pyrimidine Chemical compound FC(F)(F)C1=CC=NC(Cl)=N1 FZRBTBCCMVNZBD-UHFFFAOYSA-N 0.000 description 1
- VHCSBTPOPKFYIU-UHFFFAOYSA-N 2-chloroethanesulfonyl chloride Chemical compound ClCCS(Cl)(=O)=O VHCSBTPOPKFYIU-UHFFFAOYSA-N 0.000 description 1
- UNCQVRBWJWWJBF-UHFFFAOYSA-N 2-chloropyrimidine Chemical compound ClC1=NC=CC=N1 UNCQVRBWJWWJBF-UHFFFAOYSA-N 0.000 description 1
- HRTOQFBQOFIFEE-UHFFFAOYSA-N 2-dehydropantolactone Chemical compound CC1(C)COC(=O)C1=O HRTOQFBQOFIFEE-UHFFFAOYSA-N 0.000 description 1
- TYCFGHUTYSLISP-UHFFFAOYSA-N 2-fluoroprop-2-enoic acid Chemical compound OC(=O)C(F)=C TYCFGHUTYSLISP-UHFFFAOYSA-N 0.000 description 1
- OXUCMXDWKATUHP-UHFFFAOYSA-N 3-(nitromethyl)cyclopentan-1-one Chemical compound [O-][N+](=O)CC1CCC(=O)C1 OXUCMXDWKATUHP-UHFFFAOYSA-N 0.000 description 1
- IWQHESBNCMOQOT-UHFFFAOYSA-N 3-[(2-methylpropan-2-yl)oxycarbonylamino]propyl methanesulfonate Chemical compound CC(C)(C)OC(=O)NCCCOS(C)(=O)=O IWQHESBNCMOQOT-UHFFFAOYSA-N 0.000 description 1
- CZROYMOYXKIYPS-GFCCVEGCSA-N 3-[(3R)-3-[4-amino-3-[2-fluoro-4-(2,3,5,6-tetrafluorophenoxy)phenyl]pyrazolo[3,4-d]pyrimidin-1-yl]pyrrolidin-1-yl]propanenitrile Chemical compound NC1=C2C(=NC=N1)N(N=C2C1=C(C=C(C=C1)OC1=C(C(=CC(=C1F)F)F)F)F)[C@H]1CN(CC1)CCC#N CZROYMOYXKIYPS-GFCCVEGCSA-N 0.000 description 1
- FERWBXLFSBWTDE-UHFFFAOYSA-N 3-aminobutan-2-ol Chemical compound CC(N)C(C)O FERWBXLFSBWTDE-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- PIKNVEVCWAAOMJ-UHFFFAOYSA-N 3-fluorobenzaldehyde Chemical compound FC1=CC=CC(C=O)=C1 PIKNVEVCWAAOMJ-UHFFFAOYSA-N 0.000 description 1
- SJTBRFHBXDZMPS-UHFFFAOYSA-N 3-fluorophenol Chemical class OC1=CC=CC(F)=C1 SJTBRFHBXDZMPS-UHFFFAOYSA-N 0.000 description 1
- XYBLNTXJBVNSIS-UHFFFAOYSA-N 3-iodo-1-piperidin-3-ylpyrazolo[3,4-d]pyrimidin-4-amine Chemical compound N1=C(I)C=2C(N)=NC=NC=2N1C1CCCNC1 XYBLNTXJBVNSIS-UHFFFAOYSA-N 0.000 description 1
- FJEUKVAAPDWCDX-UHFFFAOYSA-N 3-iodo-1-pyrrolidin-3-ylpyrazolo[3,4-d]pyrimidin-4-amine Chemical compound N1=C(I)C=2C(N)=NC=NC=2N1C1CCNC1 FJEUKVAAPDWCDX-UHFFFAOYSA-N 0.000 description 1
- QHKABHOOEWYVLI-UHFFFAOYSA-M 3-methyl-2-oxobutanoate Chemical compound CC(C)C(=O)C([O-])=O QHKABHOOEWYVLI-UHFFFAOYSA-M 0.000 description 1
- OJVOGABFNZDOOZ-UHFFFAOYSA-N 3-nitrobutan-2-ol Chemical compound CC(O)C(C)[N+]([O-])=O OJVOGABFNZDOOZ-UHFFFAOYSA-N 0.000 description 1
- VDFMOBLYAGSKGY-UHFFFAOYSA-N 3-oxocyclopentane-1-carbonyl chloride Chemical compound ClC(=O)C1CCC(=O)C1 VDFMOBLYAGSKGY-UHFFFAOYSA-N 0.000 description 1
- RDSNBKRWKBMPOP-UHFFFAOYSA-N 3-oxocyclopentanecarboxylic acid Chemical compound OC(=O)C1CCC(=O)C1 RDSNBKRWKBMPOP-UHFFFAOYSA-N 0.000 description 1
- LIQBKSIZAXKCPA-UHFFFAOYSA-N 4,4,4-trifluoro-3-oxobutanoic acid Chemical compound OC(=O)CC(=O)C(F)(F)F LIQBKSIZAXKCPA-UHFFFAOYSA-N 0.000 description 1
- NXVZJLQRBJXFBV-CQSZACIVSA-N 4-[4-[4-amino-1-[(3R)-1-prop-2-enoylpyrrolidin-3-yl]pyrazolo[3,4-d]pyrimidin-3-yl]-3-fluorophenoxy]-N-methylpyridine-2-carboxamide Chemical compound C(C=C)(=O)N1C[C@@H](CC1)N1N=C(C=2C1=NC=NC=2N)C1=C(C=C(OC2=CC(=NC=C2)C(=O)NC)C=C1)F NXVZJLQRBJXFBV-CQSZACIVSA-N 0.000 description 1
- KVCQTKNUUQOELD-UHFFFAOYSA-N 4-amino-n-[1-(3-chloro-2-fluoroanilino)-6-methylisoquinolin-5-yl]thieno[3,2-d]pyrimidine-7-carboxamide Chemical compound N=1C=CC2=C(NC(=O)C=3C4=NC=NC(N)=C4SC=3)C(C)=CC=C2C=1NC1=CC=CC(Cl)=C1F KVCQTKNUUQOELD-UHFFFAOYSA-N 0.000 description 1
- UPCARQPLANFGQJ-UHFFFAOYSA-N 4-bromo-2-fluorobenzaldehyde Chemical compound FC1=CC(Br)=CC=C1C=O UPCARQPLANFGQJ-UHFFFAOYSA-N 0.000 description 1
- BWVZLXTZQHILRC-UHFFFAOYSA-N 4-chloro-2-methylsulfonylpyrimidine Chemical compound CS(=O)(=O)C1=NC=CC(Cl)=N1 BWVZLXTZQHILRC-UHFFFAOYSA-N 0.000 description 1
- KNDOFJFSHZCKGT-UHFFFAOYSA-N 4-chloroquinoline Chemical compound C1=CC=C2C(Cl)=CC=NC2=C1 KNDOFJFSHZCKGT-UHFFFAOYSA-N 0.000 description 1
- JEDALECUOKHQDK-UHFFFAOYSA-M 4-ethyl-1-[(2-methylpropan-2-yl)oxycarbonyl]piperidine-4-carboxylate Chemical compound CCC1(C([O-])=O)CCN(C(=O)OC(C)(C)C)CC1 JEDALECUOKHQDK-UHFFFAOYSA-M 0.000 description 1
- UOQXIWFBQSVDPP-UHFFFAOYSA-N 4-fluorobenzaldehyde Chemical compound FC1=CC=C(C=O)C=C1 UOQXIWFBQSVDPP-UHFFFAOYSA-N 0.000 description 1
- BTGCUCXFTSSOMF-UHFFFAOYSA-N 5-[3-[4-amino-3-[2-fluoro-4-(2,3,5,6-tetrafluorophenoxy)phenyl]pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-5H-1,3-thiazol-2-one Chemical compound NC1=C2C(=NC=N1)N(N=C2C1=C(C=C(C=C1)OC1=C(C(=CC(=C1F)F)F)F)F)C1CN(CCC1)C(=O)C1C=NC(S1)=O BTGCUCXFTSSOMF-UHFFFAOYSA-N 0.000 description 1
- FEPIARIZKHXUQD-UHFFFAOYSA-N 5-methyl-1,2-oxazole-4-carbaldehyde Chemical compound CC=1ON=CC=1C=O FEPIARIZKHXUQD-UHFFFAOYSA-N 0.000 description 1
- HXFLZWAZSSPLCO-UHFFFAOYSA-N 6,6-dimethylbicyclo[3.1.1]heptyl Chemical group C1[C-]2C([CH2+])([CH2-])[C+]1CCC2 HXFLZWAZSSPLCO-UHFFFAOYSA-N 0.000 description 1
- CYJRNFFLTBEQSQ-UHFFFAOYSA-N 8-(3-methyl-1-benzothiophen-5-yl)-N-(4-methylsulfonylpyridin-3-yl)quinoxalin-6-amine Chemical compound CS(=O)(=O)C1=C(C=NC=C1)NC=1C=C2N=CC=NC2=C(C=1)C=1C=CC2=C(C(=CS2)C)C=1 CYJRNFFLTBEQSQ-UHFFFAOYSA-N 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- HGINCPLSRVDWNT-UHFFFAOYSA-N Acrolein Chemical compound C=CC=O HGINCPLSRVDWNT-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Natural products OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- NOWKCMXCCJGMRR-UHFFFAOYSA-N Aziridine Chemical compound C1CN1 NOWKCMXCCJGMRR-UHFFFAOYSA-N 0.000 description 1
- 102000019260 B-Cell Antigen Receptors Human genes 0.000 description 1
- 108010012919 B-Cell Antigen Receptors Proteins 0.000 description 1
- 101150030812 BTK gene Proteins 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 206010005949 Bone cancer Diseases 0.000 description 1
- 208000018084 Bone neoplasm Diseases 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- PBNLGTJHTIETDK-UHFFFAOYSA-N C1(=C(C(=C(C(=C1)F)F)OC1=CC(F)=C(C2=NN(C3=C2C(=NC=N3)N)C2CN(CCC2)/C(=N/C#N)/NC)C=C1)F)F Chemical compound C1(=C(C(=C(C(=C1)F)F)OC1=CC(F)=C(C2=NN(C3=C2C(=NC=N3)N)C2CN(CCC2)/C(=N/C#N)/NC)C=C1)F)F PBNLGTJHTIETDK-UHFFFAOYSA-N 0.000 description 1
- VIBAVECRLWHMEY-UHFFFAOYSA-N C=CC(N1CCC(C[n](c2c3c(N)ncn2)nc3-c(c(F)c2)ccc2Oc(c(F)c(cc2F)F)c2F)CC1)=O Chemical compound C=CC(N1CCC(C[n](c2c3c(N)ncn2)nc3-c(c(F)c2)ccc2Oc(c(F)c(cc2F)F)c2F)CC1)=O VIBAVECRLWHMEY-UHFFFAOYSA-N 0.000 description 1
- CBOKGKWGBAKBJL-UHFFFAOYSA-N C=CC(NCC(CC1)CC1[n](c1c2c(N)ncn1)nc2-c(ccc(Oc(c(F)c(cc1F)F)c1F)c1)c1F)=O Chemical compound C=CC(NCC(CC1)CC1[n](c1c2c(N)ncn1)nc2-c(ccc(Oc(c(F)c(cc1F)F)c1F)c1)c1F)=O CBOKGKWGBAKBJL-UHFFFAOYSA-N 0.000 description 1
- WMTSAYTXYUXQAN-BBBYJDLNSA-N C=CC(N[C@@H](CC1)CC1C1c(ncnc2N)c2C(c(ccc(Oc(c(F)c(cc2F)F)c2F)c2)c2F)=NCC1)=O Chemical compound C=CC(N[C@@H](CC1)CC1C1c(ncnc2N)c2C(c(ccc(Oc(c(F)c(cc2F)F)c2F)c2)c2F)=NCC1)=O WMTSAYTXYUXQAN-BBBYJDLNSA-N 0.000 description 1
- PVXPPTHCGJIXEK-UHFFFAOYSA-N CC(C(C)[n](c1c2c(N)ncn1)nc2-c(ccc(Oc(c(F)c(cc1F)F)c1F)c1)c1F)N Chemical compound CC(C(C)[n](c1c2c(N)ncn1)nc2-c(ccc(Oc(c(F)c(cc1F)F)c1F)c1)c1F)N PVXPPTHCGJIXEK-UHFFFAOYSA-N 0.000 description 1
- VVUCIHXYRQYTJA-UHFFFAOYSA-N CC(C)(C)OC(=O)NC1CCCC(C1)OS(C)(=O)=O Chemical compound CC(C)(C)OC(=O)NC1CCCC(C1)OS(C)(=O)=O VVUCIHXYRQYTJA-UHFFFAOYSA-N 0.000 description 1
- JXZDFBVTHIDQDB-BDAKNGLRSA-N CC(C)(C)OC(=O)N[C@@H]1CC[C@@H](C1)OS(C)(=O)=O Chemical compound CC(C)(C)OC(=O)N[C@@H]1CC[C@@H](C1)OS(C)(=O)=O JXZDFBVTHIDQDB-BDAKNGLRSA-N 0.000 description 1
- KUCOCJGZICVFFW-UHFFFAOYSA-N CC(C)(C)OC(NCC[n](c1ncnc(N)c11)nc1-c(c(F)c1)ccc1Oc(c(F)c(cc1F)F)c1F)=O Chemical compound CC(C)(C)OC(NCC[n](c1ncnc(N)c11)nc1-c(c(F)c1)ccc1Oc(c(F)c(cc1F)F)c1F)=O KUCOCJGZICVFFW-UHFFFAOYSA-N 0.000 description 1
- QAIUBMMLNIFVOJ-NSCUHMNNSA-N CNC(/C=C/CNC(N(CC1)CC1C1c(ncnc2N)c2C(c(ccc(Oc(c(F)c(cc2F)F)c2F)c2)c2F)=NCC1)=O)=O Chemical compound CNC(/C=C/CNC(N(CC1)CC1C1c(ncnc2N)c2C(c(ccc(Oc(c(F)c(cc2F)F)c2F)c2)c2F)=NCC1)=O)=O QAIUBMMLNIFVOJ-NSCUHMNNSA-N 0.000 description 1
- GBYQPOVJABSPDG-UHFFFAOYSA-N CNC(N(CCC1)CC1[n](c1c2c(N)ncn1)nc2-c(ccc(Oc(c(F)c(cc1F)F)c1F)c1)c1F)=N Chemical compound CNC(N(CCC1)CC1[n](c1c2c(N)ncn1)nc2-c(ccc(Oc(c(F)c(cc1F)F)c1F)c1)c1F)=N GBYQPOVJABSPDG-UHFFFAOYSA-N 0.000 description 1
- PTYRQHRBEAQGPU-UHFFFAOYSA-N COC1=C(CNC2CC(CC2)C(=O)OCC)C=CC(=C1)OC Chemical compound COC1=C(CNC2CC(CC2)C(=O)OCC)C=CC(=C1)OC PTYRQHRBEAQGPU-UHFFFAOYSA-N 0.000 description 1
- LSDJTWDXSMQOSZ-SYJJWHGVSA-N C[C@@H](C1CC(CCC2)CN2C(C=C)=O)N=C(c(c(F)c2)ccc2Oc(c(F)c(cc2F)F)c2F)c2c1ncnc2N Chemical compound C[C@@H](C1CC(CCC2)CN2C(C=C)=O)N=C(c(c(F)c2)ccc2Oc(c(F)c(cc2F)F)c2F)c2c1ncnc2N LSDJTWDXSMQOSZ-SYJJWHGVSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- QPLDLSVMHZLSFG-UHFFFAOYSA-N Copper oxide Chemical compound [Cu]=O QPLDLSVMHZLSFG-UHFFFAOYSA-N 0.000 description 1
- 239000005751 Copper oxide Substances 0.000 description 1
- 229910021591 Copper(I) chloride Inorganic materials 0.000 description 1
- 229910021595 Copper(I) iodide Inorganic materials 0.000 description 1
- 229930105110 Cyclosporin A Natural products 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- ZBNZXTGUTAYRHI-UHFFFAOYSA-N Dasatinib Chemical compound C=1C(N2CCN(CCO)CC2)=NC(C)=NC=1NC(S1)=NC=C1C(=O)NC1=C(C)C=CC=C1Cl ZBNZXTGUTAYRHI-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 206010014733 Endometrial cancer Diseases 0.000 description 1
- 206010014759 Endometrial neoplasm Diseases 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 description 1
- MZNAJZKKBNMPIG-UHFFFAOYSA-N FC(C(CC(=O)NC1=C2C(=NC=N1)N(N=C2C1=C(C=C(C=C1)OC1=C(C(=CC(=C1F)F)F)F)F)C1CNCCC1)=O)(F)F Chemical compound FC(C(CC(=O)NC1=C2C(=NC=N1)N(N=C2C1=C(C=C(C=C1)OC1=C(C(=CC(=C1F)F)F)F)F)C1CNCCC1)=O)(F)F MZNAJZKKBNMPIG-UHFFFAOYSA-N 0.000 description 1
- ZXBSTQHJFAWHNP-UHFFFAOYSA-N FC1=C(C=CC(=C1)B1OC(C(O1)(C)C)(C)C)C(=O)C1=CC(=CC=C1)F Chemical compound FC1=C(C=CC(=C1)B1OC(C(O1)(C)C)(C)C)C(=O)C1=CC(=CC=C1)F ZXBSTQHJFAWHNP-UHFFFAOYSA-N 0.000 description 1
- HFRNRRUILBXWSO-UHFFFAOYSA-N FC1=C(C=CC(=C1)OC1=C(C(=CC(=C1F)F)F)F)C1=NN(C2=NC=NC(=C21)N)CCCNC Chemical compound FC1=C(C=CC(=C1)OC1=C(C(=CC(=C1F)F)F)F)C1=NN(C2=NC=NC(=C21)N)CCCNC HFRNRRUILBXWSO-UHFFFAOYSA-N 0.000 description 1
- QKBXFLHSJNQHKV-LLVKDONJSA-N FC1=C(C=CC(=C1)OC1=C(C(=CC(=C1F)F)F)F)C1=NN(C2=NC=NC(=C21)N)[C@H]1CN(CC1)S(=O)(=O)C=C Chemical compound FC1=C(C=CC(=C1)OC1=C(C(=CC(=C1F)F)F)F)C1=NN(C2=NC=NC(=C21)N)[C@H]1CN(CC1)S(=O)(=O)C=C QKBXFLHSJNQHKV-LLVKDONJSA-N 0.000 description 1
- HTPAALTWOPODHT-UHFFFAOYSA-N FC1=C(C=CC(=C1)OC1=C(C(=CC=C1)F)[N+](=O)[O-])C1=NN(C2=NC=NC(=C21)N)C1CNCCC1 Chemical compound FC1=C(C=CC(=C1)OC1=C(C(=CC=C1)F)[N+](=O)[O-])C1=NN(C2=NC=NC(=C21)N)C1CNCCC1 HTPAALTWOPODHT-UHFFFAOYSA-N 0.000 description 1
- RPOHCYAYEXGFMK-UHFFFAOYSA-N FC1=C(C=CC(=C1)OC1=CC(=CC=C1)F)B1OC(C(O1)(C)C)(C)C Chemical compound FC1=C(C=CC(=C1)OC1=CC(=CC=C1)F)B1OC(C(O1)(C)C)(C)C RPOHCYAYEXGFMK-UHFFFAOYSA-N 0.000 description 1
- PRTNAAJNTOCIAC-CYBMUJFWSA-N FC1=C(C=CC(=C1)OC1=CC(=CC=C1)F)C1=NN(C2=NC=NC(=C21)N)[C@H]1CNCC1 Chemical compound FC1=C(C=CC(=C1)OC1=CC(=CC=C1)F)C1=NN(C2=NC=NC(=C21)N)[C@H]1CNCC1 PRTNAAJNTOCIAC-CYBMUJFWSA-N 0.000 description 1
- 239000001263 FEMA 3042 Substances 0.000 description 1
- PNKUSGQVOMIXLU-UHFFFAOYSA-N Formamidine Chemical compound NC=N PNKUSGQVOMIXLU-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 101000934996 Homo sapiens Tyrosine-protein kinase JAK3 Proteins 0.000 description 1
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- 239000002067 L01XE06 - Dasatinib Substances 0.000 description 1
- 239000002177 L01XE27 - Ibrutinib Substances 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 238000006751 Mitsunobu reaction Methods 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- LWZNRDXTNLBAAG-HTQZYQBOSA-N N-[(1R,3R)-3-(4-amino-3-iodopyrazolo[3,4-d]pyrimidin-1-yl)cyclopentyl]prop-2-enamide Chemical compound NC1=C2C(=NC=N1)N(N=C2I)[C@H]1C[C@@H](CC1)NC(C=C)=O LWZNRDXTNLBAAG-HTQZYQBOSA-N 0.000 description 1
- OSZBWQKIIKHFNQ-VXGBXAGGSA-N N-[(1R,3R)-3-[4-amino-3-[2-fluoro-4-(2,3,5,6-tetrafluorophenoxy)phenyl]pyrazolo[3,4-d]pyrimidin-1-yl]cyclopentyl]prop-2-enamide Chemical compound NC1=C2C(=NC=N1)N(N=C2C1=C(C=C(C=C1)OC1=C(C(=CC(=C1F)F)F)F)F)[C@H]1C[C@@H](CC1)NC(C=C)=O OSZBWQKIIKHFNQ-VXGBXAGGSA-N 0.000 description 1
- IWLLDAYPUDTPDX-HZPDHXFCSA-N N-[(1R,3R)-3-[4-amino-3-[2-fluoro-4-(3-fluorophenoxy)phenyl]pyrazolo[3,4-d]pyrimidin-1-yl]cyclopentyl]prop-2-enamide Chemical compound NC1=C2C(=NC=N1)N(N=C2C1=C(C=C(C=C1)OC1=CC(=CC=C1)F)F)[C@H]1C[C@@H](CC1)NC(C=C)=O IWLLDAYPUDTPDX-HZPDHXFCSA-N 0.000 description 1
- AYCPARAPKDAOEN-LJQANCHMSA-N N-[(1S)-2-(dimethylamino)-1-phenylethyl]-6,6-dimethyl-3-[(2-methyl-4-thieno[3,2-d]pyrimidinyl)amino]-1,4-dihydropyrrolo[3,4-c]pyrazole-5-carboxamide Chemical compound C1([C@H](NC(=O)N2C(C=3NN=C(NC=4C=5SC=CC=5N=C(C)N=4)C=3C2)(C)C)CN(C)C)=CC=CC=C1 AYCPARAPKDAOEN-LJQANCHMSA-N 0.000 description 1
- OSZBWQKIIKHFNQ-NWDGAFQWSA-N N-[(1S,3R)-3-[4-amino-3-[2-fluoro-4-(2,3,5,6-tetrafluorophenoxy)phenyl]pyrazolo[3,4-d]pyrimidin-1-yl]cyclopentyl]prop-2-enamide Chemical compound NC1=C2C(=NC=N1)N(N=C2C1=C(C=C(C=C1)OC1=C(C(=CC(=C1F)F)F)F)F)[C@H]1C[C@H](CC1)NC(C=C)=O OSZBWQKIIKHFNQ-NWDGAFQWSA-N 0.000 description 1
- IWLLDAYPUDTPDX-JKSUJKDBSA-N N-[(1S,3R)-3-[4-amino-3-[2-fluoro-4-(3-fluorophenoxy)phenyl]pyrazolo[3,4-d]pyrimidin-1-yl]cyclopentyl]prop-2-enamide Chemical compound NC1=C2C(=NC=N1)N(N=C2C1=C(C=C(C=C1)OC1=CC(=CC=C1)F)F)[C@H]1C[C@H](CC1)NC(C=C)=O IWLLDAYPUDTPDX-JKSUJKDBSA-N 0.000 description 1
- OPKOKAMJFNKNAS-UHFFFAOYSA-N N-methylethanolamine Chemical compound CNCCO OPKOKAMJFNKNAS-UHFFFAOYSA-N 0.000 description 1
- ASDYEDXFTUFDOL-UHFFFAOYSA-N NC(CN1N=C(C=2C1=NC=NC=2N)C1=C(C=C(C=C1)OC1=C(C(=CC(=C1F)F)F)F)F)(C)C Chemical compound NC(CN1N=C(C=2C1=NC=NC=2N)C1=C(C=C(C=C1)OC1=C(C(=CC(=C1F)F)F)F)F)(C)C ASDYEDXFTUFDOL-UHFFFAOYSA-N 0.000 description 1
- OHNRBNJYYBFYGV-UHFFFAOYSA-N NC1=C2C(=NC=N1)N(N=C2C1=C(C=C(C=C1)C(C1=C(C=CC=C1)F)=O)F)C1CN(CCC1)C(C=C)=O Chemical compound NC1=C2C(=NC=N1)N(N=C2C1=C(C=C(C=C1)C(C1=C(C=CC=C1)F)=O)F)C1CN(CCC1)C(C=C)=O OHNRBNJYYBFYGV-UHFFFAOYSA-N 0.000 description 1
- GALXNPGYKZCSTG-UHFFFAOYSA-N NC1=C2C(=NC=N1)N(N=C2C1=C(C=C(C=C1)C(C1=CC(=CC=C1)F)=O)F)C1CN(CCC1)C(=O)C1OC1 Chemical compound NC1=C2C(=NC=N1)N(N=C2C1=C(C=C(C=C1)C(C1=CC(=CC=C1)F)=O)F)C1CN(CCC1)C(=O)C1OC1 GALXNPGYKZCSTG-UHFFFAOYSA-N 0.000 description 1
- OOXOANBXOYMTTA-UHFFFAOYSA-N NC1=C2C(=NC=N1)N(N=C2C1=C(C=C(C=C1)C(C1=CC(=CC=C1)F)=O)F)C1CN(CCC1)C(C=C)=O Chemical compound NC1=C2C(=NC=N1)N(N=C2C1=C(C=C(C=C1)C(C1=CC(=CC=C1)F)=O)F)C1CN(CCC1)C(C=C)=O OOXOANBXOYMTTA-UHFFFAOYSA-N 0.000 description 1
- PUYFCGRBBKBZEO-UHFFFAOYSA-N NC1=C2C(=NC=N1)N(N=C2C1=C(C=C(C=C1)C(C1=CC=C(C=C1)F)=O)F)C1CN(CCC1)C(C=C)=O Chemical compound NC1=C2C(=NC=N1)N(N=C2C1=C(C=C(C=C1)C(C1=CC=C(C=C1)F)=O)F)C1CN(CCC1)C(C=C)=O PUYFCGRBBKBZEO-UHFFFAOYSA-N 0.000 description 1
- ASLSBNRCIGYJNL-UHFFFAOYSA-N NC1=C2C(=NC=N1)N(N=C2C1=C(C=C(C=C1)OC1=C(C(=CC(=C1F)F)F)F)F)C(C(C)NC(C=C)=O)C Chemical compound NC1=C2C(=NC=N1)N(N=C2C1=C(C=C(C=C1)OC1=C(C(=CC(=C1F)F)F)F)F)C(C(C)NC(C=C)=O)C ASLSBNRCIGYJNL-UHFFFAOYSA-N 0.000 description 1
- OCAXCAXVCRABAP-UHFFFAOYSA-N NC1=C2C(=NC=N1)N(N=C2C1=C(C=C(C=C1)OC1=C(C(=CC(=C1F)F)F)F)F)C(CNC(C=C)=O)C Chemical compound NC1=C2C(=NC=N1)N(N=C2C1=C(C=C(C=C1)OC1=C(C(=CC(=C1F)F)F)F)F)C(CNC(C=C)=O)C OCAXCAXVCRABAP-UHFFFAOYSA-N 0.000 description 1
- DUHBQDRJRPOOEA-UHFFFAOYSA-N NC1=C2C(=NC=N1)N(N=C2C1=C(C=C(C=C1)OC1=C(C(=CC(=C1F)F)F)F)F)C1CCC(CC1)N1C(SCC1=O)=NC1=CC=CC=C1 Chemical compound NC1=C2C(=NC=N1)N(N=C2C1=C(C=C(C=C1)OC1=C(C(=CC(=C1F)F)F)F)F)C1CCC(CC1)N1C(SCC1=O)=NC1=CC=CC=C1 DUHBQDRJRPOOEA-UHFFFAOYSA-N 0.000 description 1
- NTFNTMHTJYQDQZ-UHFFFAOYSA-N NC1=C2C(=NC=N1)N(N=C2C1=C(C=C(C=C1)OC1=C(C(=CC(=C1F)F)F)F)F)C1CCC(CC1)NC(=S)NC1=CC=CC=C1 Chemical compound NC1=C2C(=NC=N1)N(N=C2C1=C(C=C(C=C1)OC1=C(C(=CC(=C1F)F)F)F)F)C1CCC(CC1)NC(=S)NC1=CC=CC=C1 NTFNTMHTJYQDQZ-UHFFFAOYSA-N 0.000 description 1
- OIVSAAWGDQUKIW-UHFFFAOYSA-N NC1=C2C(=NC=N1)N(N=C2C1=C(C=C(C=C1)OC1=C(C(=CC(=C1F)F)F)F)F)C1CCN(CC1)C(C=C)=O Chemical compound NC1=C2C(=NC=N1)N(N=C2C1=C(C=C(C=C1)OC1=C(C(=CC(=C1F)F)F)F)F)C1CCN(CC1)C(C=C)=O OIVSAAWGDQUKIW-UHFFFAOYSA-N 0.000 description 1
- SIBJSOSVHADNER-UHFFFAOYSA-N NC1=C2C(=NC=N1)N(N=C2C1=C(C=C(C=C1)OC1=C(C(=CC(=C1F)F)F)F)F)C1CN(CC1)C(=O)OC(C)(C)C Chemical compound NC1=C2C(=NC=N1)N(N=C2C1=C(C=C(C=C1)OC1=C(C(=CC(=C1F)F)F)F)F)C1CN(CC1)C(=O)OC(C)(C)C SIBJSOSVHADNER-UHFFFAOYSA-N 0.000 description 1
- AWEDBCYBRKMKBX-UHFFFAOYSA-N NC1=C2C(=NC=N1)N(N=C2C1=C(C=C(C=C1)OC1=C(C(=CC(=C1F)F)F)F)F)C1CN(CCC1)C(=O)C=1C=NC=CC=1 Chemical compound NC1=C2C(=NC=N1)N(N=C2C1=C(C=C(C=C1)OC1=C(C(=CC(=C1F)F)F)F)F)C1CN(CCC1)C(=O)C=1C=NC=CC=1 AWEDBCYBRKMKBX-UHFFFAOYSA-N 0.000 description 1
- UPQITEBGHQQOEH-UHFFFAOYSA-N NC1=C2C(=NC=N1)N(N=C2C1=C(C=C(C=C1)OC1=C(C(=CC(=C1F)F)F)F)F)C1CN(CCC1)C(=O)OC(C)(C)C Chemical compound NC1=C2C(=NC=N1)N(N=C2C1=C(C=C(C=C1)OC1=C(C(=CC(=C1F)F)F)F)F)C1CN(CCC1)C(=O)OC(C)(C)C UPQITEBGHQQOEH-UHFFFAOYSA-N 0.000 description 1
- OKMLAPABICGHDN-UHFFFAOYSA-N NC1=C2C(=NC=N1)N(N=C2C1=C(C=C(C=C1)OC1=C(C(=CC(=C1F)F)F)F)F)C1CN(CCC1)C(C(=O)C1CC1)=O Chemical compound NC1=C2C(=NC=N1)N(N=C2C1=C(C=C(C=C1)OC1=C(C(=CC(=C1F)F)F)F)F)C1CN(CCC1)C(C(=O)C1CC1)=O OKMLAPABICGHDN-UHFFFAOYSA-N 0.000 description 1
- NONKEKZAWFDISQ-UHFFFAOYSA-N NC1=C2C(=NC=N1)N(N=C2C1=C(C=C(C=C1)OC1=C(C(=CC(=C1F)F)F)F)F)C1CN(CCC1)C(C(=O)NC)=O Chemical compound NC1=C2C(=NC=N1)N(N=C2C1=C(C=C(C=C1)OC1=C(C(=CC(=C1F)F)F)F)F)C1CN(CCC1)C(C(=O)NC)=O NONKEKZAWFDISQ-UHFFFAOYSA-N 0.000 description 1
- ZLAMFBIVDGSLFO-UHFFFAOYSA-N NC1=C2C(=NC=N1)N(N=C2C1=C(C=C(C=C1)OC1=C(C(=CC(=C1F)F)F)F)F)C1CN(CCC1)C(C(Cl)Cl)=O Chemical compound NC1=C2C(=NC=N1)N(N=C2C1=C(C=C(C=C1)OC1=C(C(=CC(=C1F)F)F)F)F)C1CN(CCC1)C(C(Cl)Cl)=O ZLAMFBIVDGSLFO-UHFFFAOYSA-N 0.000 description 1
- JUXVTKDUICDETA-UHFFFAOYSA-N NC1=C2C(=NC=N1)N(N=C2C1=C(C=C(C=C1)OC1=C(C(=CC(=C1F)F)F)F)F)C1CN(CCC1)C(C=C)=O Chemical compound NC1=C2C(=NC=N1)N(N=C2C1=C(C=C(C=C1)OC1=C(C(=CC(=C1F)F)F)F)F)C1CN(CCC1)C(C=C)=O JUXVTKDUICDETA-UHFFFAOYSA-N 0.000 description 1
- ZCAGVZZLQRUSKD-UHFFFAOYSA-N NC1=C2C(=NC=N1)N(N=C2C1=C(C=C(C=C1)OC1=C(C(=CC(=C1F)F)F)F)F)C1CN(CCC1)C(CC(C(F)(F)F)=O)=O Chemical compound NC1=C2C(=NC=N1)N(N=C2C1=C(C=C(C=C1)OC1=C(C(=CC(=C1F)F)F)F)F)C1CN(CCC1)C(CC(C(F)(F)F)=O)=O ZCAGVZZLQRUSKD-UHFFFAOYSA-N 0.000 description 1
- UYVOBXAHXCWOGA-UHFFFAOYSA-N NC1=C2C(=NC=N1)N(N=C2C1=C(C=C(C=C1)OC1=C(C(=CC(=C1F)F)F)F)F)C1CN(CCC1)CC(=O)NC Chemical compound NC1=C2C(=NC=N1)N(N=C2C1=C(C=C(C=C1)OC1=C(C(=CC(=C1F)F)F)F)F)C1CN(CCC1)CC(=O)NC UYVOBXAHXCWOGA-UHFFFAOYSA-N 0.000 description 1
- RYOFUQZJCQOYAS-UHFFFAOYSA-N NC1=C2C(=NC=N1)N(N=C2C1=C(C=C(C=C1)OC1=C(C(=CC(=C1F)F)F)F)F)CC(C)(C)NC(C=C)=O Chemical compound NC1=C2C(=NC=N1)N(N=C2C1=C(C=C(C=C1)OC1=C(C(=CC(=C1F)F)F)F)F)CC(C)(C)NC(C=C)=O RYOFUQZJCQOYAS-UHFFFAOYSA-N 0.000 description 1
- HQXKEFNWMNWQFU-UHFFFAOYSA-N NC1=C2C(=NC=N1)N(N=C2C1=C(C=C(C=C1)OC1=C(C(=CC(=C1F)F)F)F)F)CCCN1C(C=CC1=O)=O Chemical compound NC1=C2C(=NC=N1)N(N=C2C1=C(C=C(C=C1)OC1=C(C(=CC(=C1F)F)F)F)F)CCCN1C(C=CC1=O)=O HQXKEFNWMNWQFU-UHFFFAOYSA-N 0.000 description 1
- ZJDIFXCDJKKPIO-NSHDSACASA-N NC1=C2C(=NC=N1)N(N=C2C1=C(C=C(C=C1)OC1=C(C(=CC(=C1F)F)F)F)F)[C@@H]1CN(CC1)C(C=C)=O Chemical compound NC1=C2C(=NC=N1)N(N=C2C1=C(C=C(C=C1)OC1=C(C(=CC(=C1F)F)F)F)F)[C@@H]1CN(CC1)C(C=C)=O ZJDIFXCDJKKPIO-NSHDSACASA-N 0.000 description 1
- GMXPTKSPLNBWGA-RYUDHWBXSA-N NC1=C2C(=NC=N1)N(N=C2C1=C(C=C(C=C1)OC1=C(C(=CC(=C1F)F)F)F)F)[C@@H]1C[C@H](CC1)N1C(C=CC1=O)=O Chemical compound NC1=C2C(=NC=N1)N(N=C2C1=C(C=C(C=C1)OC1=C(C(=CC(=C1F)F)F)F)F)[C@@H]1C[C@H](CC1)N1C(C=CC1=O)=O GMXPTKSPLNBWGA-RYUDHWBXSA-N 0.000 description 1
- NEPMSLCGMUTMMB-GFCCVEGCSA-N NC1=C2C(=NC=N1)N(N=C2C1=C(C=C(C=C1)OC1=C(C(=CC(=C1F)F)F)F)F)[C@H]1CN(CC1)C(C(=C)C)=O Chemical compound NC1=C2C(=NC=N1)N(N=C2C1=C(C=C(C=C1)OC1=C(C(=CC(=C1F)F)F)F)F)[C@H]1CN(CC1)C(C(=C)C)=O NEPMSLCGMUTMMB-GFCCVEGCSA-N 0.000 description 1
- QPIOBMQXWPXXSS-LLVKDONJSA-N NC1=C2C(=NC=N1)N(N=C2C1=C(C=C(C=C1)OC1=C(C(=CC(=C1F)F)F)F)F)[C@H]1CN(CC1)C(C(=C)F)=O Chemical compound NC1=C2C(=NC=N1)N(N=C2C1=C(C=C(C=C1)OC1=C(C(=CC(=C1F)F)F)F)F)[C@H]1CN(CC1)C(C(=C)F)=O QPIOBMQXWPXXSS-LLVKDONJSA-N 0.000 description 1
- CVVRXNKVVLCNLB-SECBINFHSA-N NC1=C2C(=NC=N1)N(N=C2C1=C(C=C(C=C1)OC1=C(C(=CC(=C1F)F)F)F)F)[C@H]1CN(CC1)C(C(=O)O)=O Chemical compound NC1=C2C(=NC=N1)N(N=C2C1=C(C=C(C=C1)OC1=C(C(=CC(=C1F)F)F)F)F)[C@H]1CN(CC1)C(C(=O)O)=O CVVRXNKVVLCNLB-SECBINFHSA-N 0.000 description 1
- NVETZNUVVZWQPA-SECBINFHSA-N NC1=C2C(=NC=N1)N(N=C2C1=C(C=C(C=C1)OC1=C(C(=CC(=C1F)F)F)F)F)[C@H]1CN(CC1)C(C(C(F)(F)F)=O)=O Chemical compound NC1=C2C(=NC=N1)N(N=C2C1=C(C=C(C=C1)OC1=C(C(=CC(=C1F)F)F)F)F)[C@H]1CN(CC1)C(C(C(F)(F)F)=O)=O NVETZNUVVZWQPA-SECBINFHSA-N 0.000 description 1
- QVOWFUJGFPVJKG-SECBINFHSA-N NC1=C2C(=NC=N1)N(N=C2C1=C(C=C(C=C1)OC1=C(C(=CC(=C1F)F)F)F)F)[C@H]1CN(CC1)C(C(Cl)Cl)=O Chemical compound NC1=C2C(=NC=N1)N(N=C2C1=C(C=C(C=C1)OC1=C(C(=CC(=C1F)F)F)F)F)[C@H]1CN(CC1)C(C(Cl)Cl)=O QVOWFUJGFPVJKG-SECBINFHSA-N 0.000 description 1
- WWVKQKZDYDOYRS-LLVKDONJSA-N NC1=C2C(=NC=N1)N(N=C2C1=C(C=C(C=C1)OC1=C(C(=CC(=C1F)F)F)F)F)[C@H]1CN(CC1)C(CCCl)=O Chemical compound NC1=C2C(=NC=N1)N(N=C2C1=C(C=C(C=C1)OC1=C(C(=CC(=C1F)F)F)F)F)[C@H]1CN(CC1)C(CCCl)=O WWVKQKZDYDOYRS-LLVKDONJSA-N 0.000 description 1
- BYZDRHVNBVCRBV-UHFFFAOYSA-N NC1=C2C(=NC=N1)N(N=C2C1=C(C=C(C=C1)OC1=C(C(=CC=C1F)F)F)F)C1CN(CCC1)C(C=C)=O Chemical compound NC1=C2C(=NC=N1)N(N=C2C1=C(C=C(C=C1)OC1=C(C(=CC=C1F)F)F)F)C1CN(CCC1)C(C=C)=O BYZDRHVNBVCRBV-UHFFFAOYSA-N 0.000 description 1
- QLRDEQPODCORHJ-UHFFFAOYSA-N NC1=C2C(=NC=N1)N(N=C2C1=C(C=C(C=C1)OC1=CC(=CC=C1)F)F)C1CN(CC1)C(C=C)=O Chemical compound NC1=C2C(=NC=N1)N(N=C2C1=C(C=C(C=C1)OC1=CC(=CC=C1)F)F)C1CN(CC1)C(C=C)=O QLRDEQPODCORHJ-UHFFFAOYSA-N 0.000 description 1
- VKJCEWUQMIITSJ-UHFFFAOYSA-N NC1=C2C(=NC=N1)N(N=C2C1=C(C=C(C=C1)OC1=CC(=CC=C1)F)F)C1CN(CCC1)C(C=C)=O Chemical compound NC1=C2C(=NC=N1)N(N=C2C1=C(C=C(C=C1)OC1=CC(=CC=C1)F)F)C1CN(CCC1)C(C=C)=O VKJCEWUQMIITSJ-UHFFFAOYSA-N 0.000 description 1
- MBGRQJDYENHVIB-MRXNPFEDSA-N NC1=C2C(=NC=N1)N(N=C2C1=C(C=C(C=C1)OC1=CC(=CC=C1)F)F)[C@H]1CN(CC1)C(=O)OC(C)(C)C Chemical compound NC1=C2C(=NC=N1)N(N=C2C1=C(C=C(C=C1)OC1=CC(=CC=C1)F)F)[C@H]1CN(CC1)C(=O)OC(C)(C)C MBGRQJDYENHVIB-MRXNPFEDSA-N 0.000 description 1
- KORSFEUCZVKZOA-UHFFFAOYSA-N NC1=C2C(=NC=N1)N(N=C2C1=CC(=C(C=C1)C(C1=CC(=CC=C1)F)=O)F)C1CN(CCC1)C(C=C)=O Chemical compound NC1=C2C(=NC=N1)N(N=C2C1=CC(=C(C=C1)C(C1=CC(=CC=C1)F)=O)F)C1CN(CCC1)C(C=C)=O KORSFEUCZVKZOA-UHFFFAOYSA-N 0.000 description 1
- CFYKARIQWSFLOI-UHFFFAOYSA-N NC1=C2C(=NC=N1)N(N=C2C1=CC(=C(C=C1)C(C1=CC=C(C=C1)F)=O)F)C1CN(CCC1)C(C=C)=O Chemical compound NC1=C2C(=NC=N1)N(N=C2C1=CC(=C(C=C1)C(C1=CC=C(C=C1)F)=O)F)C1CN(CCC1)C(C=C)=O CFYKARIQWSFLOI-UHFFFAOYSA-N 0.000 description 1
- WWILDIFIHVOAGC-UHFFFAOYSA-N NC1=C2C(=NC=N1)N(N=C2I)CC1CC(CC1)NC(C=C)=O Chemical compound NC1=C2C(=NC=N1)N(N=C2I)CC1CC(CC1)NC(C=C)=O WWILDIFIHVOAGC-UHFFFAOYSA-N 0.000 description 1
- DMMVJXIRRUZMJV-CYBMUJFWSA-N NC1=NC=NC2=C1C(=NN2[C@@H]1CCN(C1)C(=O)C1=NC2=C(O1)C=CC=C2)C1=CC=C(OC2=C(F)C(F)=CC(F)=C2F)C=C1F Chemical compound NC1=NC=NC2=C1C(=NN2[C@@H]1CCN(C1)C(=O)C1=NC2=C(O1)C=CC=C2)C1=CC=C(OC2=C(F)C(F)=CC(F)=C2F)C=C1F DMMVJXIRRUZMJV-CYBMUJFWSA-N 0.000 description 1
- WBAHZPZPDHYBCL-LLVKDONJSA-N NC1=NC=NC2=C1C(=NN2[C@@H]1CCN(C1)C(=O)C1=NC=CO1)C1=CC=C(OC2=C(F)C(F)=CC(F)=C2F)C=C1F Chemical compound NC1=NC=NC2=C1C(=NN2[C@@H]1CCN(C1)C(=O)C1=NC=CO1)C1=CC=C(OC2=C(F)C(F)=CC(F)=C2F)C=C1F WBAHZPZPDHYBCL-LLVKDONJSA-N 0.000 description 1
- NUBNZASXRSXFRW-UHFFFAOYSA-N NCC(CC1)CC1O Chemical compound NCC(CC1)CC1O NUBNZASXRSXFRW-UHFFFAOYSA-N 0.000 description 1
- KHNTVXWKHCKYIP-WDSKDSINSA-N N[C@@H]1C[C@H](CC1)N1N=C(C=2C1=NC=NC=2N)I Chemical compound N[C@@H]1C[C@H](CC1)N1N=C(C=2C1=NC=NC=2N)I KHNTVXWKHCKYIP-WDSKDSINSA-N 0.000 description 1
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 1
- NCKZYQHUKDTIJU-UHFFFAOYSA-N Nc1ncnc2c1c(-c(ccc(Oc(c(F)c(cc1F)F)c1F)c1)c1F)n[n]2C1CNCCC1 Chemical compound Nc1ncnc2c1c(-c(ccc(Oc(c(F)c(cc1F)F)c1F)c1)c1F)n[n]2C1CNCCC1 NCKZYQHUKDTIJU-UHFFFAOYSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- LRBQNJMCXXYXIU-PPKXGCFTSA-N Penta-digallate-beta-D-glucose Natural products OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-PPKXGCFTSA-N 0.000 description 1
- 102100030264 Pleckstrin Human genes 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 108010020346 Polyglutamic Acid Proteins 0.000 description 1
- 229940123924 Protein kinase C inhibitor Drugs 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- 208000015634 Rectal Neoplasms Diseases 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 238000011579 SCID mouse model Methods 0.000 description 1
- 229940124639 Selective inhibitor Drugs 0.000 description 1
- 241000168254 Siro Species 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 102000011011 Sphingosine 1-phosphate receptors Human genes 0.000 description 1
- 108050001083 Sphingosine 1-phosphate receptors Proteins 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 208000024313 Testicular Neoplasms Diseases 0.000 description 1
- 206010057644 Testis cancer Diseases 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 102100025387 Tyrosine-protein kinase JAK3 Human genes 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 208000035868 Vascular inflammations Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- IRFBAXPISZBJET-BDAKNGLRSA-N [(1R,3S)-3-[(2-methylpropan-2-yl)oxycarbonylamino]cyclopentyl]methanesulfonic acid Chemical compound CC(C)(C)OC(=O)N[C@H]1CC[C@H](C1)CS(=O)(=O)O IRFBAXPISZBJET-BDAKNGLRSA-N 0.000 description 1
- UOXOJYBBCUVRHC-UHFFFAOYSA-N [2-methyl-2-[(2-methylpropan-2-yl)oxycarbonylamino]propyl] methanesulfonate Chemical compound CC(C)(C)OC(=O)NC(C)(C)COS(C)(=O)=O UOXOJYBBCUVRHC-UHFFFAOYSA-N 0.000 description 1
- VLRBDCFSWXFDBY-CYBMUJFWSA-N [4-[4-amino-1-[(3R)-pyrrolidin-3-yl]pyrazolo[3,4-d]pyrimidin-3-yl]-3-fluorophenyl]-(2-fluorophenyl)methanone Chemical compound NC1=C2C(=NC=N1)N(N=C2C1=C(C=C(C=C1)C(=O)C1=C(C=CC=C1)F)F)[C@H]1CNCC1 VLRBDCFSWXFDBY-CYBMUJFWSA-N 0.000 description 1
- WYSIMSJSUWBHQP-OAHLLOKOSA-N [4-[4-amino-1-[(3R)-pyrrolidin-3-yl]pyrazolo[3,4-d]pyrimidin-3-yl]-3-fluorophenyl]-(3-fluorophenyl)methanone Chemical compound NC1=C2C(=NC=N1)N(N=C2C1=C(C=C(C=C1)C(=O)C1=CC(=CC=C1)F)F)[C@H]1CNCC1 WYSIMSJSUWBHQP-OAHLLOKOSA-N 0.000 description 1
- FGEYKOWCKWERIB-OAHLLOKOSA-N [4-[4-amino-1-[(3R)-pyrrolidin-3-yl]pyrazolo[3,4-d]pyrimidin-3-yl]-3-fluorophenyl]-(4-fluorophenyl)methanone Chemical compound NC1=C2C(=NC=N1)N(N=C2C1=C(C=C(C=C1)C(=O)C1=CC=C(C=C1)F)F)[C@H]1CNCC1 FGEYKOWCKWERIB-OAHLLOKOSA-N 0.000 description 1
- JVKNCECRGPRLKQ-UHFFFAOYSA-M [Br-].FC1=CC([Mg+])=CC=C1Cl Chemical compound [Br-].FC1=CC([Mg+])=CC=C1Cl JVKNCECRGPRLKQ-UHFFFAOYSA-M 0.000 description 1
- 229960003697 abatacept Drugs 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 125000002947 alkylene group Chemical group 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- SNAAJJQQZSMGQD-UHFFFAOYSA-N aluminum magnesium Chemical compound [Mg].[Al] SNAAJJQQZSMGQD-UHFFFAOYSA-N 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 125000002178 anthracenyl group Chemical group C1(=CC=CC2=CC3=CC=CC=C3C=C12)* 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 125000002029 aromatic hydrocarbon group Chemical group 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229940092117 atgam Drugs 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 230000006472 autoimmune response Effects 0.000 description 1
- 229960003005 axitinib Drugs 0.000 description 1
- RITAVMQDGBJQJZ-FMIVXFBMSA-N axitinib Chemical compound CNC(=O)C1=CC=CC=C1SC1=CC=C(C(\C=C\C=2N=CC=CC=2)=NN2)C2=C1 RITAVMQDGBJQJZ-FMIVXFBMSA-N 0.000 description 1
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 1
- 229960002170 azathioprine Drugs 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 239000012965 benzophenone Substances 0.000 description 1
- 150000008366 benzophenones Chemical class 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000004622 benzoxazinyl group Chemical group O1NC(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- 229910000085 borane Inorganic materials 0.000 description 1
- FMXUOEWIOGFMRP-UHFFFAOYSA-N boron;2,3-dimethylbutane-2,3-diol Chemical compound [B].CC(C)(O)C(C)(C)O.CC(C)(O)C(C)(C)O FMXUOEWIOGFMRP-UHFFFAOYSA-N 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- OUEWZYXUSMEJCC-UHFFFAOYSA-N butane-1,3-dione Chemical compound CC(=O)C[C]=O OUEWZYXUSMEJCC-UHFFFAOYSA-N 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000033077 cellular process Effects 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- FOCAUTSVDIKZOP-UHFFFAOYSA-N chloroacetic acid Chemical compound OC(=O)CCl FOCAUTSVDIKZOP-UHFFFAOYSA-N 0.000 description 1
- 229940106681 chloroacetic acid Drugs 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229910000431 copper oxide Inorganic materials 0.000 description 1
- OXBLHERUFWYNTN-UHFFFAOYSA-M copper(I) chloride Chemical compound [Cu]Cl OXBLHERUFWYNTN-UHFFFAOYSA-M 0.000 description 1
- LSXDOTMGLUJQCM-UHFFFAOYSA-M copper(i) iodide Chemical compound I[Cu] LSXDOTMGLUJQCM-UHFFFAOYSA-M 0.000 description 1
- OPQARKPSCNTWTJ-UHFFFAOYSA-L copper(ii) acetate Chemical compound [Cu+2].CC([O-])=O.CC([O-])=O OPQARKPSCNTWTJ-UHFFFAOYSA-L 0.000 description 1
- LDHQCZJRKDOVOX-NSCUHMNNSA-N crotonic acid Chemical compound C\C=C\C(O)=O LDHQCZJRKDOVOX-NSCUHMNNSA-N 0.000 description 1
- 229940045803 cuprous chloride Drugs 0.000 description 1
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 1
- 125000000392 cycloalkenyl group Chemical group 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 229960002448 dasatinib Drugs 0.000 description 1
- 230000009849 deactivation Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000003534 dna topoisomerase inhibitor Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 229940112141 dry powder inhaler Drugs 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- MTCMFVTVXAOHNQ-UHFFFAOYSA-N ethyl 2-(bromomethyl)prop-2-enoate Chemical compound CCOC(=O)C(=C)CBr MTCMFVTVXAOHNQ-UHFFFAOYSA-N 0.000 description 1
- FHGRPBSDPBRTLS-UHFFFAOYSA-N ethyl 4-bromobut-2-enoate Chemical compound CCOC(=O)C=CCBr FHGRPBSDPBRTLS-UHFFFAOYSA-N 0.000 description 1
- MSMGXWFHBSCQFB-UHFFFAOYSA-N ethyl cyanoformate Chemical compound CCOC(=O)C#N MSMGXWFHBSCQFB-UHFFFAOYSA-N 0.000 description 1
- OJCSPXHYDFONPU-UHFFFAOYSA-N etoac etoac Chemical compound CCOC(C)=O.CCOC(C)=O OJCSPXHYDFONPU-UHFFFAOYSA-N 0.000 description 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
- 229960005167 everolimus Drugs 0.000 description 1
- 210000005002 female reproductive tract Anatomy 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 229960000556 fingolimod Drugs 0.000 description 1
- KKGQTZUTZRNORY-UHFFFAOYSA-N fingolimod Chemical compound CCCCCCCCC1=CC=C(CCC(N)(CO)CO)C=C1 KKGQTZUTZRNORY-UHFFFAOYSA-N 0.000 description 1
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- LRBQNJMCXXYXIU-QWKBTXIPSA-N gallotannic acid Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@H]2[C@@H]([C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-QWKBTXIPSA-N 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 125000006038 hexenyl group Chemical group 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 150000005828 hydrofluoroalkanes Chemical class 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 229960001507 ibrutinib Drugs 0.000 description 1
- XYFPWWZEPKGCCK-GOSISDBHSA-N ibrutinib Chemical compound C1=2C(N)=NC=NC=2N([C@H]2CN(CCC2)C(=O)C=C)N=C1C(C=C1)=CC=C1OC1=CC=CC=C1 XYFPWWZEPKGCCK-GOSISDBHSA-N 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 108091005434 innate immune receptors Proteins 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- 125000005956 isoquinolyl group Chemical group 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- TYQCGQRIZGCHNB-JLAZNSOCSA-N l-ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(O)=C(O)C1=O TYQCGQRIZGCHNB-JLAZNSOCSA-N 0.000 description 1
- 229960000681 leflunomide Drugs 0.000 description 1
- VHOGYURTWQBHIL-UHFFFAOYSA-N leflunomide Chemical compound O1N=CC(C(=O)NC=2C=CC(=CC=2)C(F)(F)F)=C1C VHOGYURTWQBHIL-UHFFFAOYSA-N 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- BRKADVNLTRCLOW-UHFFFAOYSA-M magnesium;fluorobenzene;bromide Chemical compound [Mg+2].[Br-].FC1=CC=[C-]C=C1 BRKADVNLTRCLOW-UHFFFAOYSA-M 0.000 description 1
- FPYJFEHAWHCUMM-UHFFFAOYSA-N maleic anhydride Chemical compound O=C1OC(=O)C=C1 FPYJFEHAWHCUMM-UHFFFAOYSA-N 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- HNQIVZYLYMDVSB-UHFFFAOYSA-N methanesulfonimidic acid Chemical compound CS(N)(=O)=O HNQIVZYLYMDVSB-UHFFFAOYSA-N 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- VCXZJBRVEJBECK-UHFFFAOYSA-N methyl 2,5-dihydropyrrole-1-carboxylate Chemical compound COC(=O)N1CC=CC1 VCXZJBRVEJBECK-UHFFFAOYSA-N 0.000 description 1
- RIJWDPRXCXJDPK-UHFFFAOYSA-N methyl 3-cyclopropyl-3-oxopropanoate Chemical compound COC(=O)CC(=O)C1CC1 RIJWDPRXCXJDPK-UHFFFAOYSA-N 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- YNTOKMNHRPSGFU-UHFFFAOYSA-N n-Propyl carbamate Chemical compound CCCOC(N)=O YNTOKMNHRPSGFU-UHFFFAOYSA-N 0.000 description 1
- XBXCNNQPRYLIDE-UHFFFAOYSA-M n-tert-butylcarbamate Chemical compound CC(C)(C)NC([O-])=O XBXCNNQPRYLIDE-UHFFFAOYSA-M 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 229960002009 naproxen Drugs 0.000 description 1
- CMWTZPSULFXXJA-VIFPVBQESA-M naproxen(1-) Chemical compound C1=C([C@H](C)C([O-])=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-M 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 239000006199 nebulizer Substances 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 150000002828 nitro derivatives Chemical class 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- JFNLZVQOOSMTJK-KNVOCYPGSA-N norbornene Chemical compound C1[C@@H]2CC[C@H]1C=C2 JFNLZVQOOSMTJK-KNVOCYPGSA-N 0.000 description 1
- 125000002868 norbornyl group Chemical group C12(CCC(CC1)C2)* 0.000 description 1
- 238000011580 nude mouse model Methods 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- WCPAKWJPBJAGKN-UHFFFAOYSA-N oxadiazole Chemical compound C1=CON=N1 WCPAKWJPBJAGKN-UHFFFAOYSA-N 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- WLJNZVDCPSBLRP-UHFFFAOYSA-N pamoic acid Chemical compound C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 WLJNZVDCPSBLRP-UHFFFAOYSA-N 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 229960005489 paracetamol Drugs 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 125000002255 pentenyl group Chemical group C(=CCCC)* 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 150000008094 phenoxybenzenes Chemical class 0.000 description 1
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N phenylbenzene Natural products C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 1
- RPGWZZNNEUHDAQ-UHFFFAOYSA-N phenylphosphine Chemical compound PC1=CC=CC=C1 RPGWZZNNEUHDAQ-UHFFFAOYSA-N 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- WVJYYXZISOKSCL-UHFFFAOYSA-N piperidin-3-ylmethyl methanesulfonate Chemical compound CS(=O)(=O)OCC1CCCNC1 WVJYYXZISOKSCL-UHFFFAOYSA-N 0.000 description 1
- HQDFLAJBNTUALB-UHFFFAOYSA-N piperidin-4-ylmethyl methanesulfonate Chemical compound CS(=O)(=O)OCC1CCNCC1 HQDFLAJBNTUALB-UHFFFAOYSA-N 0.000 description 1
- 229960002702 piroxicam Drugs 0.000 description 1
- QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 description 1
- 108010026735 platelet protein P47 Proteins 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920002643 polyglutamic acid Polymers 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920000137 polyphosphoric acid Polymers 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- QCVLYKIRAQZTRY-UHFFFAOYSA-M potassium;cyanoformate Chemical compound [K+].[O-]C(=O)C#N QCVLYKIRAQZTRY-UHFFFAOYSA-M 0.000 description 1
- 229960005205 prednisolone Drugs 0.000 description 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
- WGYKZJWCGVVSQN-UHFFFAOYSA-N propylamine Chemical group CCCN WGYKZJWCGVVSQN-UHFFFAOYSA-N 0.000 description 1
- 239000003881 protein kinase C inhibitor Substances 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- QRCLPHOOCYZYAK-UHFFFAOYSA-N pyrrolidin-3-ylmethyl methanesulfonate Chemical compound CS(=O)(=O)OCC1CCNC1 QRCLPHOOCYZYAK-UHFFFAOYSA-N 0.000 description 1
- QJRYYOWARFCJQZ-UHFFFAOYSA-N pyrrolidine-1-carbonitrile Chemical compound N#CN1CCCC1 QJRYYOWARFCJQZ-UHFFFAOYSA-N 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- 125000005493 quinolyl group Chemical group 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 239000000018 receptor agonist Substances 0.000 description 1
- 229940044601 receptor agonist Drugs 0.000 description 1
- 206010038038 rectal cancer Diseases 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 229910001961 silver nitrate Inorganic materials 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 235000009518 sodium iodide Nutrition 0.000 description 1
- 235000010288 sodium nitrite Nutrition 0.000 description 1
- XZPVPNZTYPUODG-UHFFFAOYSA-M sodium;chloride;dihydrate Chemical compound O.O.[Na+].[Cl-] XZPVPNZTYPUODG-UHFFFAOYSA-M 0.000 description 1
- OAVGBZOFDPFGPJ-UHFFFAOYSA-N sotrastaurin Chemical compound C1CN(C)CCN1C1=NC(C=2C(NC(=O)C=2C=2C3=CC=CC=C3NC=2)=O)=C(C=CC=C2)C2=N1 OAVGBZOFDPFGPJ-UHFFFAOYSA-N 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000009495 sugar coating Methods 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 description 1
- 229960001967 tacrolimus Drugs 0.000 description 1
- 235000015523 tannic acid Nutrition 0.000 description 1
- 229920002258 tannic acid Polymers 0.000 description 1
- 229940033123 tannic acid Drugs 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 description 1
- 125000004213 tert-butoxy group Chemical group [H]C([H])([H])C(O*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- UWDNUXDBNIPKHY-MRXNPFEDSA-N tert-butyl (3R)-3-[4-amino-3-[2-fluoro-4-(2-fluorobenzoyl)phenyl]pyrazolo[3,4-d]pyrimidin-1-yl]pyrrolidine-1-carboxylate Chemical compound NC1=C2C(=NC=N1)N(N=C2C1=C(C=C(C=C1)C(C1=C(C=CC=C1)F)=O)F)[C@H]1CN(CC1)C(=O)OC(C)(C)C UWDNUXDBNIPKHY-MRXNPFEDSA-N 0.000 description 1
- TXOKSXKNUQIBOC-GOSISDBHSA-N tert-butyl (3R)-3-[4-amino-3-[2-fluoro-4-(3-fluorobenzoyl)phenyl]pyrazolo[3,4-d]pyrimidin-1-yl]pyrrolidine-1-carboxylate Chemical compound NC1=C2C(=NC=N1)N(N=C2C1=C(C=C(C=C1)C(C1=CC(=CC=C1)F)=O)F)[C@H]1CN(CC1)C(=O)OC(C)(C)C TXOKSXKNUQIBOC-GOSISDBHSA-N 0.000 description 1
- CMNNOFKMXKKMJR-GOSISDBHSA-N tert-butyl (3R)-3-[4-amino-3-[2-fluoro-4-(4-fluorobenzoyl)phenyl]pyrazolo[3,4-d]pyrimidin-1-yl]pyrrolidine-1-carboxylate Chemical compound NC1=C2C(=NC=N1)N(N=C2C1=C(C=C(C=C1)C(C1=CC=C(C=C1)F)=O)F)[C@H]1CN(CC1)C(=O)OC(C)(C)C CMNNOFKMXKKMJR-GOSISDBHSA-N 0.000 description 1
- WALSOOMQXOEDAB-OAHLLOKOSA-N tert-butyl (3R)-3-[4-amino-3-[2-fluoro-4-[2-(methylcarbamoyl)pyridin-4-yl]oxyphenyl]pyrazolo[3,4-d]pyrimidin-1-yl]pyrrolidine-1-carboxylate Chemical compound NC1=C2C(=NC=N1)N(N=C2C1=C(C=C(C=C1)OC1=CC(=NC=C1)C(NC)=O)F)[C@H]1CN(CC1)C(=O)OC(C)(C)C WALSOOMQXOEDAB-OAHLLOKOSA-N 0.000 description 1
- XASPGLPXANLVTJ-UHFFFAOYSA-N tert-butyl 2-amino-3-hydroxybutanoate Chemical compound CC(O)C(N)C(=O)OC(C)(C)C XASPGLPXANLVTJ-UHFFFAOYSA-N 0.000 description 1
- UIJXHKXIOCDSEB-UHFFFAOYSA-N tert-butyl 3-hydroxypiperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCCC(O)C1 UIJXHKXIOCDSEB-UHFFFAOYSA-N 0.000 description 1
- LFKDJXLFVYVEFG-UHFFFAOYSA-N tert-butyl carbamate Chemical compound CC(C)(C)OC(N)=O LFKDJXLFVYVEFG-UHFFFAOYSA-N 0.000 description 1
- SBWYTQQSTIUXOP-UHFFFAOYSA-N tert-butyl n-(1-hydroxy-2-methylpropan-2-yl)carbamate Chemical compound CC(C)(C)OC(=O)NC(C)(C)CO SBWYTQQSTIUXOP-UHFFFAOYSA-N 0.000 description 1
- GJGLBUZZTLPCOT-UHFFFAOYSA-N tert-butyl n-(3-hydroxypropyl)-n-methylcarbamate Chemical compound OCCCN(C)C(=O)OC(C)(C)C GJGLBUZZTLPCOT-UHFFFAOYSA-N 0.000 description 1
- XDJCYKMWJCYQJM-UHFFFAOYSA-N tert-butyl n-(3-hydroxypropyl)carbamate Chemical compound CC(C)(C)OC(=O)NCCCO XDJCYKMWJCYQJM-UHFFFAOYSA-N 0.000 description 1
- XTVWTTVLXSZYBZ-UHFFFAOYSA-N tert-butyl n-[(3-hydroxycyclopentyl)methyl]carbamate Chemical compound CC(C)(C)OC(=O)NCC1CCC(O)C1 XTVWTTVLXSZYBZ-UHFFFAOYSA-N 0.000 description 1
- FQFILJKFZCVHNH-UHFFFAOYSA-N tert-butyl n-[3-[(5-bromo-2-chloropyrimidin-4-yl)amino]propyl]carbamate Chemical compound CC(C)(C)OC(=O)NCCCNC1=NC(Cl)=NC=C1Br FQFILJKFZCVHNH-UHFFFAOYSA-N 0.000 description 1
- ISTGQSQWSKCNFJ-UHFFFAOYSA-N tert-butyl n-ethylcarbamate Chemical compound CCNC(=O)OC(C)(C)C ISTGQSQWSKCNFJ-UHFFFAOYSA-N 0.000 description 1
- 201000003120 testicular cancer Diseases 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000003039 tetrahydroisoquinolinyl group Chemical group C1(NCCC2=CC=CC=C12)* 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- 125000003507 tetrahydrothiofenyl group Chemical group 0.000 description 1
- 125000004632 tetrahydrothiopyranyl group Chemical group S1C(CCCC1)* 0.000 description 1
- OSBSFAARYOCBHB-UHFFFAOYSA-N tetrapropylammonium Chemical compound CCC[N+](CCC)(CCC)CCC OSBSFAARYOCBHB-UHFFFAOYSA-N 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- 229940044693 topoisomerase inhibitor Drugs 0.000 description 1
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 description 1
- 229960000303 topotecan Drugs 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
- A61P5/20—Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of PTH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C303/00—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides
- C07C303/36—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides of amides of sulfonic acids
- C07C303/38—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides of amides of sulfonic acids by reaction of ammonia or amines with sulfonic acids, or with esters, anhydrides, or halides thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
- C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C311/08—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C43/00—Ethers; Compounds having groups, groups or groups
- C07C43/02—Ethers
- C07C43/257—Ethers having an ether-oxygen atom bound to carbon atoms both belonging to six-membered aromatic rings
- C07C43/29—Ethers having an ether-oxygen atom bound to carbon atoms both belonging to six-membered aromatic rings containing halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
- C07C45/27—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by oxidation
- C07C45/29—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by oxidation of hydroxy groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
- C07C49/76—Ketones containing a keto group bound to a six-membered aromatic ring
- C07C49/80—Ketones containing a keto group bound to a six-membered aromatic ring containing halogen
- C07C49/813—Ketones containing a keto group bound to a six-membered aromatic ring containing halogen polycyclic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
- C07D215/233—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/34—One oxygen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/025—Boronic and borinic acid compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/04—Esters of boric acids
Definitions
- the present invention relates to a series of novel polyfluoro-substituted pyrazolopyrimidines and processes for their preparation, pharmaceutical compositions containing them as active ingredients and methods for inhibiting Bruton's kinase activity.
- the invention also relates to a series of novel polyfluoro-substituted benzophenones and corresponding boronic esters, polyfluoro-substituted phenoxybenzenes and corresponding boronic esters, and novel processes for their preparation.
- Bruton's tyrosine kinase belongs to the Tec family. It consists of a unique N-terminal domain, namely the PH (pleckstrin homology) domain, the TH (Tec homology) homology region, the SH3 (Src homology 3) domain, the SH2 (Src homology 2) domain, and the catalytic domain.
- the SH 1/TK (Src homologyl/Tyrosine kinase) domain or kinase domain composition is referred to (Akinley et al: Ibrutinib and novel BTK inhibitors in clinical development. Journal of Hematology & Oncology 2013, 6:59).
- B lymphocytes the correct expression of different protein regions of BTK gene plays a key role in the function of B cells and various transduction pathways.
- BTK Downstream of the BTK function, there are a variety of receptors, including growth factors, B cell antigens, chemokines and innate immune receptors, which initiate a diverse range of cellular processes such as cell proliferation, survival, differentiation, exercise, angiogenesis, Cytokine production, antigen expression, etc. Therefore, BTK plays an important role in many hematopoietic signaling pathways, and is also important in B cell activation, development, survival, and signaling (Kurosaki, Molecular mechanisms in B cell antigen receptor signaling. Curr OPImm, 1997, 9 ( 3): 309-18).
- the CD20 antibody rituximab (Rituxan) is a protein-based therapeutic agent that depletes B cells and is used as an inflammatory disease such as rheumatoid arthritis for the treatment of autoimmune diseases such as chronic lymphocytic leukemia and autoantibodies. Therefore, protein kinases that play a key role in inhibiting B cell activation should be helpful for pathology of B cell-associated diseases.
- BTK-deficient mice BTK-deficient mice and BTK-sufficient mouse model tests
- Kil LP et al: Bruton's tyrosine kinase mediated signaling enhances leukemogenesis in a mouse model for chronic lymphocytic leukemia .Am JBlood Res 2013, 3(1): 71-83.
- CLL chronic lymphocytic leukemia
- BTK-deleted mice completely abolish chronic lymphocytic leukemia, and overexpression of BTK accelerates the onset of leukemia and increases mortality.
- BTK inhibitors are not ideal: in addition to inhibiting BTK, it also inhibits other various kinases (such as ETK, EGF, BLK, FGR, HCK, YES, BRK and JAK3, etc.), thereby producing more side effects. Side effects of better selective inhibitors may be smaller.
- other various kinases such as ETK, EGF, BLK, FGR, HCK, YES, BRK and JAK3, etc.
- BTK inhibitors produce a variety of derivatives in vivo, which also affects the efficacy and side effects.
- the pharmacokinetics of BTK inhibitors are also known to be improved.
- the present invention relates to a BTK inhibitor for use as a method of treating or inhibiting an autoimmune disease or condition, a xenogenic immune disease or condition, an inflammatory disease, and a cancer or condition. This includes administering to the patient an effective amount of a compound expressed by the formula (I) or (II), or a pharmaceutically acceptable salt thereof.
- Ar 1 and Ar 2 are each independently of the formula (III) or (IV):
- a 1 , A 2 , A 3 , A 4 , A 5 , A 6 , A 7 , A 8 , A 9 and A 10 are each independently C or N, and when N, there is no substituent thereon. connection;
- R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 may be independently represented by hydrogen, hydrazine, amino, halogen, hydroxy, carboxy, nitro, cyano, amide.
- R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 are preferably hydrogen, deuterium, halogen, more preferably hydrogen, fluorine;
- R 6 , R 7 , R 8 or R 9 may form a 6-8 membered saturated or unsaturated heteroaryl ring or heterocyclic ring with NH 2 on the pyrimidine ring;
- Ar 1 may also be selected from substituted or unsubstituted benzoaryl, benzoheteroaryl, wherein the substituent is preferably anthracene, amino, halogen, hydroxy, carboxy, nitro, cyano, amide, lower alkyl sulfonamide , (C2-C6)alkenyl, (C2-C6)alkynyl, trifluoromethyl, trifluoromethoxy, (C1-C6)alkyl, (C1-C6)alkoxy, (C3-C10 a cycloalkyl group wherein the alkyl group, alkoxy group or cycloalkyl group may be further optionally oxime, halogen, amino, hydroxy, carboxy, nitro, cyano, (C1-C6)alkyl, (C1- C6) substituted by alkoxy
- M 1 is a saturated or unsaturated C1-C8 carbon chain, aryl, arylalkyl, alkylaryl, heteroaryl, heteroarylalkyl, alkylheteroaryl, cycloalkyl, ring Alkylalkyl, alkylcycloalkyl, heterocycloalkyl, heterocycloalkylalkyl, alkylheterocycloalkyl; these carbon chains, aryl, heteroaryl, cycloalkyl and heterocycloalkyl
- the hydrogen atom on the carbon or nitrogen atom may optionally be oxime, amino, halogen, hydroxy, carboxy, nitro, cyano, amide, (C2-C6)alkenyl, (C2-C6)alkynyl, trifluoromethyl Substituted with a trifluoromethoxy group, an alkyl group, a cycloalkyl group, an alkoxy group, a cycloalkoxy group, an amino group,
- R 10 , R 11 may be independently represented as amino, cycloamino, aryl, heteroaryl ring, heterocycloalkyl, oxoheterocyclyl, trifluoromethyl, trifluoromethoxy, trifluoroacetyl, Amido, acyl, decyl, (C2-C6)alkenyl, (C2-C6)alkynyl, (C1-C6)alkyl, (C3-C10)cycloalkyl, (C1-C6)alkoxy, (C1-C6) oxoalkyl group, wherein amino group, amide group, acyl group, (C2-C6) alkenyl group, alkyl group, alkoxy group or cycloalkyl group may further be oxime, halogen, amino group, hydroxyl group, hydroxyl group Alkyl, carboxyl, ester, amide, nitro, cyano, trifluoroacetyl, trifluoromethyl, triflu
- the carbon of the aromatic ring or heterocyclic ring or the hydrogen of the nitrogen atom may be optionally substituted by an alkyl group, a cycloalkyl group, an alkoxy group, a cycloalkoxy group, an amino group, a cyano group, an amide group or a halogen;
- Ar 1 is optimally selected from the following formula:
- Q is preferably O, thereby constituting (X) and (XI):
- Ar 2 , M 1 , Y and R 10 are as defined above.
- Ar 2 is preferably a substituted phenyl or heteroaryl group, preferably a substituted phenyl group, further preferably More preferably
- M 1 is a saturated or unsaturated C1-C8 carbon chain, aryl, arylalkyl, alkylaryl, heteroaryl, heteroarylalkyl, alkylheteroaryl, cycloalkyl , cycloalkylalkyl, alkylcycloalkyl, heterocycloalkyl, heterocycloalkylalkyl, alkylheterocycloalkyl.
- the hydrogen atoms on the carbon or nitrogen atom of these carbon chains, aryl, heteroaryl, cycloalkyl and heterocycloalkyl groups may be optionally alkyl, cycloalkyl, alkoxy, cycloalkoxy, amino, Substituted by CN, amido or halogen.
- M 1 is preferably piperidinyl or pyrrolidinyl
- R 10 is selected from the group consisting of amino, cycloamino, aryl, heteroaryl ring, heterocycloalkyl, oxoheterocyclyl, trifluoromethyl, trifluoromethoxy, trifluoroacetyl, amide, acyl , mercapto, (C2-C6) alkenyl, (C2-C6)alkynyl, (C1-C6)alkyl, (C3-C10)cycloalkyl, (C1-C6)alkoxy, (C1-C6 An oxoalkyl group, wherein the amino group, the amide group, the acyl group, the (C2-C6) alkenyl group, the alkyl group, the alkoxy group or the cycloalkyl group may be further optionally selected from the group consisting of hydrazine, halogen, amino, hydroxy, hydroxyalkane.
- Base carboxyl group, ester group, amide group, nitro group, cyano group, trifluoroacetyl group, trifluoromethyl group, trifluoromethoxy group, (C1-C6) alkyl group, (C1-C6) alkoxy group, C1-C6) alkylene oxide, substituted by (C3-C10)cycloalkyl.
- R 10 is most preferably a vinyl group.
- alkyl alkenyl and “alkynyl” are, unless otherwise stated, preferably a straight or branched alkyl group of one to six carbon atoms or a straight chain of two to six carbon atoms or Branched alkenyl and alkynyl groups, for example, methyl, ethyl, propyl, butyl, pentyl or hexyl, vinyl, propenyl, butenyl, pentenyl or hexenyl and their derivatives Structure.
- hydroxy refers to a group having the formula -OH.
- halogen or halo means fluoro, chloro, bromo or iodo.
- cycloalkyl refers to a mono- or polycyclic carbocyclic ring wherein each ring contains from 3 to 10 carbon atoms, and any of the rings may contain one or more double or triple bonds. Examples include groups such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloalkenyl, and cycloheptyl.
- cycloalkyl additionally includes spiro ring systems in which the cycloalkyl ring has a common carbon ring atom.
- heterocycloalkyl is a five- to six-membered non-aromatic heterocyclic ring which may have one or more of the same selected from the group consisting of a nitrogen atom, an oxygen atom, and a sulfur atom (which may be oxidized). Or different heteroatoms.
- the heterocycloalkyl group can be unsaturated or can be fused to a benzene ring. However, nitrogen-bridged hydrocarbons are not included.
- the heterocycloalkyl group may include, for example, azacyclopropyl, azetidinyl, pyrrolidinyl, piperidinyl, homopiperidinyl, morpholinyl, thiomorpholinyl, piperazinyl, Tetrahydrofuranyl, tetrahydrothiophenyl, dihydrooxazolyl, tetrahydropyranyl, tetrahydrothiopyranyl, indanyl, tetrahydroquinolyl, tetrahydroisoquinolinyl, and benzoxazinyl Preferred are dihydrooxazolyl, oxadiazolyl, oxadiazolanyl and furyl.
- cyclic amino group is a 3- to 8-membered non-aromatic cyclic amine in the group defined by “heterocycloalkyl” which has at least one nitrogen atom and may have a nitrogen atom, an oxygen atom and sulfur. One or more of the same or different heteroatoms in the atom (which may be oxidized), wherein at least one of the nitrogen atoms is bonded. However, nitrogen bridged hydrocarbons are not included.
- the "cyclic amino group” may include, for example, aziridine, azetidinyl, pyrrolidinyl, piperidinyl, homopiperidinyl, morpholino, thiomorpholino, and piperazinyl.
- aryl is an aromatic hydrocarbon group, preferably an aryl group having 6 to 10 carbon atoms, more preferably a phenyl group, a naphthyl group and an anthracenyl group, and most preferably a phenyl group.
- heteroaryl is a monovalent five- or six-membered aromatic heterocyclic group having one or more of the same or different heteroatoms selected from the group consisting of a nitrogen atom, an oxygen atom and a sulfur atom, and is compatible with benzene.
- the ring is fused.
- Heteroaryl may include, for example, pyridinyl, pyrazinyl, pyrimidinyl, pyridazinyl, pyrrolyl, pyrazolyl, imidazolyl, oxazolyl, thiazolyl, thienyl, furyl, oxadiazole , thiadiazolyl, quinolyl, isoquinolyl, benzothiazolyl, benzoxazolyl, indolyl, oxazolyl, quinoxalinyl and quinazolinyl, preferably pyridazine Base, pyridyl, pyrazinyl, thiazolyl, pyrazolyl and thiooxazolyl.
- bridged ring group means “bridged cyclic hydrocarbon group” and “aza bridged hydrocarbon group”
- bridged cyclic hydrocarbon group is a saturated or unsaturated bicyclic or polycyclic bridged hydrocarbon group having two or three cycloalkyl rings having 3 to 10 carbon atoms. Non-bridged cycloalkyl groups are not included. Particularly preferred are bicyclic or polycyclic bridged hydrocarbon groups having 4 to 16 carbon atoms.
- the bridged cyclic hydrocarbon group may include, for example, bicyclo [2.1.1] hexyl, bicyclo [2.2.1] heptyl, bicyclo [2.2.2] octyl, bicyclo [4.3.1] fluorenyl, bicyclo [3.3.1 Sulfhydryl, borneol, borneol, norbornyl, norbornene, 6,6-dimethylbicyclo[3.1.1]heptyl, tricyclobutyl, and adamantyl, preferably adamantyl Or bicyclo [2.2.1] heptyl.
- nitro refers to a group having -NO 2 .
- amino refers to a group having the structure -NH 2 .
- the amino group may have one, two or three groups such as an alkyl group, an alkenyl group, an alkynyl group, an aryl group, and the like.
- cyano refers to a group of the formula -CN.
- alkoxy refers to a moiety in which a group containing an alkyl group is bonded to an oxygen atom, such as a methoxy group.
- the oxygen atom of the alkoxy group of the alkoxy moiety is bonded to the other part of the molecule. Examples of such groups include methoxy, ethoxy, propoxy, iso-propoxy, butoxy and tert-butoxy.
- alkyl "cycloalkyl", “heterocycloalkyl", “aryl” and “heteroaryl” are as defined above.
- carboxy refers to a carboxyl group, -CO 2 H, or a salt thereof.
- trifluoromethyl refers to a group having the formula -CF 3.
- trifluoromethoxy means a group having the structure of formula -OCF 3.
- pharmaceutically acceptable salt refers to a salt which is present in acid or base form, non-limiting examples of which are (a) acidic addition salts, inorganic acids (eg, hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid) , nitric acid, etc.), organic acid salts, organic acids such as vinegar Acid, oxalic acid, tartaric acid, succinic acid, malic acid, ascorbic acid, benzoic acid, tannic acid, pamoic acid, Alginic acid, poly glutamic acid, and salicylic acid; (b) base addition salts, formed with metal cations such as zinc, calcium, sodium, potassium, and the like.
- acidic addition salts eg, hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid
- organic acid salts organic acids such as vinegar Acid, oxalic acid, tartaric acid, succinic acid, malic acid, ascorbic acid, benzoic acid, tannic acid,
- the invention is exemplified by the examples and the compounds disclosed herein.
- Particular compounds of the invention are selected from the group consisting of the compounds of the disclosed examples and their pharmaceutically acceptable salts and their individual diastereomeric compounds or salts.
- the present invention actively explores the synthetic route, and eliminates various preparation schemes (see Schemes 1-3), and successfully designs a new method for synthesizing pyrazolopyrimidines (see Schemes 4-11 and specific reaction examples).
- the resulting borate ester is subjected to a Suzuki reaction with a substituted 3-iodo-1H-pyrazolo[3,4-d]pyrimidin-4-amine under the action of a suitable catalyst (e.g., Pd-118) to give the title compound.
- a suitable catalyst e.g., Pd-118
- the literature is known to synthesize a method to try 2: 3-fluoro-4-bromo-phenol (or 3-fluoro-4-chloro-phenol) and 3-fluorobenzeneboronic acid to form 1-bromo-2-fluoro-4-(3-fluorophenoxy Benzo)benzene (or 1-chloro-2-fluoro-4-(3-fluorophenoxy)benzene) is then converted to the corresponding boronic ester to give the target compound.
- 1-bromo-2-fluoro-4-(3-fluorophenoxy)benzene (or 1-chloro-2-fluoro-) was synthesized according to literature methods.
- the fluorine-substituted starting material A1 may form the intermediate C1 with the substituted phenol B1 in the presence of a base such as potassium carbonate and in a suitable solvent such as DMF.
- a suitable base such as potassium acetate
- a suitable solvent such as 1,4-dioxane
- intermediate C1 can be combined with a bis-pinacol borate in a suitable catalyst (eg [1]
- the reaction is carried out by the action of 1'-bis(diphenylphosphino)ferrocene]palladium dichloride to provide intermediate D1.
- the starting material 1H-pyrazolo[3,4-d]pyrimidin-4-amine can be reacted with NIS in a suitable solvent such as DMF to give intermediate F1.
- Intermediate F1 and alcohol G1 are subjected to Mitsunobu reaction with a catalyst under appropriate conditions to form intermediate H1.
- a suitable base such as potassium phosphate
- intermediate H1 can be reacted with borate D1 in a suitable catalyst such as Pd-118.
- the reaction was carried out to provide intermediate I1.
- the Boc group of I1 can be removed to give the amine compound J1.
- the amine compound J1 can be reacted with an electrophile to give the product K1.
- Intermediate F1 can be reacted with Boc protected bromo (or mesylate) A2 in the presence of a suitable base such as potassium carbonate or cesium carbonate in a suitable solvent such as (DMF) to afford intermediate B2.
- a suitable solvent such as 1,4-dioxane and water
- a suitable base such as sodium carbonate
- a suitable catalyst such as palladium (triphenylphosphine) 4
- the Suzuki cross-coupling reaction of the bulk B2 and the heterocyclic boronic ester D1 can give the intermediate C2.
- the Boc group of C2 can be removed to give the amine compound D2.
- the amine compound D2 can be reacted with an electrophile to give the product E2.
- a suitable solvent such as 1,4-dioxane and water
- a suitable base such as sodium carbonate
- a suitable catalyst such as palladium (triphenylphosphine) 4
- the Suzuki cross-coupling reaction can be carried out on the F1 and the heterocyclic boronic ester D1 to give the intermediate A3.
- Intermediate F1 can be reacted with Boc protected bromo (or mesylate) A2 in the presence of a suitable base such as potassium carbonate or cesium carbonate in a suitable solvent such as (DMF) to afford intermediate C2.
- a suitable base such as potassium carbonate or cesium carbonate
- a suitable solvent such as (DMF)
- the Boc group of C2 can be removed to give the amine compound D2.
- the amine compound D2 can be reacted with an electrophile to give the product E2.
- a suitable solvent in e.g., in the presence of a suitable base (such as potassium or cesium carbonate), intermediates, and F 1 may be Boc protected bromide (or mesylate) reaction of Intermediate A4 B4 .
- a suitable solvent such as 1,4-dioxane and water
- a suitable base such as sodium carbonate
- a suitable catalyst such as palladium (triphenylphosphine) 4
- the Suzuki cross-coupling reaction can be carried out on the A4 and heterocyclic boronate D1 to give the product E2.
- the starting material Grinard Reagent A5 can form intermediate alcohol C5 with bromo (or chloro) aryl aldehyde B5.
- Intermediate C5 can be oxidized to ketone D5 by the action of a suitable oxidizing agent such as tetrapropylammonium perruthenate and N-methyloxymorpholine in a suitable solvent such as dichloromethane.
- intermediate D5 can be combined with a bis-pinacol borate in a suitable catalyst (eg The reaction is carried out under the action of [1,1'-bis(diphenylphosphino)ferrocene]palladium dichloride) to provide intermediate E5.
- a suitable base such as potassium acetate
- a suitable solvent such as 1,4-dioxane
- a suitable solvent such as 1,4-dioxane and water
- a suitable base such as sodium carbonate
- a suitable catalyst such as palladium (triphenylphosphine) 4
- a Suzuki cross-coupling reaction can be carried out on the A4 and heterocyclic boronate E5 to give the product F5.
- Compound D2 can react with maleic anhydride to form intermediate A6 in the presence of a suitable base such as triethylamine in a suitable solvent such as dichloromethane.
- Intermediate A6 is cleaved in polyphosphoric acid at the appropriate temperature (e.g., 100 ° C - 110 ° C) to afford product B6.
- the fluorine-substituted starting material A7 can form the intermediate B7 with the substituted phenol B1 in the presence of a base such as potassium carbonate and in a suitable solvent such as DMF.
- the nitro compound B7 can be reduced to the amine C7 in a suitable reducing agent such as iron powder and ammonium chloride in a suitable solvent such as ethanol and water.
- Intermediate C7 produces a fluorine-substituted intermediate D7 under the action of sodium nitrite and pyridine hydrogen fluoride.
- intermediate D7 can be combined with a bis-pinacol borate in a suitable catalyst (eg [1] The reaction is carried out by the action of 1'-bis(diphenylphosphino)ferrocene]palladium dichloride to provide intermediate E7.
- a suitable base such as potassium phosphate
- a suitable solvent such as 1,4-dioxane and water
- intermediate G1 can interact with the boronate E7 in a suitable catalyst (eg, Pd-118).
- the reaction was carried out to provide intermediate F7. Under acidic conditions, the Boc group of F7 can be removed to give the amine compound G7.
- the amine compound G7 can be reacted with an electrophile to give the product H7.
- a Suzuki cross-coupling reaction can be carried out on the A4 and heterocyclic boronate E7 to give the product A8.
- the present invention provides compounds of the formulae (I) to (XIII), and enantiomers and diastereomers thereof, or pharmaceutically acceptable salts thereof.
- the compounds of the present invention comprising the formulae (I) to (IX) include one or more stable isotopes or radioisotopes including, but not limited to, 2 H, 3 H, 13 C, 14 C, 15 N, 18 O and so on.
- the present invention introduces the 1 H isotope 2 H into a BTK inhibitor for the first time.
- the present invention provides a process for the preparation of the compounds of the formulae (I) to (XIII), and their enantiomers and diastereomers.
- the present invention provides a method for modulating the activity of BTK and treating or inhibiting a disease associated with BTK activity. It has been confirmed that the compound of the present invention has an inhibitory effect on BTK activity, and the present invention provides an active ingredient in a medicament for treating and/or preventing diseases caused by the compounds of the formulae (I) to (XIII),
- a disease is a disease caused by unfavorable cytokine signaling, including but not limited to:
- autoimmune diseases such as chronic lymphatic thyroiditis, hyperthyroidism, insulin-dependent diabetes mellitus, myasthenia gravis, chronic ulcerative colitis, pernicious anemia with chronic atrophic gastritis, pulmonary hemorrhagic nephritis syndrome (goodpasture syndrome), pemphigus vulgaris, pemphigoid, primary biliary cirrhosis, multiple cerebrospinal sclerosing, acute idiopathic polyneuritis, systemic lupus erythematosus, rheumatoid arthritis Systemic vascular Inflammation, scleroderma, pemphigus, mixed connective tissue disease, autoimmune hemolytic anemia, thyroid autoimmune disease, ulcerative colitis, etc.;
- xenogeneic immune diseases such as serum diseases, asthma, allergic rhinitis and drug allergies
- inflammatory diseases such as keratitis, rhinitis, stomatitis, mumps, pharyngitis, tonsillitis, bronchitis, bronchitis, pneumonia, myocarditis, gastritis, gastroenteritis, cholecystitis, appendicitis, etc.;
- Cancer includes, but is not limited to, various B cell malignancies (including small lymphocytic lymphoma (SLL), chronic lymphocytic leukemia (CLL), diffuse large B-cell lymphoma (DLBCL), multiple myeloma and Mantle cell lymphoma (MCL) and other diseases that inhibit BTK kinase activity in patients;
- SLL small lymphocytic lymphoma
- CLL chronic lymphocytic leukemia
- DLBCL diffuse large B-cell lymphoma
- MCL Mantle cell lymphoma
- diseases that inhibit BTK kinase activity are beneficial to patients including, but not limited to, brain tumors, bladder cancer, stomach cancer, ovarian cancer, pancreatic cancer, breast cancer, head and neck cancer, cervical cancer, endometrial cancer, rectal cancer, and renal cancer.
- esophageal cancer pre-existing adenocarcinoma, thyroid cancer, bone cancer, skin cancer, colon cancer, female genital tract tumor, lymphoma, multiple myeloma and testicular cancer.
- the method comprises administering to a patient in need thereof an effective amount of a compound of claims 1-12.
- compositions of the compounds of the invention may be used alone or in combination with one or more additional agents, depending on standard pharmaceutical practice, the pharmaceutical formulation of the BTK inhibitor and the additional agent
- the routes of administration may be the same or different, and the administration times may be the same or different.
- Such additional agents include, but are not limited to, tyrosine kinase inhibitors (eg, axitinib, dasatinib, ectinib, etc.), topoisomerase inhibitors (eg, topotecan, etc.) ), protein kinase C inhibitors (such as AEB-071, etc.), sphingosine-1-phosphate receptor agonists (such as fingolimod, KRP-203, etc.), anti-T cell immunoglobulin (such as AtGam, etc.) Anti-IL-2 receptor antibodies (such as dalizumab), amide (CTX), ifosfamide (IFO), doxorubicin (ADM), daunorubicin (DNR), vincristine (VCR), vinblastine (VBL), etoposide (VP16), virgin (Vumon), carboplatin (CBP) and methotrexate (MTX) cyclosporin A, tacrolimus, sir
- the carrier, the excipient, and other additives conventionally used in pharmaceutical preparations can be used to prepare a compound containing one or two or more compounds of the formula (I)-(IX) or a pharmaceutically acceptable salt thereof as an active ingredient.
- Pharmaceutical composition a compound containing one or two or more compounds of the formula (I)-(IX) or a pharmaceutically acceptable salt thereof as an active ingredient.
- a dosage form for parenteral administration such as a nasal preparation or an inhalation is administered for therapeutic administration.
- the symptoms, age, sex, and the like of each patient to be treated should be considered in order to appropriately determine the dose of the compound.
- an adult patient takes a daily dose of a compound of about 0.001 mg/kg to 100 mg/kg, and the dose is taken once or divided into 2 to 4 times.
- adult patients are administered once or more times per day in a dose range of 0.0001 mg/kg to 10 mg/kg. Further, in the case of administration by inhalation, in general, an adult patient is administered once or more times per day in a dose range of 0.0001 mg/kg to 1 mg/kg.
- the solid composition for oral administration may be in the form of a tablet, a powder, a granule or the like.
- one or more active substances are combined with at least one inert excipient (eg, lactose, mannitol, glucose, hydroxypropylcellulose, microcrystalline cellulose, starch, poly Mixing with vinylpyrrolidone, magnesium aluminum silicate, etc.).
- the composition may also contain inert additives such as a lubricant (e.g., magnesium stearate), a disintegrant (e.g., sodium carboxymethyl starch), and a dissolution aid, according to a conventional method.
- Tablets or pills may also be coated with a sugar coating or a gastric or enteric coating as needed.
- the liquid composition for oral administration includes a pharmaceutically acceptable emulsion, solution, suspension, syrup, or elixir, and the like, and contains an inert diluent (e.g., purified water, ethanol) which can be usually used.
- an inert diluent e.g., purified water, ethanol
- the composition may also contain adjuvants such as solubilizers, wetting agents, suspending agents, and sweetening, flavoring, perfuming, and preservatives.
- Injections for parenteral administration include sterile aqueous or nonaqueous solutions, suspensions, emulsions.
- the diluent for the aqueous solution may, for example, include distilled water for injection and physiological saline.
- the diluent for the non-aqueous solution may, for example, include propylene glycol, polyethylene glycol, vegetable oils such as olive oil, alcohols such as ethanol, and polysorbate 80.
- Such compositions may also contain additives such as isotonic agents, preservatives, wetting agents, emulsifying agents, dispersing agents, stabilizers, solubilizers.
- compositions may be sterilized by filtration through a bacteria-retaining filter, addition of a bactericide, or light irradiation. Further, these compositions may be prepared into a sterile solid composition which is dissolved or suspended by using sterile water or a sterile injectable solvent before use.
- Transmucosal agents such as inhalants and nasal sprays can be used in a solid, liquid, or semi-solid state, and these transmucosal agents can be prepared according to a conventionally known method.
- excipients such as lactose and starch
- pH adjusters such as lactose and starch
- antiseptic agents such as lactose and starch
- surfactants such as surfactants
- lubricating agents such as sodium bicarbonate
- stabilizers such as a metered dose inhalation device or a nebulizer.
- the compound may be combined with a pharmaceutically acceptable carrier and administered as a solution or suspension.
- a dry powder inhaler or the like can be used for single administration or multiple administration, and a dry powder or a capsule containing a powder can be used. Alternatively, it may be administered by a pressurized aerosol spray or the like by using a suitable propellant (for example, a suitable gas such as chlorofluoroalkane, hydrofluoroalkane, or carbon dioxide).
- a suitable propellant for example, a suitable gas such as chlorofluoroalkane, hydrofluoroalkane, or carbon dioxide.
- the reaction was carried out under microwave irradiation and subjected to a nitrogen atmosphere for 30 minutes at 85 °C.
- the reaction solution was diluted with water (10 mL) and then th
- the combined organic phases were dried over anhydrous sodium sulfate (MgSO4).
- the reaction was carried out under microwave irradiation and subjected to a nitrogen atmosphere for 30 minutes at 85 °C.
- the reaction solution was diluted with water (10 mL) and then th
- the combined organic phases were dried over anhydrous sodium sulfate and concentrated to dryness.
- the obtained crude product was separated on a C18 reverse phase column by high performance liquid chromatography (mobile phase: acetonitrile/water, gradient elution 10% to 100% by volume)
- the volatile component was evaporated under reduced pressure, and then lyophilized to give the title compound (42 mg, yield: 10%).
- the reaction was carried out under microwave irradiation and subjected to a nitrogen atmosphere for 30 minutes at 85 °C.
- the reaction solution was diluted with water (10 mL) and then th
- the combined organic phases were dried over anhydrous sodium sulfate and concentrated to dryness.
- the obtained crude product was separated on a C18 reverse phase column by high performance liquid chromatography (mobile phase: acetonitrile/water/0.5% HCl, gradient elution 10% to 100%) (volume ratio))
- the volatile component was distilled off under reduced pressure and lyophilized to give the title compound hydrochloride (10 mg, yield: 4%).
- the reaction was stirred under microwave irradiation and under nitrogen for 30 minutes at 85 °C.
- the reaction was diluted with water (50 mL) andEtOAc
- the combined organic phases were dried over anhydrous sodium sulfate and concentrated to dryness.
- the obtained crude product was separated on a C18 reverse phase column by high performance liquid chromatography (mobile phase: acetonitrile/water/0.5% HCl, gradient elution 10% to 100%) (volume ratio))
- the volatile component was distilled off under reduced pressure and lyophilized to give the title compound hydrochloride (150 mg, yield: 4%).
- reaction solution was poured into ice water (300 mL), and then extracted four times with ethyl acetate (100 mL). The combined organic layers were dried over anhydrous sodium sulfate and evaporated to dryness.
- reaction mixture was stirred at 0 ° C for 1 hour, then quenched with water (5mL), then diluted with dichloromethane (50mL), twice with water (30mL) and brine (30mL). The organic phase was dried over anhydrous sodium sulfate (MgSO4). Rate: 64%).
- reaction mixture was stirred at 0 ° C for 1 hour, then diluted with water (5 mL), then diluted with dichloromethane (10 mL), twice with water (5 mL) and brine (5 mL). The organic phase was dried over anhydrous sodium sulfate (MgSO4). .
- the crude product was separated on a C18 reverse phase column by high performance liquid chromatography (mobile phase: acetonitrile/water/0.7 %NH 4 HCO 3 , gradient elution 10% to 100% by volume), the volatile component was evaporated under reduced pressure and lyophilized to give the title compound (19 g, yield: 23%).
- reaction solution was stirred under a nitrogen atmosphere and stirred at 80 ° C for 40 minutes under microwave irradiation. After cooling to room temperature, it was extracted three times with ethyl acetate (50 mL). The combined organic layer was dried over anhydrous sodium sulfate and evaporated to dryness.
- the reaction mixture was stirred at 0 ° C for 1 hour, then diluted with water (5 mL), then diluted with dichloromethane (10 mL), twice with water (5 mL) and brine (5 mL).
- the organic phase was dried over anhydrous sodium sulfate and concentrated to dryness.
- the obtained crude product was separated on a C18 reverse phase column by high performance liquid chromatography (mobile phase: acetonitrile/water/0.5% HCl, gradient elution 10% to 100% (volume)
- the title compound hydrochloride (6.3 mg, yield: 10%) was obtained by evaporation of the volatile component under reduced pressure.
- the obtained crude product was separated on a C18 reverse phase column by high performance liquid chromatography (mobile phase: acetonitrile/water/0.5% HCl, gradient elution 10% to 100%) (volume ratio)), the volatile component was distilled off under reduced pressure, and then lyophilized to give the hydrochloride salt of Example 16 (11 mg, yield: 5%) and the hydrochloride salt of Example 17 (3.8 mg, yield: 2%).
- the reaction was carried out under microwave irradiation for 40 minutes at 85 ° C under a nitrogen atmosphere.
- the reaction solution was diluted with water (10 mL) and then th
- the combined organic phases were dried over anhydrous sodium sulfate and concentrated to dryness.
- the obtained crude product was separated on a C18 reverse phase column by high-performance liquid chromatography (mobile phase: acetonitrile/water/7 ⁇ NH 4 HCl 3 , gradient elution 10%) To 100% (volume ratio), the volatile component was evaporated under reduced pressure and lyophilized to give the title compound (5 mg, yield: 4%).
- the reaction was carried out under microwave irradiation for 40 minutes at 85 ° C under a nitrogen atmosphere.
- the reaction solution was diluted with water (10 mL) and then th
- the combined organic phases were dried over anhydrous sodium sulfate and concentrated to dryness.
- the obtained crude product was separated on a C18 reverse phase column by high performance liquid chromatography (mobile phase: acetonitrile/water/0.5% HCl, gradient elution 10% to 100%) (volume ratio))
- the volatile component was distilled off under reduced pressure and lyophilized to give the title compound hydrochloride (16 mg, yield: 22%).
- the reaction was stirred at 60 ° C for 12 hours under a nitrogen atmosphere. After cooling to room temperature, it was filtered over Celite, and then filtered and evaporated th The combined organic phase was dried over anhydrous sodium sulfate and evaporated to dryness crystals crystals crystals , yield: 46%).
- the reaction solution was diluted with water (10 mL) and then th The combined organic phases were dried over anhydrous sodium sulfate and concentrated to dryness.
- the obtained crude product was separated on a C18 reverse phase column by high performance liquid chromatography (mobile phase: acetonitrile/water/0.5% HCl, gradient elution 10% to 100%) (volume ratio)) The volatile component was distilled off under reduced pressure and lyophilized to give the title compound hydrochloride (2 mg, yield: 2%).
- Example 23 (18 mg, yield: 11%) and Example 24 (3.5 mg, yield: 2%).
- Triethylamine (3.02 g) was added dropwise to a solution of tert-butyl 3-(hydroxymethyl)pyrrolidine-l-carboxylate (2.0 g, 10.0 mmol, 1.0 eq.) in dichloromethane (20 mL). , 30.0 mmol, 3.0 eq.) and methanesulfonyl chloride (2.28 g, 20 mmol, 2.0 eq.). The reaction was stirred at 0<0>C for 1 h then quenched with water (20 mL). The combined organic layers were dried with anhydrous sodium
- Triethylamine (1.9 g) was added dropwise to a solution of tert-butyl 3-(hydroxymethyl)piperidine-1-carboxylate (2.0 g, 9.3 mmol, 1.0 eq.) in dichloromethane (20 mL). , 18.6 mmol, 2.0 eq.) and methanesulfonyl chloride (2.12 g, 18.6 mmol, 2.0 eq.). The reaction was stirred at 0<0>C for 1 h then quenched with water (20 mL). The combined organic layers were dried with anhydrous sodium
- the reaction was carried out under microwave irradiation and subjected to a nitrogen atmosphere for 30 minutes at 85 °C.
- the reaction solution was diluted with water (10 mL) and then th
- the combined organic phase was dried over anhydrous sodium sulfate and evaporated to dryness crystals crystalsssssssssss %).
- the reaction was stirred at 80 ° C for 12 hours under a nitrogen atmosphere.
- the reaction solution was diluted with water (10 mL) and then th
- the combined organic phase was dried over anhydrous sodium sulfate and evaporated to dryness crystals crystalsssssssssssss %).
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- Neurology (AREA)
- Dermatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Gastroenterology & Hepatology (AREA)
- Biomedical Technology (AREA)
- Emergency Medicine (AREA)
- Neurosurgery (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Virology (AREA)
- Otolaryngology (AREA)
- Ophthalmology & Optometry (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (24)
- 由通式(I)和(II)表示的化合物,它们的对映体和非对映体或其可药用的盐。其中:Ar1和Ar2分别独立地选自通式(III)和(Ⅳ):式中,A1,A2,A3,A4,A5,A6,A7,A8,A9和A10各自独立地是C或者N(无取代基连接);R1,R2,R3,R4,R5,R6,R7,R8,R9各自独立地表示为氢,氘,氨基,卤素,羟基,羧基,硝基,氰基,酰胺基,低级烷基磺酰胺基,(C2-C6)烯基,(C2-C6)炔基,三氟甲基,三氟甲氧基,(C1-C6)烷基,(C1-C6)烷氧基,(C3-C10)环烷基,其中的烷基,烷氧基或环烷基上可进一步任选被氘,卤素,氨基,羟基,羧基,硝基,氰基,(C1-C6)烷基,(C1-C6)烷氧基所取代;其中,R6,R7,R8或R9还可以同嘧啶环上的NH2形成6-8元饱和的或不饱和的杂芳环或杂环;Ar1还可以选自取代或未取代的苯并芳基、苯并杂芳基,其中取代基优选氘,氨基,卤素,羟基,羧基,硝基,氰基,酰胺基,低级烷基磺酰胺基,(C2-C6)烯基,(C2-C6)炔基,三氟甲基,三氟甲氧基,(C1-C6)烷基,(C1-C6)烷氧基,(C3-C10)环烷基,其 中的烷基,烷氧基或环烷基上可进一步任选被氘,卤素,氨基,羟基,羧基,硝基,氰基,(C1-C6)烷基,(C1-C6)烷氧基所取代;Q是O或S或者C(=O)M1是一个饱和的或不饱和的C1-C8碳链,C6-C10芳基,C6-C10芳基C1-C6烷基,烷基芳基,杂芳基,杂芳基烷基,烷基杂芳基,环烷基,环烷基烷基,烷基环烷基,杂环烷基,杂环烷基烷基,烷基杂环烷基;这些碳链,芳基,杂芳基,环烷基和杂环烷基的碳或氮原子上的氢原子可任选被烷基,环烷基,烷氧基,环烷氧基,氨基,氰基,酰氨基或卤素所取代;Y是C(=O),NR11C(=O)或S(=O)2;R10,R11可独立地表示为氨基,环氨基,芳基,杂芳环基,杂环烷基,氧代杂环基,三氟甲基,三氟甲氧基,三氟乙酰基,酰胺基,酰基,胍基,(C2-C6)烯基,(C2-C6)炔基,(C1-C6)烷基,(C3-C10)环烷基,(C1-C6)烷氧基,(C1-C6)氧代烷基,其中的氨基,酰胺基,酰基,(C2-C6)烯基,烷基,烷氧基或环烷基可进一步任被氘,卤素,氨基,羟基,羟基烷基,羧基,酯基,酰胺基,硝基,氰基,三氟乙酰基,三氟甲基,三氟甲氧基,(C1-C6)烷基,(C1-C6)烷氧基,(C1-C6)氧代烷基,(C3-C10)环烷基所取代;这些芳环或杂环的碳原子或氮原子上的氢可任选被烷基,环烷基,烷氧基,环烷氧基,氨基,氰基,酰氨基,卤素所取代;
- 如权利要求1-2任一所述的化合物,它们的对映体和非对映体或其可药用的盐。其中:Ar1为取代或未取代的苯基或杂芳基,优选为取代或未取代的苯基,其中苯基或杂芳基上取代基各自独立地为氢,氘,氨基,卤素,羟基,羧基,硝基,氰基,酰胺基,低级烷基磺酰胺基,(C2-C6)烯基,(C2-C6)炔基,三氟甲基,三氟甲氧基,(C1-C6)烷基,(C1-C6)烷氧基,(C3-C10)环烷基,其中的烷基,烷氧基或环烷基可进一步任被氘,卤素,氨基,羟基,羧基,硝基,氰基,(C1-C6)烷基,(C1-C6)烷氧基所取代;
- 如权利要求1-3任一所述的化合物,它们的对映体和非对映体或其可药用的盐。其中:Q是O或S或者C(=O),优选为O。
- 如权利要求1-6任一所述的化合物,它们的对映体和非对映体或其可药用的盐。其中,M1优选为饱和的或不饱和的C1-C8碳链,环烷基,环烷基烷基,烷基环烷基,杂环烷基,杂环烷基烷基,烷基杂环烷基。这些碳链,芳基,杂芳基,环烷基和杂环烷基的碳原子或氮原子上的氢可任选被氘,氨基,卤素,羟基,羧基,硝基,氰基,三氟乙酰基,三氟甲基,三氟甲氧基,烷基,环烷基,烷氧基,氨基,氰基,酰氨基或卤素所取代。
- 如权利要求1-7任一所述的化合物,它们的对映体和非对映体或其可药用的盐,其中,Y优选为C(=O)或者NHC(=O),更优选为C(=O)
- 如权利要求1-8任一所述的化合物,它们的对映体和非对映体或其可药用的盐,其中所述的化合物由下列结构式(IX)所表达:其中:R1,R2,R3,R4,R5,M1,和R10的定义如权利要求1所述;其中:R1,R2,R3,R4,R5,优选为氢、氟、氯、溴、碘,R1,R2,R4和R5进一步优选为氟原子,R3进一步优选为氢原子;其中:M1优选为哌啶基或者吡咯烷基,更优选为吡咯烷基;其中:R10优选为(C2-C6)烯基,其中烯基上的氢原子可各自独立地被:氘,卤素,氨基,环氨基,羟基,羟基烷基,羧基,酯基,酰胺基,硝基,氰基,三氟乙酰基,三氟甲基,三氟甲氧基,(C1-C6)烷基,(C1-C6)烷氧基,(C3-C10)环烷基所取代;
- 一种药物组合物,它包括一种惰性载体和权利要求1-12中任一项所述的化合物,优选权利要求12的化合物。
- 一种药物,它包括一种惰性载体和权利要求1-12中任意一项所述的化合物或其可药用的盐作为活性成分,优选权利要求12的化合物。
- 一种抑制在患者体内BTK活性的方法,包括给予所述患者有效剂量的如权利要求1-12中的化合物。
- 一种用于治疗或抑制自身免疫性疾病(autoimmune diseases)或病症的方法,所述方法包括给需要的患者有效剂量的如权利要求1-12中的化合物或权利要求13的组合物,所述自身免疫性疾病包括,但不限于器官特异性自身免疫疾病,如慢性淋巴性甲状腺炎、甲状腺功能亢进、胰岛素依赖型糖尿病、重症肌无力、慢性溃疡性结肠炎、恶性贫血伴慢性萎缩性胃炎、肺出血肾炎综合征(goodpasture syndrome)、寻常天皰疮、类天皰疮、原发性胆汁性肝硬变、多发性脑脊髓硬化症、急性特发性多神经炎等;系统性自身免疫疾病,如系统性红斑狼疮、类风湿性关节炎、系统性脉管炎、硬皮病、天疱疮、混合结缔组织病、自身免疫性溶血性贫血、甲状腺自身免疫病、溃疡性结肠炎等。
- 一种用于治疗或抑制异种免疫性疾病或病症的方法,所述方法包括给需要的患者有效剂量的如权利要求1-12中的化合物或权利要求13的组合物,所述异种免疫性疾病包括,但不限于血清病、哮喘、过敏性鼻炎和药物过敏等。
- 一种用于治疗或抑制炎性疾病或病症的方法,所述方法包括给需要的患者有效剂量的如权利要求1-12中的化合物或权利要求13的组合物,所述炎性疾病包括,但不限于角膜炎、鼻炎、口腔炎、腮腺炎、咽炎、扁桃体炎、气管炎、支气管炎、肺炎、心肌炎、胃炎、肠胃炎、胆囊炎、阑尾炎等。
- 一种用于治疗或抑制癌症或其他疾病的方法,所述方法包括给需要的患者有效剂量的如权利要求1-12中的化合物或权利要求13的组合物,所述癌症或其他疾病包括,但不限于各种B细胞恶性肿瘤(包括小淋巴细胞淋巴瘤(SLL),慢性淋巴细胞白血病(CLL),弥漫性大B细胞淋巴瘤(DLBCL),华氏巨球蛋白血症(Waldenstrom Macroglobulinemia),滤泡性淋巴瘤(Follicular Lymphom),多发性骨髓瘤和套细胞淋巴瘤(MCL)以及其他抑制BTK激酶活性对病人有益处的疾病。
- 权利要求1-12的化合物在制备治疗或抑制自身免疫性疾病(autoimmune diseases)的药物中的用途,所述自身免疫性疾病包括,但不限于器官特异性自身免疫疾病,如慢性淋巴性甲状腺炎、甲状腺功能亢进、胰岛素依赖型糖尿病、重症肌无力、慢性溃疡性结肠炎、恶性贫血伴慢性萎缩性胃炎、肺出血肾炎综合征(goodpasture syndrome)、寻常天皰疮、类天皰 疮、原发性胆汁性肝硬变、多发性脑脊髓硬化症、急性特发性多神经炎等,系统性自身免疫疾病,如系统性红斑狼疮、类风湿性关节炎、系统性脉管炎、硬皮病、天疱疮、、混合结缔组织病,、自身免疫性溶血性贫血、甲状腺自身免疫疾病、溃疡性结肠炎等。
- 权利要求1-12的化合物在制备治疗或抑制异种免疫性疾病的药物中的用途,所述异种免疫性疾病包括,但不限于血清病、哮喘、过敏性鼻炎和药物过敏等。
- 权利要求1-12的化合物在制备治疗或抑制炎性疾病的药物中的用途,所述炎性疾病包括,但不限于角膜炎、鼻炎、口腔炎、腮腺炎、咽炎、扁桃体炎、气管炎、支气管炎、肺炎、心肌炎、胃炎、肠胃炎、胆囊炎、阑尾炎等。
- 权利要求1-12的化合物在制备治疗癌症或其他疾病的药物中的用途,其中所述癌症或其他疾病包括,但不限于各种B细胞恶性肿瘤(包括小淋巴细胞淋巴瘤(SLL),慢性淋巴细胞白血病(CLL),弥漫性大B细胞淋巴瘤(DLBCL),华氏巨球蛋白血症(Waldenstrom Macroglobulinemia),滤泡性淋巴瘤(Follicular Lymphom),多发性骨髓瘤和套细胞淋巴瘤(MCL))以及其他抑制BTK激酶活性对病人有益处的疾病。
- 权利要求1-12的化合物和各种CD20抗体联合用药治疗癌症或其他疾病的药物中的用途,其中所述癌症或其他疾病包括,但不限于各种B细胞恶性肿瘤(包括小淋巴细胞淋巴瘤(SLL),慢性淋巴细胞白血病(CLL),弥漫性大B细胞淋巴瘤(DLBCL),华氏巨球蛋白血症(Waldenstrom Macroglobulinemia),滤泡性淋巴瘤(Follicular Lymphoma),多发性骨髓瘤和套细胞淋巴瘤(MCL))以及其他抑制BTK激酶活性对病人有益处的疾病。
Priority Applications (16)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2016565402A JP6670756B2 (ja) | 2014-04-29 | 2015-04-27 | ブルトン型チロシンキナーゼ(btk)インヒビターとしての多フルオロ置換化合物 |
ES15785217T ES2857251T3 (es) | 2014-04-29 | 2015-04-27 | Compuestos polifluorados que actúan como inhibidores de la tirosina cinasa de bruton |
EA201692176A EA032100B1 (ru) | 2014-04-29 | 2015-04-27 | Полифторзамещенное соединение в качестве ингибитора тирозинкиназы брутона (btk) |
MX2021013118A MX2021013118A (es) | 2014-04-29 | 2015-04-27 | Compuestos polifluorados que actuan como inhibidores de la tirosina cinasa de bruton. |
AU2015252654A AU2015252654C1 (en) | 2014-04-29 | 2015-04-27 | Polyfluorinated compounds acting as Bruton's tyrosine kinase inhibitors |
KR1020167028059A KR20160144378A (ko) | 2014-04-29 | 2015-04-27 | 브루톤 티로신 키나제 억제제로서 작용하는 폴리플루오로화 화합물 |
EP15785217.9A EP3138842B1 (en) | 2014-04-29 | 2015-04-27 | Polyfluorinated compounds acting as bruton's tyrosine kinase inhibitors |
CA2947338A CA2947338C (en) | 2014-04-29 | 2015-04-27 | Multi-fluoro-substituted compound as bruton's tyrosine kinase (btk) inhibitor |
CN201580010345.8A CN106061976B (zh) | 2014-04-29 | 2015-04-27 | 多氟化合物作为布鲁顿酪氨酸激酶抑制剂 |
KR1020237032203A KR102669966B1 (ko) | 2014-04-29 | 2015-04-27 | 브루톤 티로신 키나제 억제제로서 작용하는 폴리플루오로화 화합물 |
MX2016014248A MX2016014248A (es) | 2014-04-29 | 2015-04-27 | Compuestos polifluorados que actuan como inhibidores de la tirosina cinasa de bruton. |
BR112016025132A BR112016025132A2 (pt) | 2014-04-29 | 2015-04-27 | compostos polifluorados agindo como inibidores de tirosina quinase de bruton |
US15/075,033 US9532990B2 (en) | 2014-04-29 | 2016-03-18 | Polyfluorinated compounds acting as bruton tyrosine kinase inhibitors |
IL248546A IL248546B (en) | 2014-04-29 | 2016-10-27 | A multi-fluorinated compound as an inhibitor of proton tyrosine kinase |
US15/356,014 US9861636B2 (en) | 2014-04-29 | 2016-11-18 | Polyfluorinated compounds acting as bruton tyrosine kinase inhibitors |
US15/820,614 US10300066B2 (en) | 2014-04-29 | 2017-11-22 | Polyfluorinated compounds acting as bruton tyrosine kinase inhibitors |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410175783.7A CN105017256A (zh) | 2014-04-29 | 2014-04-29 | 多氟化合物作为布鲁顿酪氨酸激酶抑制剂 |
CN201410175783.7 | 2014-04-29 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/075,033 Continuation-In-Part US9532990B2 (en) | 2014-04-29 | 2016-03-18 | Polyfluorinated compounds acting as bruton tyrosine kinase inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2015165279A1 true WO2015165279A1 (zh) | 2015-11-05 |
Family
ID=54358137
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2015/000290 WO2015165279A1 (zh) | 2014-04-29 | 2015-04-27 | 多氟化合物作为布鲁顿酪氨酸激酶抑制剂 |
Country Status (14)
Country | Link |
---|---|
US (3) | US9532990B2 (zh) |
EP (1) | EP3138842B1 (zh) |
JP (2) | JP6670756B2 (zh) |
KR (1) | KR20160144378A (zh) |
CN (3) | CN105017256A (zh) |
AU (1) | AU2015252654C1 (zh) |
BR (1) | BR112016025132A2 (zh) |
CA (1) | CA2947338C (zh) |
EA (2) | EA037227B1 (zh) |
ES (1) | ES2857251T3 (zh) |
HK (1) | HK1256857A1 (zh) |
IL (1) | IL248546B (zh) |
MX (2) | MX2021013118A (zh) |
WO (1) | WO2015165279A1 (zh) |
Cited By (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016168704A1 (en) | 2015-04-16 | 2016-10-20 | Icahn School Of Medicine At Mount Sinai | Ksr antagonists |
US9717745B2 (en) | 2015-03-19 | 2017-08-01 | Zhejiang DTRM Biopharma Co. Ltd. | Pharmaceutical compositions and their use for treatment of cancer and autoimmune diseases |
WO2017163078A1 (en) * | 2016-03-24 | 2017-09-28 | Mission Therapeutics Limited | 1-cyano-pyrrolidine derivatives as dbu inhibitors |
WO2018002958A1 (en) | 2016-06-30 | 2018-01-04 | Sun Pharma Advanced Research Company Limited | Novel hydrazide containing compounds as btk inhibitors |
JP2018513205A (ja) * | 2015-02-12 | 2018-05-24 | 上▲海▼度▲徳▼医▲藥▼科技有限公司 | イブルチニブの製造方法 |
WO2018175512A1 (en) * | 2017-03-22 | 2018-09-27 | Suzhou Baijibugong Pharmaceutical Technology Co. Ltd. | Bruton's tyrosine kinase inhibitors |
EP3272752A4 (en) * | 2015-03-19 | 2018-10-31 | Zhejiang DTRM Biopharma Co., Ltd. | Optimised combination therapy and use thereof to treat cancer and autoimmune disease |
JP2019535820A (ja) * | 2016-11-15 | 2019-12-12 | ハンヂョウ ハーツ ファーマシューティカル カンパニー リミテッド | 選択性ブルトン型チロシンキナーゼ阻害剤及びその使用 |
WO2020188015A1 (en) | 2019-03-21 | 2020-09-24 | Onxeo | A dbait molecule in combination with kinase inhibitor for the treatment of cancer |
WO2020187626A1 (de) | 2019-03-15 | 2020-09-24 | Bayer Aktiengesellschaft | Speziell substituierte 3-phenyl-5-spirocyclopentyl-3-pyrrolin-2-one und deren verwendung als herbizide |
EP3138842B1 (en) * | 2014-04-29 | 2020-12-09 | Zhejiang DTRM Biopharma Co., Ltd. | Polyfluorinated compounds acting as bruton's tyrosine kinase inhibitors |
US10927110B2 (en) | 2016-09-29 | 2021-02-23 | Mission Therapeutics Limited | Cyano-subtituted heterocycles with activity as inhibitors of USP30 |
WO2021038540A1 (en) | 2019-08-31 | 2021-03-04 | Sun Pharma Advanced Research Company Limited | Cycloalkylidene carboxylic acids and derivatives as btk inhibitors |
WO2021089791A1 (en) | 2019-11-08 | 2021-05-14 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for the treatment of cancers that have acquired resistance to kinase inhibitors |
WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
WO2021252488A1 (en) | 2020-06-08 | 2021-12-16 | Halia Therapeutics, Inc. | Inhibitors of nek7 kinase |
US11590167B2 (en) | 2016-12-03 | 2023-02-28 | Juno Therapeutic, Inc. | Methods and compositions for use of therapeutic T cells in combination with kinase inhibitors |
US11622965B2 (en) | 2017-10-27 | 2023-04-11 | Zhejiang DTRM Biopharma Co. Ltd. | Methods for treating lymphoid malignancies |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10124003B2 (en) | 2013-07-18 | 2018-11-13 | Taiho Pharmaceutical Co., Ltd. | Therapeutic agent for FGFR inhibitor-resistant cancer |
ES2724929T3 (es) | 2013-07-18 | 2019-09-17 | Taiho Pharmaceutical Co Ltd | Fármaco antitumoral para la administración intermitente de un inhibidor de FGFR |
WO2016079693A1 (en) * | 2014-11-19 | 2016-05-26 | Sun Pharmaceutical Industries Limited | A process for the preparation of ibrutinib |
CN106146511A (zh) * | 2015-04-03 | 2016-11-23 | 安润医药科技(苏州)有限公司 | 吡唑并嘧啶衍生物、制备方法、药物组合物及用途 |
CN106146512B (zh) * | 2015-04-09 | 2018-07-17 | 北京睿创康泰医药研究院有限公司 | 依鲁替尼的制备方法 |
US11883404B2 (en) | 2016-03-04 | 2024-01-30 | Taiho Pharmaceuticals Co., Ltd. | Preparation and composition for treatment of malignant tumors |
KR20240014585A (ko) | 2016-03-04 | 2024-02-01 | 다이호야쿠힌고교 가부시키가이샤 | 악성 종양 치료용 제제 및 조성물 |
CN106146518A (zh) * | 2016-06-30 | 2016-11-23 | 苏州爱玛特生物科技有限公司 | 一种布鲁顿酪氨酸激酶抑制剂中间体及其制备方法 |
CN106831788B (zh) * | 2017-01-22 | 2020-10-30 | 鲁南制药集团股份有限公司 | 伊布替尼精制方法 |
CN107501270B (zh) * | 2017-09-01 | 2019-06-28 | 宏腾建设集团有限公司 | 一种含有磺酰吖丙啶结构的化合物、药物组合物以及其应用 |
CN109970740A (zh) * | 2017-12-27 | 2019-07-05 | 广东众生药业股份有限公司 | 4-氨基-嘧啶并氮杂环衍生物及其制备方法和用途 |
CN111867594A (zh) | 2018-03-19 | 2020-10-30 | 大鹏药品工业株式会社 | 包含烷基硫酸钠的药物组合物 |
WO2020096042A1 (ja) * | 2018-11-09 | 2020-05-14 | 大鵬薬品工業株式会社 | ジメトキシベンゼン化合物の製造方法 |
CN111171035B (zh) * | 2018-11-13 | 2021-03-30 | 山东大学 | 4-苯氧基苯基吡唑并嘧啶酰胺衍生物的制备方法和应用 |
CN111454268B (zh) * | 2019-01-18 | 2023-09-08 | 明慧医药(上海)有限公司 | 作为布鲁顿酪氨酸激酶抑制剂的环状分子 |
JP7323896B2 (ja) * | 2019-06-27 | 2023-08-09 | 杭州和正医薬有限公司 | カゼインキナーゼ1ε阻害剤、医薬組成物及びその使用 |
PT4036095T (pt) | 2019-09-26 | 2024-02-19 | Jumbo Drug Bank Co Ltd | Derivados de 4-fluoro-1h-pirazolo[3,4-c]piridina como inibidores seletivos de tirosina cinase de bruton (btk) para o tratamento de linfoma de células b e doenças autoimunes |
EP3865535A1 (en) | 2020-02-11 | 2021-08-18 | Bosti Trading Ltd. | New method of synthesis of chitosan derivatives and uses thereof |
TW202144465A (zh) | 2020-02-11 | 2021-12-01 | 瑞士商諾和席卓股份有限公司 | 合成聚葡萄胺糖衍生物之新方法及其用途 |
AU2020436612A1 (en) * | 2020-03-16 | 2022-09-01 | Flash Therapeutics, Llc | Compounds for treating or inhibiting recurrence of acute myeloid leukemia |
CN113943294A (zh) * | 2020-07-15 | 2022-01-18 | 成都海博为药业有限公司 | 一种作为btk抑制剂的化合物及其制备方法与用途 |
WO2022081512A1 (en) * | 2020-10-12 | 2022-04-21 | Synubi Pharmaceuticals Llc | Compositions and methods of treatment of neuroinflammatory diseases with bruton's tyrosine kinase inhibitors |
CN112574046A (zh) * | 2020-12-17 | 2021-03-30 | 深圳市华先医药科技有限公司 | 一种制备(1r,3s)-3-氨基环戊醇盐酸盐的方法 |
US20240100172A1 (en) | 2020-12-21 | 2024-03-28 | Hangzhou Jijing Pharmaceutical Technology Limited | Methods and compounds for targeted autophagy |
EP4039688A3 (en) * | 2021-02-03 | 2022-11-23 | Accutar Biotechnology Inc. | Substituted pyrrolopyrimidine and pyrazolopyrimidine as bruton's tyrosine kinase (btk) degraders |
CN117835822A (zh) | 2021-08-06 | 2024-04-05 | 诺和席卓股份有限公司 | 包含可溶性交联壳聚糖的复合凝胶、聚合物支架、聚集体和薄膜的制备及其用途 |
AR126678A1 (es) | 2021-08-06 | 2023-11-01 | Novochizol Sa | Composiciones para el cuidado de las plantas y usos de las mismas |
CN114605418B (zh) * | 2022-03-15 | 2023-09-05 | 广东医科大学附属医院 | 一类具有抗肿瘤活性的依鲁替尼丙烯酰胺类衍生物及其合成方法与应用 |
CN117430610A (zh) * | 2023-10-11 | 2024-01-23 | 宁夏医科大学 | 一种氘代稠合杂环化合物及其制备方法和应用 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102656173A (zh) * | 2009-10-12 | 2012-09-05 | 药品循环公司 | 布鲁顿酪氨酸激酶抑制剂 |
WO2013191965A1 (en) * | 2012-06-18 | 2013-12-27 | Principia Biopharma Inc. | Reversible covalent pyrrolo- or pyrazolopyrimidines useful for the treatment cancer and autoimmune diseases |
CN103534258A (zh) * | 2011-05-17 | 2014-01-22 | 普林斯匹亚生物制药公司 | 酪氨酸激酶抑制剂 |
WO2014022569A1 (en) * | 2012-08-03 | 2014-02-06 | Principia Biopharma Inc. | Treatment of dry eye |
US8673925B1 (en) * | 2013-04-09 | 2014-03-18 | Principia Biopharma Inc. | Tyrosine kinase inhibitors |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040127470A1 (en) * | 1998-12-23 | 2004-07-01 | Pharmacia Corporation | Methods and compositions for the prevention or treatment of neoplasia comprising a Cox-2 inhibitor in combination with an epidermal growth factor receptor antagonist |
GB0402143D0 (en) * | 2004-01-30 | 2004-03-03 | Smithkline Beecham Corp | Novel compounds |
EP2526933B1 (en) * | 2006-09-22 | 2015-02-25 | Pharmacyclics, Inc. | Inhibitors of Bruton's tyrosine kinase |
EP1921149A1 (en) | 2006-11-13 | 2008-05-14 | AEterna Zentaris GmbH | Microorganisms as carriers of nucleotide sequences coding for antigens and protein toxins, process of manufacturing and uses thereof |
CA3001152A1 (en) | 2007-03-28 | 2008-10-09 | Pharmacyclics Llc | Inhibitors of bruton's tyrosine kinase |
JP5369183B2 (ja) * | 2008-07-16 | 2013-12-18 | ファーマサイクリックス,インク. | 固形腫瘍の治療用のブルートンのチロシンキナーゼの阻害剤 |
CN102115476A (zh) * | 2011-03-23 | 2011-07-06 | 常州大学 | 一种2H-吡唑并[3,4-d]嘧啶衍生物及合成方法 |
WO2012158795A1 (en) * | 2011-05-17 | 2012-11-22 | Principia Biopharma Inc. | Pyrazolopyrimidine derivatives as tyrosine kinase inhibitors |
MX2014000518A (es) * | 2011-07-13 | 2014-05-30 | Pharmacyclics Inc | Inhibidores de la tirosina quinasa de bruton. |
CA2879400A1 (en) * | 2012-07-30 | 2014-02-06 | Concert Pharmaceuticals, Inc. | Deuterated ibrutinib |
CN104540455A (zh) * | 2012-07-31 | 2015-04-22 | 安全电线控股有限责任公司 | 深度可控的贾姆什迪针 |
MX361815B (es) * | 2012-09-10 | 2018-12-17 | Principia Biopharma Inc | Compuestos pirazolopirimidinicos como inhibidores de cinasas. |
US9479134B2 (en) * | 2013-03-04 | 2016-10-25 | Texas Instruments Incorporated | Position detecting system |
WO2014143807A2 (en) | 2013-03-15 | 2014-09-18 | Stromatt Scott | Anti-cd37 antibody and bcr pathway antagonist combination therapy for treatment of b-cell malignancies and disorders |
KR102304108B1 (ko) | 2013-04-08 | 2021-09-23 | 바이엘 파마 악티엔게젤샤프트 | 림프종 치료를 위한 치환된 2,3-디히드로이미다조[1,2-c]퀴나졸린의 용도 |
EP2983670A4 (en) | 2013-04-08 | 2017-03-08 | Pharmacyclics LLC | Ibrutinib combination therapy |
US9694011B2 (en) * | 2013-05-21 | 2017-07-04 | Jiangsu Medolution Ltd | Substituted pyrazolopyrimidines as kinases inhibitors |
CN105017256A (zh) * | 2014-04-29 | 2015-11-04 | 浙江导明医药科技有限公司 | 多氟化合物作为布鲁顿酪氨酸激酶抑制剂 |
CN106146508A (zh) * | 2015-03-19 | 2016-11-23 | 浙江导明医药科技有限公司 | 优化的联合用药及其治疗癌症和自身免疫疾病的用途 |
-
2014
- 2014-04-29 CN CN201410175783.7A patent/CN105017256A/zh active Pending
-
2015
- 2015-04-27 MX MX2021013118A patent/MX2021013118A/es unknown
- 2015-04-27 CA CA2947338A patent/CA2947338C/en active Active
- 2015-04-27 KR KR1020167028059A patent/KR20160144378A/ko active Application Filing
- 2015-04-27 AU AU2015252654A patent/AU2015252654C1/en active Active
- 2015-04-27 CN CN201580010345.8A patent/CN106061976B/zh active Active
- 2015-04-27 CN CN201810371229.4A patent/CN108295073B/zh active Active
- 2015-04-27 WO PCT/CN2015/000290 patent/WO2015165279A1/zh active Application Filing
- 2015-04-27 ES ES15785217T patent/ES2857251T3/es active Active
- 2015-04-27 JP JP2016565402A patent/JP6670756B2/ja active Active
- 2015-04-27 EA EA201892740A patent/EA037227B1/ru unknown
- 2015-04-27 BR BR112016025132A patent/BR112016025132A2/pt not_active Application Discontinuation
- 2015-04-27 EA EA201692176A patent/EA032100B1/ru unknown
- 2015-04-27 EP EP15785217.9A patent/EP3138842B1/en active Active
- 2015-04-27 MX MX2016014248A patent/MX2016014248A/es unknown
-
2016
- 2016-03-18 US US15/075,033 patent/US9532990B2/en active Active
- 2016-10-27 IL IL248546A patent/IL248546B/en active IP Right Grant
- 2016-11-18 US US15/356,014 patent/US9861636B2/en active Active
-
2017
- 2017-11-22 US US15/820,614 patent/US10300066B2/en active Active
-
2018
- 2018-12-12 HK HK18115945.4A patent/HK1256857A1/zh unknown
-
2019
- 2019-12-05 JP JP2019220363A patent/JP7005582B2/ja active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102656173A (zh) * | 2009-10-12 | 2012-09-05 | 药品循环公司 | 布鲁顿酪氨酸激酶抑制剂 |
CN103534258A (zh) * | 2011-05-17 | 2014-01-22 | 普林斯匹亚生物制药公司 | 酪氨酸激酶抑制剂 |
WO2013191965A1 (en) * | 2012-06-18 | 2013-12-27 | Principia Biopharma Inc. | Reversible covalent pyrrolo- or pyrazolopyrimidines useful for the treatment cancer and autoimmune diseases |
WO2014022569A1 (en) * | 2012-08-03 | 2014-02-06 | Principia Biopharma Inc. | Treatment of dry eye |
US8673925B1 (en) * | 2013-04-09 | 2014-03-18 | Principia Biopharma Inc. | Tyrosine kinase inhibitors |
Non-Patent Citations (1)
Title |
---|
LEVY, A. ET AL.: "Dications of Fluorenylidenes. The Effect of Substituent Electronegativity and Position on the Antiaromaticity of Substituted Tetrabenzo [5.5] Fulvalene Dications", J. ORG. CHEM., vol. 68, no. 10, 16 May 2003 (2003-05-16), pages 3990 - 3998, XP055234354, ISSN: 0022-3263 * |
Cited By (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3138842B1 (en) * | 2014-04-29 | 2020-12-09 | Zhejiang DTRM Biopharma Co., Ltd. | Polyfluorinated compounds acting as bruton's tyrosine kinase inhibitors |
JP2018513205A (ja) * | 2015-02-12 | 2018-05-24 | 上▲海▼度▲徳▼医▲藥▼科技有限公司 | イブルチニブの製造方法 |
US10214532B2 (en) | 2015-02-12 | 2019-02-26 | Shanghai Dude Medical Science and Technology Co., Ltd. | Process for preparing ibrutinib |
EP3257855A4 (en) * | 2015-02-12 | 2018-07-11 | Shanghai Dude Medical Science and Technology Co., Ltd. | Method for preparing ibrutinib |
AU2016232923B2 (en) * | 2015-03-19 | 2020-08-27 | Zhejiang Dtrm Biopharma Co., Ltd. | Optimised combination therapy and use thereof to treat cancer and autoimmune disease |
US10537587B2 (en) | 2015-03-19 | 2020-01-21 | Zhejiang DTRM Biopharma Co. Ltd. | Pharmaceutical compositions and their use for treatment of cancer and autoimmune diseases |
US9717745B2 (en) | 2015-03-19 | 2017-08-01 | Zhejiang DTRM Biopharma Co. Ltd. | Pharmaceutical compositions and their use for treatment of cancer and autoimmune diseases |
US11369620B2 (en) | 2015-03-19 | 2022-06-28 | Zhejiang DTRM Biopharma Co. Ltd. | Pharmaceutical compositions and their use for treatment of cancer and autoimmune diseases |
US10098900B2 (en) | 2015-03-19 | 2018-10-16 | Zhejiang DTRM Biopharma Co. Ltd. | Pharmaceutical compositions and their use for treatment of cancer and autoimmune diseases |
EP3272752A4 (en) * | 2015-03-19 | 2018-10-31 | Zhejiang DTRM Biopharma Co., Ltd. | Optimised combination therapy and use thereof to treat cancer and autoimmune disease |
US10596183B2 (en) | 2015-03-19 | 2020-03-24 | Zhejiang DTRM Biopharma Co. Ltd. | Pharmaceutical compositions and their use for treatment of cancer and autoimmune diseases |
US10548897B2 (en) | 2015-04-16 | 2020-02-04 | Icahn School Of Medicine At Mount Sinai | KSR antagonists |
WO2016168704A1 (en) | 2015-04-16 | 2016-10-20 | Icahn School Of Medicine At Mount Sinai | Ksr antagonists |
EP3283466A4 (en) * | 2015-04-16 | 2018-09-12 | Icahn School of Medicine at Mount Sinai | Ksr antagonists |
WO2017163078A1 (en) * | 2016-03-24 | 2017-09-28 | Mission Therapeutics Limited | 1-cyano-pyrrolidine derivatives as dbu inhibitors |
CN108884068A (zh) * | 2016-03-24 | 2018-11-23 | 特殊治疗有限公司 | 作为dub抑制剂的1-氰基-吡咯烷衍生物 |
US11352339B2 (en) | 2016-03-24 | 2022-06-07 | Mission Therapeutics Limited | 1-cyano-pyrrolidine derivatives as DUB inhibitors |
CN108884068B (zh) * | 2016-03-24 | 2021-02-26 | 特殊治疗有限公司 | 作为dub抑制剂的1-氰基-吡咯烷衍生物 |
WO2018002958A1 (en) | 2016-06-30 | 2018-01-04 | Sun Pharma Advanced Research Company Limited | Novel hydrazide containing compounds as btk inhibitors |
US10927110B2 (en) | 2016-09-29 | 2021-02-23 | Mission Therapeutics Limited | Cyano-subtituted heterocycles with activity as inhibitors of USP30 |
JP2019535820A (ja) * | 2016-11-15 | 2019-12-12 | ハンヂョウ ハーツ ファーマシューティカル カンパニー リミテッド | 選択性ブルトン型チロシンキナーゼ阻害剤及びその使用 |
US11590167B2 (en) | 2016-12-03 | 2023-02-28 | Juno Therapeutic, Inc. | Methods and compositions for use of therapeutic T cells in combination with kinase inhibitors |
US10933063B2 (en) | 2017-03-22 | 2021-03-02 | Xibin Liao | Bruton's tyrosine kinase inhibitors |
WO2018175512A1 (en) * | 2017-03-22 | 2018-09-27 | Suzhou Baijibugong Pharmaceutical Technology Co. Ltd. | Bruton's tyrosine kinase inhibitors |
US11554118B2 (en) | 2017-03-22 | 2023-01-17 | Xibin Liao | Bruton's tyrosine kinase inhibitors |
US11974999B2 (en) | 2017-03-22 | 2024-05-07 | Xibin Liao | Bruton's tyrosine kinase inhibitors |
US11622965B2 (en) | 2017-10-27 | 2023-04-11 | Zhejiang DTRM Biopharma Co. Ltd. | Methods for treating lymphoid malignancies |
WO2020187626A1 (de) | 2019-03-15 | 2020-09-24 | Bayer Aktiengesellschaft | Speziell substituierte 3-phenyl-5-spirocyclopentyl-3-pyrrolin-2-one und deren verwendung als herbizide |
WO2020188015A1 (en) | 2019-03-21 | 2020-09-24 | Onxeo | A dbait molecule in combination with kinase inhibitor for the treatment of cancer |
WO2021038540A1 (en) | 2019-08-31 | 2021-03-04 | Sun Pharma Advanced Research Company Limited | Cycloalkylidene carboxylic acids and derivatives as btk inhibitors |
WO2021089791A1 (en) | 2019-11-08 | 2021-05-14 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for the treatment of cancers that have acquired resistance to kinase inhibitors |
WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
WO2021252488A1 (en) | 2020-06-08 | 2021-12-16 | Halia Therapeutics, Inc. | Inhibitors of nek7 kinase |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN108295073B (zh) | 多氟化合物作为布鲁顿酪氨酸激酶抑制剂 | |
CN111377917B (zh) | 杂环类化合物、中间体、其制备方法及应用 | |
CN105452239B (zh) | 作为jak抑制剂的联吡唑衍生物 | |
TWI624467B (zh) | 選擇性經取代之喹啉化合物 | |
CN104918945B (zh) | 作为jak抑制剂的三环稠合噻吩衍生物 | |
WO2016145935A1 (zh) | 优化的联合用药及其治疗癌症和自身免疫疾病的用途 | |
CN115850268A (zh) | 作为cftr增效剂的吡咯并嘧啶 | |
TW201722933A (zh) | 苯內醯胺化合物 | |
TW201443023A (zh) | 作爲rock抑制劑之酞□酮及異喹啉酮 | |
WO2019000682A1 (zh) | Rho相关蛋白激酶抑制剂、包含其的药物组合物及其制备方法和用途 | |
CN102985417A (zh) | 作为jak1抑制剂的哌啶-4-基氮杂环丁烷衍生物 | |
TW201414737A (zh) | 作爲激酶抑制劑之咪唑并三□甲腈 | |
CN107253963A (zh) | 吡啶酮和氮杂吡啶酮化合物及使用方法 | |
CN102341398A (zh) | 磺酰化四氢吡咯并吡嗪及其作为药物的用途 | |
CN101417999A (zh) | 哌嗪类衍生物,其制备方法及其在医药上的应用 | |
TW201734020A (zh) | 布魯頓氏酪胺酸激酶抑制劑及其使用方法 | |
WO2020143763A1 (zh) | 卤代烯丙基胺类化合物及其应用 | |
TW201710250A (zh) | 經取代之喹喏啉衍生物 | |
WO2022194269A1 (zh) | 新型egfr降解剂 | |
WO2019085996A1 (zh) | 作为mTORC1/2双激酶抑制剂的吡啶并嘧啶类化合物 | |
WO2021139599A1 (zh) | RORγt抑制剂及其制备方法和用途 | |
CN114401722A (zh) | 酪氨酸激酶的抑制剂 | |
WO2023125845A1 (zh) | 芳杂双环化合物及其抗病毒用途 | |
KR102669966B1 (ko) | 브루톤 티로신 키나제 억제제로서 작용하는 폴리플루오로화 화합물 | |
WO2023227125A1 (zh) | 作为CDKs抑制剂的新型并杂环类新化合物及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 15785217 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 20167028059 Country of ref document: KR Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2016565402 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 248546 Country of ref document: IL |
|
ENP | Entry into the national phase |
Ref document number: 2947338 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/A/2016/014248 Country of ref document: MX |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2015252654 Country of ref document: AU Date of ref document: 20150427 Kind code of ref document: A |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112016025132 Country of ref document: BR |
|
REEP | Request for entry into the european phase |
Ref document number: 2015785217 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 201692176 Country of ref document: EA Ref document number: 2015785217 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 112016025132 Country of ref document: BR Kind code of ref document: A2 Effective date: 20161027 |